IL-36 member activation and secretion, and their role in immune defence by Macleod, Thomas James
IL-36 member activation and secretion, and their role
in immune defence
Thomas James Macleod
Submitted in accordance with the requirements for
the degree of Doctor of Philosophy
The University of Leeds
Faculty of Medicine and Health
November 2016
iThe candidate confirms that the work submitted is his/her own, except where
work which has formed part of jointly authored publications has been
included. The contribution of the candidate and the other authors to this work
has been explicitly indicated below. The candidate confirms that appropriate
credit has been given within the thesis where reference has been made to
the work of others.
Chapter 4 uses data published in Macleod, T., Doble, R., McGonagle, D.,
Wasson, C.W., Alase, A., Stacey, M., Wittmann, M., Neutrophil Elastase-
mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor
antagonist. Scientific Reports 6, 24880 (2016). Conceived and designed
experiments; M.S., M.W., R.D., T.M. Conducted experiments; T.M., R.D.,
A.A. Contributed to cell culture; A.A., C.W.W. Wrote manuscript; T.M., M.S.,
M.W.
This copy has been supplied on the understanding that it is copyright material
and that no quotation from the thesis may be published without proper
acknowledgement
© 2016 The University of Leeds and Thomas James Macleod
ii
Acknowledgements
I would firstly like to thank everyone in the lab that has helped me through the
years; particularly Rosie for showing me the ropes in the first year, Joe in the
last year for experimental guidance, and Becky throughout for making it such
a pleasant place to work. I would also like to thank my supervisors Martin
Stacey and Miriam Wittmann for their undying respective skepticism and
optimism (and of course their continual support and guidance) and Delyth
Reid for passing on some of her excellent skills in hybridoma production and
housing me for a night. I’d also like to give thanks to Chris, for his never-
ending persistence in maintaining a functional tissue culture room, Chi for
making sure I have some form of a social life, and frankly anyone reading this
– particularly if you manage to get through to the end. Lastly, I’d like to thank
my family for their continual support (financial and otherwise!) throughout the
PhD and writing process, Will for the thesis soundtrack contributions, and
Cliff for just always being there. And of course huge thanks goes to Lucy for
putting up with me and providing a constant welcome source of distraction.
iii
Abstract
The IL-36 cytokines are a recently identified subset of the IL-1 superfamily
that are becoming firmly established as instigators of pathogenic
inflammation in a number of inflammatory conditions.  IL-36γ, in particular, 
has been strongly linked to psoriatic inflammation of the skin. As with many
IL-1 proteins, the IL-36 cytokines must undergo post-translational truncation
in order to become biologically active, however the manner in which this
occurs and their subsequent release from cells is poorly understood.
Furthermore, research into these questions is greatly hindered by the lack of
available IL-36 specific antibodies.
This work has  therefore focused on 1) producing IL-36γ specific monoclonal 
antibodies to facilitate further IL-36 research, 2) the post-translational
processing by endogenous and exogenous proteases, 3) the physiological
role of IL-36 in epithelial barrier homeostasis.
The results of this work include successful production and characterisation of
4 anti-IL-36γ monoclonal antibodies and subsequent development of an IL-
36γ ELISA that has been used to identify IL-36γ as a reliable psoriasis-
specific disease marker. Secondly, an epithelial protease, cathepsin S, has
been identified as able to cleave and activate IL-36γ and has been shown to 
be widely expressed within the skin compartment. Furthermore, it has
identified that exogenous proteases produced by the opportunistic pathogen
Aspergillus fumigatus are capable of cleaving and activating IL-36γ to initiate 
IL-36-mediated inflammation.  Finally, IL-36γ was shown to promote epithelial 
barrier function by enhancing epithelial proliferation and providing resistance
against apoptosis, which may be indicative of a role in wound healing.
Overall from these findings we propose that the IL-36 cytokines may act as
sensors of epithelial damage in response to protease-dependant activation
that play a prominent role in the first line of defence against invading
pathogens.
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1Chapter 1 - Introduction
21.1 Structure and cellular population of the skin
The skin can be separated into two distinct layers; the epidermis and dermis.
The epidermis is the upper-most layer and sits a-top the dermis, separated
by a basement membrane as shown in Figure 1-1. The epidermis consists
primarily of tightly packed keratinocytes that progressively differentiate as
they progress outward through the epidermis consequently forming a highly
organized structure. As such, the epidermis is separated into four distinct
layers, each consisting of keratinocytes at distinct stages of differentiation.
The first layer of the epidermis, termed the stratum basale, comprises of
undifferentiated proliferating basal keratinocytes attached to the basement
membrane via hemidesmosomes which provide the epidermis with a
continual turnover of cells. The next layer, the stratum spinosum, consists of
keratinocytes that have begun to differentiate, attached to one another via
desmosomes. At the third layer, the stratum granulosum, intermediately
differentiated keratinocytes have begun to lose their nuclei and take on a
granular appearance. Finally, the stratum corneum consists of terminally
differentiated keratinocytes (corneocytes) that are anuclear, encased in
cornified envelope proteins and tightly attached to one another via
corneodesmosomes forming a physical barrier to the outside world [1]. As
the keratinocytes differentiate they express different proteins (such as
keratin), and secrete polar lipids that are converted to non-polar lipids that
contribute to the epidermal barrier function [2]. Through identification of
these differentially-expressed proteins the differentiation state of
keratinocytes can be defined. Although the vast majority of the epidermis is
made up of keratinocytes, other cells can also be found. Langerhans cells
are often found in the stratum spinosum whilst melanocytes and sensory
merkel cells are found in the stratum basale and a low number of CD8+ T
cells can be found in both [3, 4].
The dermis can be divided into two defined layers; the inner stratum
reticulare and outer stratum pappilare, beyond which lies the basement
membrane and epidermis. The dermis has a more complex anatomy than
the epidermis consisting of several cell types and numerous integrated
3tissues, but the predominant resident cells are fibroblasts. The fibroblasts
secrete fibrous proteins such as collagen and elastin that form an
extracellular matrix in which numerous nerve type cells and immune cells
reside. The dermis is populated by a much more diverse set of specialized
immune cells than the epidermis, including antigen presenting cells,
conventional and non-conventional T cells. The dermis also contains both a
capillary and lymphatic network providing the dermis with blood and allowing
the influx and efflux of migratory immune cells in response to inflammatory
mediators produced by both the dermis and epidermis [3, 5].
Figure 1-1 Diagram illustrating the cellular structure of the skin
This diagram illustrates the stratified epidermis formed by keratinocyte differentiation and the
cells found within both the dermis and epidermis. The red line represents the basement
membrane that separates the two [3].
41.2 Skin function in immunity, inflammation and
disease (Immune response of the skin)
As the largest organ of the body that separates the vulnerable mesenchymal
tissues and internal organs from the hazardous external environment, the
skin (and other epithelial surfaces) is the first line of defense against invading
pathogens and other harmful factors. The ability of the skin to ward off
invading pathogens doesn’t stop at the physical barrier formed by the
structured epidermis and the antimicrobial environment it creates. This was
recognized in 1983 by Streilein who introduced the concept of skin-
associated lymphoid tissue (SALT) and subsequently the ‘skin immune
system (SIS)’, identifying the importance of the blood and lymphatic system
and immune cell trafficking to and from the skin [6, 7].
It has since been established that the skin is capable of mounting a strong
immune response to prevent microbial invasion, acting immediately through
innate measures and by effectively mobilizing an adaptive immune response.
However, skin inflammation must be tightly controlled ultimately culminating
in wound healing and bringing a resolution to the induced inflammation.
Indeed, dysregulation of these tightly controlled immune processes are often
linked to inflammatory skin disease.
1.2.1 Initiation of an immune response
In addition to creating a physical barrier against external pathogens,
epidermal keratinocytes are capable of directly sensing and responding to an
infection. Keratinocytes can detect a microbial presence through the
expression of receptors termed pattern recognition receptors (PRRs). PRRs
recognise evolutionarily conserved microbial components that are
indispensable to the microbes’ existence, such as bacterial flagellin or viral
RNA, and were conceptualised by Janeway as pathogen-associated
molecular patterns (PAMPs) [8]. The PRRs are made up of a number of
distinct families, but the most abundant in the skin are the toll-like receptors
(TLRs). The TLR family consists of 9 trans-membrane receptors, each
5recognising distinct PAMPs. TLR 1, 2, 4, 5 and 6 are expressed on the cell
surface and primarily recognise PAMPs of bacterial and fungal cell wall or
membrane origin. TLR 3, 7, 8 and 9 recognise nucleic acids of viral and
bacterial origin and are expressed within intracellular endosomes. Ligation of
a PAMP to its respective TLR will activate the host cell, leading to activation
of nuclear factor κB (NF-κB) and subsequent expression of a host of innate 
and adaptive immune mediators [9]. Through the expression of TLRs 1-6,
and 9, epidermal keratinocytes are capable of responding to a wide variety of
pathogens and hence initiating an immune response [10]. Whilst TLRs are
responsible for recognition of a wide variety of pathogens, another class of
PRR termed C-type lectin receptors (CLRs) are of great importance in the
recognition of fungal carbohydrate PAMPs. Keratinocytes express a range of
CLRs including Dectin-1 and Mannose Receptor C type 1 that recognise
fungal pathogens via cell-wall β1,3-glucan and mannose respectively [11], 
prevalent on fungal pathogens such as Candida albicans and Aspergillus
fumigatus. Ligation of PAMPs to CLRs also activates the host cell,
transducing signalling via SYK activity, similarly activating NF-κB and 
Mitogen-activate protein kinases (MAPKs), resulting in a subsequent cytokine
response [12]. In addition to sensing pathogens via PAMPs, keratinocytes
can also recognise and respond to danger signals in the form of damage
associated molecular patterns (DAMPs). DAMPs are molecules such as
irritants, ultraviolet light, or host-cell derived molecules termed ‘alarmins’
including IL-1α and the S100 proteins, that are released upon damage 
caused by necrosis or trauma and as such notify neighbouring cells of
danger [13-16]. As with PAMPs, they are primarily recognised via detection
by PRRs. One such example is the detection of extracellular ATP released
upon cell damage by nucleotide-binding domain, leucine-rich repeat-
containing (NOD) like receptors (NLR). The NLRs are another family of
PRRs highly expressed in the skin. Activation of NLRs leads to
inflammasome activation and the subsequent release of pro-inflammatory
mediators [17].
In response to TLR or CLR ligation, keratinocytes will express and secrete a
range of cytokines and chemokines with which they can direct an immune
6response, attracting both innate and adaptive immune cells and polarising
them to the phenotype required to combat the pathogens detected.
However, even before mobilisation of the immune system, keratinocytes can
directly fight invading pathogens through the expression of anti-microbial
peptides (AMPs). AMPs are evolutionarily conserved small cationic proteins
that directly kill microbes by binding to and forming pores in their cell
membranes [18]. Keratinocytes produce a number of AMPs, the most
studied of which are the cathelicidin LL37 and human β defensins (hBDs), 
which are active against bacterial and fungal microbes. Of particular
importance is hBD2, the expression and release of which is inducible in
keratinocytes upon activation of TLR2 and TLR4 as well as in response to
other inflammatory mediators such as IL-1 and tumour necrosis factor α 
(TNFα) [19, 20].  hBDs have not only been demonstrated to have potent 
bactericidal activity, but also have chemotactic properties, capable of binding
and signalling though the chemokine receptor CCR6 expressed on DC, IL-17
producing type 3 innate lymphocyte subset (ILC3) and TH17 cells. As such,
AMPs both directly fight invading pathogens and contribute to the
mobilisation of the immune system [21, 22].
Upon detection of a pathogenic intrusion via PRRs, keratinocytes will secrete
a range of inflammatory mediators and thus begin to influence the
surrounding cutaneous tissue and initiate an influx of leukocytes. Of great
significance in skin immunity is the release of IL-1 family cytokines
(discussed in section 1.3). Members of the IL-1 family have a broad range of
effects on multiple cell types, ranging from activation of DC and CD4+ T cells
to maturation and clonal expansion of B cells, and will also act in an
autocrine fashion to further activate surrounding keratinocytes [23, 24].
Keratinocytes are significant producers of chemokines and as mentioned
above can attract different leukocyte subtypes into the skin compartment.
For example, an influx of neutrophils is mediated – among others - through
the secretion of IL-8 (CXCL8). CCR6+ effector T cells (TH17 and TH22 cells)
will migrate in response to local secretion of chemokine CCL20 [25, 26].
However, a specific immune response is dependent on professional antigen
presenting cells. Langerhans cells and dermal DCs are activated by
7keratinocyte produced mediators and in the presence of pathogens, following
uptake and processing, will undergo maturation and migrate to the local
draining lymph nodes where they present their antigens to naïve T cells [27,
28]. Depending on the antigens presented and the accompanying co-
stimulation, Langerhans cells and dermal DCs initiate clonal expansion of
specific T helper cells which then follow a chemokine gradient back to the
site of infection. Once at the site of infection activated T helper cells secrete
various immune mediators to enhance and strengthen the immune response.
Of those that infiltrate into the skin, a number differentiate into memory T
helper cells and remain there. These skin-resident T helper cells, identifiable
by a cutaneous lymphocyte-associated antigen (CLA), are re-activated in the
context of secondary antigen challenge and are therefore important skin-
based effector cells [29, 30].
As previously mentioned, inflammation initiated after skin damage and
microbial offense will result in an influx of neutrophils following an IL-8
chemokine gradient. Indeed it is well established that neutrophils are
amongst the first immune infiltrate, present within minutes of tissue damage
[31]. Neutrophils are crucial in the first steps of clearing a wound and
mounting a strong response. In addition to their traditional phagocytic role,
neutrophils secrete a host of antimicrobial molecules such as enzymes,
superoxide radicals and neutrophil extracellular traps (NETs) and are
extremely proficient at killing microbes [32, 33]. Furthermore they can also
react to a wide range of stimuli and release a great amount of inflammatory
mediators to further direct an immune response. An influx of neutrophils is
shortly followed by monocytes and macrophages.
An effective cutaneous immune response results from the coordinated action
of skin resident and infiltrating leukocytes. However, in order to properly
repair a compromised skin barrier the inflammation must be brought to a
resolution in order for wound healing to occur.
1.2.2 Resolution of inflammation and wound healing
Neutrophils are known to be short lived. Once they have undertaken their
phagocytic role at the site of inflammation they then become apoptotic and
8die. As outlined above, following neutrophil influx, monocytes and
macrophages begin to traffic to the site of inflammation following a
chemokine gradient. In addition to reinforcing the inflammatory immune
response these monocytes and macrophages also clear the site of the
apoptotic neutrophils. It is in this process, driven by macrophages and
neutrophil apoptosis, that resolution of inflammation begins and skin barrier
homeostasis can be regained.
As macrophages begin to enter the site of inflammation a depletion of
neutrophil chemotactic chemokines begins, halting the influx of neutrophils
and allowing resolution to progress. This is achieved in a number of ways.
Macrophage-specific metalloproteinases such as MMP12 cleave neutrophil
chemokines such as IL-8 to inactive forms, preventing them binding to
chemokine receptors and hence preventing neutrophil chemotaxis [34].
Some chemokines are cleaved to produce receptor antagonists, allowing
binding but preventing signal transduction [35]. Furthermore chemokines are
sequestered by apoptotic neutrophils. As neutrophils undergo apoptosis they
increase expression of chemokine receptor CCR5 which depletes
surrounding pro-inflammatory chemokines such as macrophage inflammatory
protein-1α and -1β (MIP-1α, MIP-1β) [36].   
Once neutrophil influx is abrogated neutrophil apoptosis becomes abundant.
An increase in macrophage presence promotes this through the expression
of high amounts of death receptor ligands such as Fas-ligand and TNF [37,
38]. As neutrophils become apoptotic they secrete mediators that further
inhibit neutrophil influx such as annexin A1, and start expressing molecules
that mark them for clearance by macrophages termed ‘eat me’ signals, such
as phosphatidylserine [39-41]. Upon phagocytosing apoptotic neutrophils,
macrophages undergo a phenotypic change from pro-inflammatory cells and
begin to act in an anti-inflammatory capacity. They secrete IL-10, IL-1
receptor antagonist (IL-1Ra) and transforming growth factor-β (TGF-β), 
important suppressors of inflammation and promoters of cell proliferation, as
well as a host of lipid mediators such as protectins and resolvins which
promote inflammation resolution by reducing neutrophil activity and
promoting monocyte migration [42, 43].
9In repair processes, alternatively activated macrophages (M2 macrophages)
have been identified as critical, acting to further supress inflammation and
induce reparative cell growth through secretion of growth factors [44].
Secretion of vascular endothelial growth factor (VEGF) induces angiogenesis
providing a supply of oxygen to regenerating tissue, whilst TGF-β induces 
fibroblast differentiation into myofibroblasts which contribute to wound repair
through production of interstitial fibrillar collagens [45, 46]. At the same time,
secretion of MMPs by M2 macrophages allows for keratinocyte migration to
occur and secretion of epidermal growth factor (EGF) and TGF-β induce 
epidermal proliferation [47]. Finally, basement membrane repair is promoted
through the production of laminin, and the normal stratified epidermal
structure is restored through keratinocyte differentiation and keratin
production [48, 49].
The importance of immune response control becomes evident when stages
in the initiation or resolution of inflammation become dysregulated.
1.2.3 Inflammatory disease in the skin
Examples of dysregulated inflammatory responses in the skin often manifest
in inflammatory skin disease. Atopic dermatitis (AD) and psoriasis are
amongst the most common and most extensively studied cutaneous
inflammatory diseases and are both examples of highly heterogeneous
multifactorial conditions involving environmental and genetic factors. AD and
psoriasis have in common that leukocytes infiltrate into the epidermal
compartment and thus keratinocyte lymphocyte interaction occurs.
In brief, AD is a common skin disease affecting up to 20% of children of
school entry age in the UK [50]. Features of the disease are predominance of
type 2 immune activation involving IL-4 and IL-13 driven cellular responses,
IgE class type switch and high susceptibility to Staphylococcus aureus skin
infection. The dominant clinical sign is pruritus and associated impairment of
life quality, commonly due to loss of sleep [51].
Psoriasis is considered by many to be an autoinflammatory condition with
possible associated autoimmune reactions that effects approximately 3% of
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the population [52]. The condition has a significant impact on quality of life.
It affects the skin and joints, and the more severe cases are being found to
be associated with metabolic conditions, such as coronary heart disease and
atherosclerosis. There are now up to 16 loci that have been associated with
psoriasis susceptibility, emphasising the heterogeneous genetic nature of the
condition [53]. Psoriasis is also phenotypically heterogeneous, and can be
separated into 3 distinct clinical subtypes; vulgaris, guttate, and pustular.
Psoriasis vulgaris, characterised by the dry red scaly plaques most
commonly associated with psoriasis, is the most common form of psoriasis
affecting 85-90% of sufferers [54]. Guttate psoriasis is characterised by
small plaques of approximately 1 cm in diameter that often presents in an
acute onset and is strongly associated with Streptococcal infection in young
children and adolescents [55]. Pustular psoriasis has both generalised and
localised manifestations, but generally features pustular lesions with marked
infiltration of neutrophils into the dermis and epidermis [56]. Generalised
pustular psoriasis (GPP) is a rare but potentially life threatening condition in
which a subset of patients have been strongly associated with loss-of-
function mutations in the gene encoding IL-36 receptor antagonist (IL-36Ra)
[57].
Psoriasis can be triggered by a number of environmental factors that initiates
an overactive self-perpetuating inflammatory loop often driven by multiple
genetic factors that gives rise to the psoriatic lesions associated with the
condition. Dysregulated inflammation leads to an abnormal influx of
numerous inflammatory cell types into both the dermis and epidermis. These
cells secrete pro-inflammatory cytokines and factors that recruit and activate
T cell populations, the culmination of which results in increased epidermal
proliferation and undifferentiated keratinocytes, ultimately leading to a
compromised skin barrier and the associated scaly or flaky skin [58].
Psoriasis has primarily been thought of as a T cell driven disease, with T cell-
associated cytokines such as TNFα, IL-22 and IL-17 playing critical roles in 
its development, and myeloid cytokines such as IL-23 inducing T cell
differentiation [59, 60]. More recently, however, pro-inflammatory cytokines
of the innate immune system have been recognised as playing pivotal roles
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in psoriatic inflammation. The IL-36 family became of particular interest once
noted by Blumberg et al. to be highly up-regulated in psoriatic skin, and are
amongst the most highly up-regulated genes when comparing lesional to
non-lesional skin [61]. The role of IL-36 cytokines in psoriasis and
pathological inflammation is explored in greater detail in section 1.4.
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1.3 The IL-1 family
The IL-1 family is very strongly associated with inflammation and the innate
immune response. They are comprised of several distinct cytokine members
that signal via their respective IL-1 family receptors and as a result have a
wide-reaching influence on multiple cell types. Though typically associated
with inflammation, the IL-1 family also contains members that work to
regulate both general and specific IL-1 mediated inflammation. Given their
importance in both inducing and regulating inflammation, and their far-
reaching influence, the IL-1 family is of great interest in the context of
inflammatory disease.
Their existence was first observed in the 1940s after it was noted that a
factor in rabbit neutrophil-conditioned supernatant, then termed Leukocytic
Pyrogen, could induce a rapid onset fever in rabbits [62]. Later it was
identified that monocyte-conditioned media contained a factor capable of
augmenting lymphocyte proliferation following antigen contact [63].
Eventually, in the late 1970s, these factors were purified and identified as the
same protein, given the interleukin nomenclature of IL-1 [64]. Shortly
afterwards, cDNA isolation revealed there were in fact two distinct forms of
IL-1; IL-1α and IL-1β [65, 66].  Since then, the IL-1 family has grown to 
include another 9 family members, identified by protein purification and
cloned from cDNA of various cells types or by in silico identification from
gene data banks.
The IL-1 family consists of 11 cytokines. These were originally given an IL-
1F identity from 1-11, but are now known by unique interleukin nomenclature
and have been grouped into three sub families; the IL-1 subfamily, the IL-18
subfamily and the IL-36 subfamily (detailed in Table 1-1). All members of the
IL-1 cytokines, with the exception of IL-1Ra, lack a signal peptide and are
produced as immature intracellular proteins that must be processed into
mature proteins. This processing removes a portion of the N-terminus, and it
is by the size of the pro-piece removed that the IL-1 family is divided into
subfamilies.  The IL-1 subfamily, consisting of IL-1α, IL-1β and IL-33, has the 
largest pro-piece. The IL-18 subfamily has a comparatively smaller pro-piece
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and consists of IL-18 and IL-37. The smallest pro-piece belongs to the IL-36
subfamily which is made up of 5 proteins; IL-36α, IL-36β, IL-36γ, IL-36 
receptor antagonist (IL-36Ra) and IL-38 [67]. The IL-1 cytokines are thought
to have arisen from a common ancestral gene as they have a highly
conserved genetic structure, resulting in each protein folding into a 12-
stranded β-barrel [68]. 
Sub-family Cytokine
agonist/antagonist
Receptor
complex
Cleavage
required for
activity
IL-1
IL-1α 
IL-1β 
IL-33
IL-1Ra
IL-1R1/IL-1RAcP
ST2/IL-1RAcP
IL-1R1




IL-18 IL-18
IL-37
IL-18Rα/IL-18Rβ 
IL-18Rα 


IL-36
IL-36α 
IL-36β 
IL-36γ 
(IL-38)
IL-36Ra
IL-36R/IL-1RAcP
IL-36R



?

Table 1-1 IL-1 family cytokines
Table shows IL-1 family cytokines, their associated signalling complexes and whether
proteolytic processing is necessary for cytokine activation [69-71].
The IL-1 family cytokines signal through IL-1 receptors which belong to a
large receptor superfamily called Toll-IL-1-receptor (TIR) domain-containing
receptors. The IL-1 receptors consist of extracellular Ig-like domains to
which the cytokines bind, and a cytosolic TIR domain that mediates receptor
signalling. Binding of agonist to receptor causes recruitment of an accessory
protein, creating a receptor complex capable of transducing a signal via
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MyD88 and MAP kinases, often culminating in activation of NF-κB.  As 
shown in Figure 1-2 the IL-1 cytokines bind distinct IL-1 receptors but all
require recruitment of the IL-1R accessory protein (IL-1RAcP) for signal
transduction (with the exception of IL-18 which has a unique accessory
protein IL-18Rβ) [72].  In addition to the IL-1 family receptors through which 
IL-1 members transduce signals there are IL-1 family receptors that act in a
regulatory capacity. IL-1R2 is a decoy receptor which binds IL-1 but lacks a
TIR domain and as such cannot transduce a signal. It therefore acts to
sequester IL-1α and IL-1β without producing pro-inflammatory signals [73].  
IL-1R8 is another regulatory receptor which is recruited to IL-1 receptors
similarly to IL-1RAcP but is incapable of transducing signals due to mutations
in its TIR domain [74].
Figure 1-2: IL-1 family receptors
Diagram illustrating the IL-1 family receptors, their respective ligands, and the downstream
signalling pathways [69].
IL-37
IL-37
IL-18Rα IL-18Rβ
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1.3.1 Activation and function of IL-1 cytokines
IL-1 family cytokines influence all aspects of an immune response, ranging
from polarization of T helper cells to TH1, TH2, or TH17 phenotypes to the
activation and regulation innate immune cells such as neutrophils,
monocytes, macrophages and dendritic cells.
As previously mentioned, several IL-1 family cytokines require post-
translational processing in order to become biologically active. Each IL-1
cytokine contains a consensus sequence motif of A-X-D, where A is an
aliphatic residue, X is any residue and D is aspartic acid, within its 1st IL-1
beta-sheet. In order for full activity of an IL-1 cytokine to manifest, some IL-1
members require N-terminal truncation to within 9 amino acids of the A-X-D
motif [71]. However, the manner in which the IL-1 proteins are truncated
varies, and for many this process is poorly understood.
IL-1β and IL-18 activation is dependent upon caspase-1 cleavage that occurs 
at a caspase-1 consensus cleavage site 9 amino acids upstream of the A-X-
D motif [75]. Activation of caspase-1 involves the formation of a cytosolic
signalling complex termed the inflammasome that is present within most
cells. An inflammasome is made up of a number of protein elements
including a cytoplasmic PRR (primarily one of the NLR family), the adaptor
molecule apoptosis-associated speck-like protein containing a caspase
activation and recruitment domain (CARD) (ASC), and caspase-1 [76].
Inflammasomes are typically formed by NLR members such as NLR pyrin
domain-containing 3 (NLRP3), and are named accordingly, but can also be
initiated by other cytoplasmic sensors such as absent in melanoma 2 (AIM2)
and pyrin [77]. Upon PRR activation, the cytoplasmic sensor will recruit ASC
which in turn recruits caspase-1 and facilitates its activation [78, 79]. Once
caspase-1 is active, cleavage of the caspase-1 sensitive IL-1 proteins can
occur, mediating their activation and subsequent secretion from the cell.
Of the IL-1 family cytokines, IL-1β and IL-18 require inflammasome activation 
and subsequent caspase-1 processing to produce mature forms, and this is
known to occur in a two-step process. Firstly cells must be primed, often
through TLR stimulation, to initiate NF-κB dependent synthesis of pro-IL-1β, 
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pro-IL-18 and the sensor components of the inflammasome [80]. A second
signal, activating the inflammasome sensor component, is then required to
initiate the formation of the inflammasome and activation of caspase-1, which
in turn processes the immature IL-1β and IL-18 proteins allowing for their 
secretion [81].  IL-1β is expressed by hematopoietic cells in response to PRR 
activation or stimulation by various inflammatory cytokines including IL-1
itself.  In addition to its traditional fever-inducing function IL-1β influences the 
ILC3s to produce IL-17 and IL-22 and promotes TH17 differentiation [69, 82].
Its dysregulated production is highly linked to autoinflammatory conditions
such as neonatal onset multisystem inflammatory disease (NOMID)
characterized by fever, rash and arthritis.  Whilst the production of IL-1β 
requires an inflammatory stimulus, pro-IL-18 is constitutively expressed by
most cell types. The primary producers of IL-18 are activated macrophages
and monocytes, although keratinocytes are known to contribute to the
production of active IL-18 in inflamed skin. Active IL-18, in the presence of
IL-12 and IL-15, is considered as a TH1 and ILC1 associated cytokine
promoting proliferation of TH1 cells and production of interferon-γ (IFN-γ).  In 
the absence of IL-12 and IL-15, IL-18 can also induce a TH2 phenotype [83].
IL-18 is therefore important in a number of inflammatory skin conditions,
including atopic eczema and psoriasis [84].
IL-1α, unlike IL-1β, does not require N-terminal truncation as it is biologically 
active in its pro-form.  Although both IL-1α and IL-1β signal through the same 
receptor and as such have very similar biological functions, IL-1α has some 
very distinct characteristics that set it apart from IL-1β.  Whereas IL-1β is 
secreted upon maturation and can circulate systemically, IL-1α typically 
associates with the plasma membrane of the producing cell and so acts in a
local capacity [85].  IL-1β is primarily produced by hematopoietic cells, such 
as macrophages and monocytes, but IL-1α is more widely expressed with 
notably high levels in epithelial tissues, including keratinocytes [86]. With
activity in its immature form it has been postulated that IL-1α acts as a DAMP 
in the event of cellular damage causing its release into the extracellular
matrix [87].  Furthermore, the immature form of IL-1α contains a nuclear 
localisation sequence (NLS) within its pro-piece which binds DNA, indicating
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transcription factor activity [88]. Indeed some studies have identified
oncogene functionality of IL-1α [89].  
IL-1α is not the only IL-1 family member to have dual nuclear factor and 
cytokine activity. IL-33 and IL-37 both contain a NLS and can both regulate
gene expression. IL-33 is expressed by a wide variety of cells, including
keratinocytes, both constitutively and in response to stimuli [90]. Similarly to
IL-1α, IL-33 is able to bind its receptor in its pro-form and is released 
primarily through cell death, functioning as a DAMP [87, 91]. As a soluble
protein, IL-33 is known as a TH2 cytokine that drives the polarization of ILC2s
and TH2 cells and is important in allergic inflammatory disease such as
asthma [69, 90]. Whilst as a cytokine IL-33 acts in an inflammatory capacity,
its nuclear localisation appears to have regulatory consequences. IL-33’s N
terminal NLS mediates its trafficking to the nucleus where IL-33 is thought to
act as a transcriptional repressor by inducing chromatin compaction [92, 93].
IL-37 is also known to have anti-inflammatory activity, but to a much greater
extent than IL-33. On both the extracellular and intracellular level IL-37 has
been identified to regulate inflammation. IL-37 is produced in five isoforms
by alternative splicing (IL-37a-e), each with their own specific expression
profiles.  Its expression is inducible by TGF-β in addition to TLR activation 
and IL-1β stimulation [94].  Upon stimulation with LPS, IL-37 has been 
demonstrated to traffic to the nucleus in a caspase-1 dependent manner
where it exerts potent anti-inflammatory mechanisms (as yet not dissected)
resulting in a decrease in both kinase phosphorylation and inflammatory
cytokine production [95, 96]. IL-37 is structurally very similar to IL-18 and is
able to bind the IL-18 receptor α chain.  By doing so IL-37 appears to recruit 
the regulatory IL-1 receptor IL-1R8 (SIGIRR) and further exert anti-
inflammatory activity [97].
IL-1-mediated inflammation is also controlled through the action of IL-1
members IL-1 receptor antagonist (IL-1Ra) and IL-36 receptor antagonist (IL-
36Ra). Whereas IL-37 is known to be a potent regulator of general
inflammation, IL-1Ra and IL-36Ra very specifically regulate IL-1 and IL-36
mediated inflammation by antagonising their specific receptors.
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1.3.2 The IL-36 subfamily
The IL-36 subfamily consists of 4 members; IL-36α, IL-36β, IL-36γ and IL-
36Ra, grouped together as they share the same receptor complex and have
similar biological function [70].  The IL-36 agonists (IL-36α, IL-36β and IL-
36γ) are able to transduce a signal upon binding of their receptor (IL-36R) as 
they facilitate recruitment of the IL-1R accessory protein (IL-1RAcP) thus
enabling signal transduction. IL-36Ra however is able to bind to the IL-36R
but cannot recruit IL-1RAcP and hence acts as a receptor antagonist,
preventing signal transduction [98, 99]. IL-38 is very homologous to IL-36Ra
and may also share the same receptor, so might be thought of as an IL-36
cytokine [100]. Unlike IL-1 and IL-18 members, their expression is quite
restricted, with highest levels being expressed by epithelial cells of skin, joint
and lung tissue. As with other IL-1 family members, the IL-36 cytokines
require N-terminal cleavage for maturation.  Unlike IL-1β and IL-18 the IL-36 
cytokines contain no N-terminal consensus cleavage site, which for a while
mislead the research field engendering the theory that, like IL-1α and IL-33, 
the IL-36 cytokines did not require N-terminal truncation to transduce a
signal. This theory was dispelled when it was demonstrated, by
progressively removing N-terminal amino acids of each protein, truncation to
9 amino acids upstream of the A-X-D motif yielded increases in activity of up
to 10 000 fold [99]. Indeed recent crystallographic data suggests truncation
of the N-terminus 9 amino acids upstream of the A-X-D motif is necessary for
the IL-36 proteins to engage their receptor [101]. The post-translational
processing of IL-36 members is a subject of on-going investigation that is
explored in greater depth later.
With regards to the expression of the IL-36 cytokines, each member is
slightly different. IL-36Ra is constitutively expressed by keratinocytes,
whereas expression of the agonists requires a stimulus. All IL-36 members
are expressed in epithelial tissue of the skin and lung, IL-36β mRNA is 
detectable in synovial tissue and IL-36α expression has been identified in 
human adipose tissue. IL-36 members are also thought to be expressed at
low levels in joint, gut and brain tissue [67, 102-105]. Although the IL-36
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members are predominantly expressed by epithelial tissue, their expression
has also been identified in macrophages, monocytes and dendritic cells. The
expression of IL-36 agonists is inducible by stimulation with inflammatory
cytokines including TNFα, IL-17 and in an autocrine fashion by the IL-36 
agonists themselves, and may be induced after activation of a number of
TLRs [102, 106]. Their release from the cell is poorly understood and is an
ongoing subject of investigation.  As yet the only release of IL-36γ was 
observed in keratinocytes after TLR3 stimulation by polyinosinic:polycytidylic
acid (poly(I:C)), and the mechanism of release was not clearly identified
[107].
Given their abundant expression in the skin, the IL-36 members play a
significant role in skin-based inflammation. As they all signal through the
same receptor complex they influence their cellular environment in the same
way, so any differences between each cytokine will arise through their
differential expression. The IL-36R is widely expressed, so many cell types
respond to IL-36 stimulation. In the skin both keratinocytes and fibroblasts
are IL-36 responsive, secreting a range of pro-inflammatory mediators in
response to stimulation, notably including chemokines IL-8 and CCL20 [106,
108]. IL-36 cytokines have been shown to induce maturation of monocyte-
derived dendritic cells (MDDCs), causing an up-regulation in MHCII antigens,
CD83 and CD86 thus promoting T cell differentiation, and induce LCs to
produce a range of inflammatory cytokines including TNFα and IL-6 [102, 
109]. IL-36 members therefore induce the production of TH1 and TH17
polarising cytokines, promote chemotaxis of activated leukocytes and
maturation of dendritic cells to ultimately drive TH1 cell and TH17 cell
proliferation. The IL-36 cytokines are greatly overexpressed in psoriatic skin,
in which a TH1 and TH17 response is prominent, so it is of no surprise that
the IL-36 cytokines are of great interest in the context of psoriatic disease
[110].
1.4 IL-36 in disease
The IL-36 cytokines are strong inducers of inflammation and are emerging as
being influential in a number of inflammatory conditions. Indeed it is in the
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context of psoriatic inflammation that the IL-36 family is primarily studied.
However, their involvement is notable in a number of other pathologies and
they have also been indicated to have a role in immune defense.
1.4.1 IL-36 in psoriasis and inflammatory disease
The observation that IL-36 members are overexpressed in psoriatic skin first
initiated interest in IL-36 and psoriatic inflammation [108, 110]. Furthermore
it was observed that IL-36γ is one of the top 30 up-regulated genes when 
comparing non-lesional and lesional psoriatic skin, and that IL-36 expression
is far more inducible in psoriatic keratinocytes than healthy keratinocytes [61,
111]. Further evidence that IL-36 plays a significant central role in the
pathogenesis of psoriatic inflammation has been demonstrated through the
development of a number of mouse models. Mice with forced transgenic
overexpression of IL-36α presented with a phenotype very comparable to 
human psoriasis, exhibiting acanthosis, hyperkeratosis and an inflammatory
infiltrate [110]. Although these psoriasis-like plaques spontaneously resolved
after 2-3 weeks, subsequent treatment with phorbol ester bought a return of
plaques within a few days that even more closely resembled human
psoriasis. Furthermore the phorbol ester treated mice had an increased
expression of a variety of psoriasis-associated inflammatory mediators
including IL-23, IL-17 and IL-22 [112]. These cytokines are considered
important in the pathogenesis of psoriasis, stimulating keratinocytes to
produce growth factors and other inflammatory mediators, driving both
epidermal and TH17 cell proliferation and survival. Indeed blocking these
pathways in the phorbol ester treated mice by targeting TNFα, IL-17 and IL-
23 was very effective at preventing the skin lesions. Mouse studies have
been conducted whereby psoriasis-like lesions are induced through the
addition of imiquimod, a TLR7 agonist that has been demonstrated to
strongly induce IL-36. Treatment with imiquimod causes skin thickening,
expression of IL-17 and a notable infiltrate of inflammatory cells into the skin.
These imiquimod induced effects, however, are completely ablated when
performed on IL-36R-deficient mice, implicating a central role for IL-36 [113].
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IL-36 cytokines induce the expression of a number of proteins associated
with psoriasis, including TH17-polarising cytokines. In turn TH17 cytokines
have been demonstrated to increase expression of IL-36 members, indicating
the presence of a TH17-inducing feedback loop [106, 108]. It has also been
shown that IL-36 stimulation of keratinocytes induces secretion CCL20,
promoting influx of TH17 cells and γδ T cells that will further amplify the 
psoriatic inflammation through the secretion of IL-17 and IL-22. Furthermore
IL-36 has been demonstrated to induce secretion of AMPs, the
overexpression of which is a hallmark in psoriasis. Interestingly IL-36 has
been suggested to increase expression of LL37, which has itself been
implicated in the pathogenesis of psoriasis through binding self-RNA and
promoting activation of dendritic cells upon stimulation of TLR7 and TLR8
[108, 114]. The importance of IL-36 in psoriasis was further demonstrated
after identifying nonsense and missense mutations in the gene encoding IL-
36Ra (IL36RN), illustrating the consequences of dysregulated IL-36-
mediated inflammation. With a complete lack of IL-36 regulation, patients
developed a severe systemic life-threatening form of psoriasis called general
pustular psoriasis (GPP). The loss-of-function IL-36Ra mutations have been
termed deficiency of IL-36 receptor antagonist (DITRA) due to the similarity
with deficiency of IL-1 receptor antagonist (DIRA), and have been identified
in a number of different populations. DITRA is the first case of a single gene
mutation giving rise to a psoriatic condition, providing strong evidence of the
importance IL-36-mediated inflammation plays in psoriasis [57, 115, 116].
In addition to psoriasis, the IL-36 cytokines have been implicated in
rheumatoid arthritis and atopic dermatitis, and there is growing interest
around their involvement in pulmonary disease and inflammatory bowel
disease.  IL-36α expression is overexpressed by synoviocytes in both 
rheumatoid and psoriatic arthritis, and stimulation of cultured synoviocytes
with IL-36β is seen to induce secretion of IL-8 and IL-6 [117, 118].  Recent 
RNA trascriptome analysis comparing lesional and non-lesional skin of AD
patients has identified increased expression of IL-36 cytokines in lesional
skin, albeit to a lesser extent than in psoriasis [119].  IL-36α and IL-36γ 
expression has recently been identified to be enhanced in inflamed mucosa
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of patients with inflammatory bowel disease, in particular ulcerative colitis.
This same study showed IL-36 stimulation of intestinal epithelial cell lines
induced expression of a host of inflammatory chemokines and enhanced
activation of NF-κB, highlighting their propensity for promoting pathogenic gut 
inflammation [120].
There is a lot of evidence for a role of IL-36 in inflammatory pulmonary
disease such as asthma and chronic obstructive pulmonary disease (COPD).
Human bronchial epithelial cells have been shown to strongly produce IL-36γ 
in response to a number of inflammatory stimuli, including IL-17, IL-1β, TNFα 
and challenge with cigarette smoke (the causative agent in COPD) [121].
Rhinovirus has also been shown to induce IL-36γ expression, and in analogy 
to psoriatic keratinocytes is more inducible in bronchial epithelial cells from
asthmatic donors than healthy cells [122]. Furthermore bronchial epithelial
cells respond to IL-36 through NF-κB and MAPK activation producing 
neutrophil and TH17 chemokines IL-8, CXCL3 and CCL20 [103]. The effect
of IL-36 on lung inflammation has been studied more in depth in mice.
Intranasal administration of IL-36γ results in rapid infiltration of neutrophils 
and other immune cells and an increase in mucus production [123].
Neutrophil infiltration has been implicated in the pathogenesis of a number of
pulmonary diseases including asthma, acute respiratory distress syndrome
and COPD, so as an inducer of neutrophil chemotaxis IL-36 is thought to
contribute to the development of these conditions.
1.4.2 IL-36 in immune defence and wound healing
The majority of research on the IL-36 subfamily has been conducted in the
context of pathogenic inflammation and as yet there is very little
understanding with regards to their function in the immune system under
normal conditions. With this said, there is emerging evidence suggesting that
IL-36 might play a role in immune defence and wound healing at epidermal
barriers. It has been demonstrated that both live and heat-killed Aspergillus
fumigatus conidia and hyphae strongly induce expression of IL-36γ through 
TLR4 and dectin-1 pathways. Furthermore specifically inhibiting IL-36
signalling by IL-36Ra reduced A. fumigatus-induced expression of IL-17 and
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IFNγ, suggesting IL-36 may be important in driving TH17 and TH1 responses
in response to Aspergillus infection [124]. Given the IL-36 proteins give rise
to a psoriatic phenotype, and that a psoriatic phenotype is very similar to that
seen when fighting a fungal infection, it is perhaps logical that IL-36 proteins
are important in fungal immunity.
It has also been postulated that IL-36 cytokines may play a role in wound
healing. Although IL-36 has been implicated in the pathogenesis of
inflammatory bowel disease, there is evidence to suggest the IL-36/IL-36R
axis has a role in resolution and repair of damaged epithelial mucosa. This
was demonstrated through inducing colitis by dextran sodium sulphate (DSS)
in mice that lacked IL-36R. It was observed that IL-36R knock out mice
initially had less severe colitis than wild type mice, indicating an inflammatory
role for IL-36R signalling. However, wild type mice eventually recovered after
stopping DSS treatment, whereas colitis in the IL-36R knock out mice
progressed to the point the animals had to be euthanized. It was
subsequently noted that IL-36R was crucial for the continued expression of
IL-22 in colons of wild type mice, an important pro-resolving cytokine that
promotes epithelial growth, restitution and protects from intestinal
inflammation [125].
IL-36 is well established as a pro-inflammatory cytokine family that has a
pathogenic role in a number of inflammatory conditions, but it is poorly
understood in its normal function and may have a long term function in
inflammation resolution. This is an area of IL-36 research that should be
increased as it may yield insight into ways of better regulating IL-36-mediated
inflammation and promoting inflammation resolution.
1.5 Post-translational processing of inflammatory
mediators
As mentioned above, many IL-1 members are synthesized as immature
proteins that require post-translational proteolysis in order to gain biological
activity.  Traditionally, as is the case with IL-1β and IL-18, this occurs in a 
caspase-1 dependent fashion involving formation of an inflammasome
24
proceeded by secretion of the mature cytokines. However, many IL-1 family
proteins are processed by a range of different proteases, in both intracellular
and extracellular environments. Post-translational proteolytic processing of
inflammatory mediators is not limited to the IL-1 family. It is a method utilized
by the immune system to regulate numerous inflammatory processes with
both pro-inflammatory and regulatory consequences.
1.5.1 IL-1 post-translational processing
As mentioned above, IL-1β and IL-18 are both processed to their mature 
forms in a caspase-1 dependent manner after initiation of an inflammasome
complex [75, 126]. Other members, however, do not contain a caspase-1
consensus cleavage site and thus are processed by other means.
Furthermore, whilst many IL-1 family cytokines require proteolytic processing
to become biologically active, some members are active in their immature
form [91]. Yet, these have still been demonstrated to be susceptible to
proteolytic cleavage having both activating and inactivating effects.
Additionally, whilst cleavage of IL-1 family members often occurs within the
cell, and in the case of IL-1β and IL-18 is a prerequisite of protein secretion, 
many IL-1 members are released in their immature forms and processed by
extracellular proteases.
IL-1α is biologically active in its immature form and is released from cells 
upon mechanical tissue damage, acting as a DAMP to alert neighboring cells
to danger [15, 127].  Whilst IL-1α is released in its immature form, it also 
undergoes intracellular truncation in activated cells by the calcium-dependent
cysteine protease calpain, following which it is released into the extracellular
space [128]. Comparisons between the unprocessed and calpain-processed
IL-1α show that truncation causes up to a 5-fold increase in IL-1α activity by 
increasing its affinity for IL-1R, indicating activation of cells and calpain-
mediated IL-1α processing may produce a stronger immune response than 
tissue damage alone [129].  Extracellular IL-1α is also processed to its 
mature form by neutrophil-derived proteases such as neutrophil elastase that
are present in the extracellular environment, increasing its activity to a similar
extent as calpain [129].
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IL-33, like IL-1α, is active in its immature form and released primarily upon 
cell damage but can undergo post-translational processing to affect its
biological activity. Processing of immature IL-33 can both increase and
decrease its activity. Apoptotic caspases-3 and -7 have been demonstrated
to inactivate IL-33, perhaps as a method of controlling inflammation during
apoptosis, whilst similarly to IL-1α, processing of extracellular IL-33 by 
neutrophil-derived proteases increases its activity by up to 10-fold [130, 131].
Extracellular processing of IL-1 members is also observed with IL-1β and IL-
18. Neutrophil and mast cell derived proteases have been demonstrated to
process and activate pro-IL-1β and pro-IL-18 in the event of pre-cursor 
release into the extracellular environment after tissue damage or pyroptosis
[132, 133]. These findings all show post-processing is an integral part of IL-1
biology; not only intracellular activation and secretion, but in immune
modulation in the extracellular environment.
1.5.2 IL-36 post-translational processing
The IL-36 members are unique in the sense that all other IL-1 family
members are either activated by caspase-1 or have biological activity in their
full length immature form. Unlike others of the IL-1 family, the IL-36 proteins
contain no caspase-1 cleavage motif, yet, as identified by Towne et al.,
require precise truncation 9 amino acids upstream of the A-X-D motif.
However, as illustrated in Figure 1-3, the amino acid sequence surrounding
the cleavage sites bear little homology to one another. As a result, despite
understanding where cleavage must occur, the responsible physiological
proteases have remained elusive. It has been postulated that as the
sequences surrounding the cleavage sites are markedly different, a number
of different proteases may be responsible for their cleavage. There has been
very little evidence to suggest the IL-36 cytokines undergo intracellular
processing, and the method of release from cells is equally poorly
understood. However, analogous to other IL-1 family cytokines, there is
evidence to suggest that extracellular IL-36 cytokines are susceptible to
proteolytic processing by neutrophil-derived proteases, which may act to
enhance cytokine activity [134]. Work conducted by Henry et al. identified
neutrophil elastase, cathepsin G and proteinase 3 as capable of processing
IL-36 cytokines resulting in an increase in their biological activity despite not
producing the active forms of IL-36α or IL-36γ, and furthermore identified 
cathepsin G to produce the active truncation of IL-36β, highlighting the 
importance of neutrophils in processing extracellular IL-36. However, as of
yet, the active forms of IL-36 cytokines identified by Towne et al. have not
been isolated in vivo, and only extracellular activation of the cytokines has
been shown in vitro.
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 IL-36α:  ------------MEKALKIDTPQQGSIQDINHRVWVLQDQTLIAVPRKDRMSPV
 IL-36β:  -------------MNPQREAAPKSYAIRDSRQMVWVLSGNSLIAAPLSRSIKPV
 IL-36γ:  MRGTPGDADGGGRAVYQSMCKPITGTINDLNQQVWTLQGQNLVAVPRSDSVTPV
IL-36Ra: ----------------MVLSGALCFRMKDSALKVLYLHNNQLLAG--GLHAGKV
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pathway, however can be processed by a number of proteases, such as
metalloproteinases, increasing its activity after N-terminal truncation [135,
136]. Similarly to the IL-1 family members, some CXC chemokines contain a
motif in their N-terminus (ELR motif), and it has been shown that N-terminal
truncation of these CXC chemokines up to the ELR motif enhances their
biological activity [137, 138]. However, cleavage within the ELR motif
deactivates chemokine activity. MMP12 cleavage of CXC chemokines in
their ELR motif is recognized as an important step in inflammation resolution
by halting inflammatory cell influx and favoring a wound healing phenotype
[34].
Proteolytic processing of both CC chemokines and CXC chemokines that
lack an ELR motif has been demonstrated to decrease their biological
activity, imparting a regulatory effect on inflammation. Indeed it has been
shown that N-terminal truncation of the monocyte chemoattractant proteins
(MCPs) of the CC family causes a loss in signal transduction whilst retaining
receptor binding capacity, generating chemokine antagonists from previously
chemotactic proteins [35, 139].
Proteases are thus critical regulators of the immune response, capable of
both enhancing and dampening an immune response, depending on the
cocktail of proteases and the balance of protease inhibitors present in the
inflammatory environment.
1.6 Project aims
IL-36 cytokines have become well established as important cytokines in the
development of pathological inflammation, with a particularly significant role
in psoriasis. However, despite this, a lot remains unclear with regards to
their mechanisms of action and the processes that regulate their activity. As
IL-1 family proteins, it is of vital importance to understand the factors that
regulate their activity in order to fully appreciate the dynamics of IL-36-
mediated inflammation. Furthermore, with such an emphasis in the literature
on elucidating their pathological role, for many years research into their
physiological function has been somewhat neglected. Yet, recent findings
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are implicating IL-36 cytokines may have an active role in immune defence.
For a comprehensive understanding of the IL-36 cytokines, it is necessary to
understand not only how they are involved in pathological inflammation, but
also how they contribute to an effective immune response under normal
conditions.
The primary aims of this research are as follows:
 To elucidate the mechanisms of IL-36 cytokine activation within the
skin compartment and gain an appreciation of how physiological IL-36-
mediated inflammation contributes to immune defence.
Additional aims were:
 To generate and characterize IL-36-specific monoclonal antibodies to
facilitate further research into IL-36 protein biology, with a particular
focus on developing an IL-36γ-specific ELISA with which endogenous 
IL-36γ can be measured. 
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Chapter 2 - Materials and Methods
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2.1. Materials
Unless otherwise stated all reagents were analytical grade and obtained from
Sigma-Aldrich, UK.
2.1.1.Buffers used
Tape stripping lysis buffer: 20 mM Tris pH 7.4, 150 mM NaCl, 1 mM DTT,
5 mM EDTA, 1 mM PMSF, 1% Triton X-100
Bacterial lysis buffer: 20 mM Tris pH 8, 10% Glycerol, 5 mM MgSO4
2TY bacterial media: 3.3% Tryptone soya broth, 1% Yeast extract (Oxoid,
Thermo Scientific)
Ni2+ column buffer: 500 mM NaCl, 20 mM Tris pH 7.4, 10% Glycerol, 20-
500 mM Imidazole
Size exclusion buffer: 150 mM NaCl, 20 mM TRIS pH 7.4
Hybridoma freezing media: Foetal Calf Serum, 10% DMSO
Western blot transfer buffer: 90 mM glycine, 25 mM Tris 20% Methanol
Western blot blocking buffer: Tween-20 0.1% in PBS + 5% milk
SDS-PAGE running buffer: 25 mM Tris, 90 mM glycine, 0.1% SDS
SDS-PAGE loading buffer: 62.5 mM Tris pH 6.8, 10% Glycerol, 2% SDS,
0.001% bromophenol blue +/- 5% β2-mercaptoethanol 
Coomassie stain: 40% Methanol, 10% Acetic Acid, 0.05% Brilliant Blue R-
250, in dH2O
Coomassie de-stain: 10% Acetic Acid, 40% Methanol, in dH2O
TBE: 0.09 M Tris, 0.09 M Boric acid, 2 mM EDTA
6x DNA loading dye: 0.05% Orange G, 30% glycerol
Nuclear isolation lysis buffer: 320 mM sucrose, 5 mM MgCl2, 10 mM
HEPES, 1% Triton X-100 at pH 7.4
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Nuclear isolation wash buffer: 320 mM sucrose, 5 mM MgCl2, 10 mM
HEPES at pH 7.4
Nuclear isolation staining buffer: 320 mM sucrose, 5 mM MgCl2, 10 mM
HEPES, 1% BSA, 0.1% NaN3 at pH 7.4
NP-40 lysis buffer: 1% NP-40 (or equivalent), 0.15 M NaCl, 10 mM EDTA,
10 mM Tris-HCl pH 8
Cell extract buffer: 20 mM Hepes, pH 7.5, 10 mM KCl, 1 mM EDTA, 1mM
DTT
Cell fractionation buffer: Tris HCl, pH 7.4, 0.25 M sucrose, 1 mM EDTA, 1
mM DTT
ELISA blocking buffer: 2% BSA, 0.1% Tween-20 in PBS
2.1.2.Cell lines and bacterial strains used
2.1.2.1. Cell lines
Human Embryonic Kidney 293 T (HEK293T) are adherent derivatives of the
human embryonic kidney 293 cell line that was established by transformation
with sheared adenovirus type 5 DNA [140]
HaCaT cells are an adherent spontaneously transformed cell line derived
from adult human keratinocytes [141]
A549 cells are adenocarcinomic human alveolar basal epithelial cells [142]
2.1.2.2 Bacterial strains
BL21(DE3) and Shuffle T7 Xpress Escherichia coli were used for cloning and
protein expression respectively:
BL21(DE3) genotype: F– ompT hsdSB(rB–, mB–) gal dcm (DE3)
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Shuffle T7 Xpress genotype: F´ lac, pro, lacIQ / Δ(ara-leu)7697 araD139 
fhuA2 lacZ::T7 gene1 Δ(phoA)PvuII phoR ahpC* galE (or U) galK 
λatt::pNEB3-r1-cDsbC (SpecR, lacIq) ΔtrxB rpsL150(StrR) Δgor Δ(malF)3 
2.2 General Methods
2.2.1 Obtaining primary cells
All human samples were taken in accordance with the Declaration of Helsinki
and participants gave their written informed consent (REC number:
11/YH/0368; 14/NE/1199). Healthy volunteers were also recruited from the
university and written consent was sought (BIOSCI09-001).
2.2.2 Peripheral blood collection
30-60 ml of peripheral blood was collected from healthy donors and psoriatic
patients in sterile Vacutainer® lithium heparin (BD Biosciences, Oxford, UK)
for isolation of neutrophils and peripheral blood mononuclear cells (PBMCs).
Ethical approval was sought from the University of Leeds for healthy donors
and national ethical approval was gained for patient material. Consent of
donors was sought and anonymity 70 was strictly adhered to. Blood was
kept at room temperature after donation and used immediately.
2.2.3 PMN isolation and culture
Whole blood was separated by using density gradient by layering Histopaque
1077 (Sigma- Aldrich, UK) in equal amounts on top of Histopaque 1119
(Sigma-Aldrich, UK). 1:2 PBS-diluted whole blood was then layered on top of
the Histopaque 1077 and centrifuged at 400 g for 30 minutes with no brake.
The polymorphonuclear cell (PMN) layer was then removed using a 10 ml
serological pipette and cells were washed with PBS. Red blood cell lysis was
conducted to remove contamination of erythrocytes by resuspended the
pellet in 0.2% NaCl and repeatedly inverting the falcon tube 10x. An equal
volume of 1.6% NaCl was then added and inverted once. Cells were
centrifuged at 350 g for 4 minutes and re-suspended in RPMI-1640
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supplemented with 5% FCS (PromoCell, Heidelberg, Germany), 0.5% L-
Glutamine (Sigma-Aldrich, UK) and 0.05 mg/ml 72 streptomycin and 50 U/ml
penicillin (Sigma-Aldrich, UK). Cells were stimulated on day of separation
and were not cultured for longer than an hour.
2.2.4 Cell Culture
Human primary fibroblasts (HPFs) and all adherent cell lines were grown in
Dulbecco’s Modified Eagle Medium (DMEM) (Lonza, Slough, UK)
supplemented with 10% foetal calf serum (FCS), 0.5% L-Glutamine (Sigma-
Aldrich, UK), 0.05 mg/ml streptomycin and 50 U/ml penicillin (Sigma-Aldrich,
UK). Cells grown in suspension were cultured in Roswell Park Memorial
Institute (RPMI) 1640 media supplemented in the same way. Human
primary keratinocytes (HPKs) were grown in Keratinocyte Growth Media Kit II
(KGM-2) (PromoCell, Heidelberg, Germany). Prior to keratinocyte
stimulation, media was changed to KGM-2 minus hydrocortisone and human
epidermal growth factor.
HPKs were grown to 70% confluence before passaging, whilst HPF and cell
lines were grown to 90% confluence. Adherent cells were washed with
sterile PBS and dissociated by incubation with trypsin (170 U/ml)-EDTA (200
mg/ml) (Lonza, Slough, UK) for two to ten minutes. Equal quantity of serum-
containing DMEM was added to HPFs and other cell lines to neutralise the
trypsin before washing and re-seeding. Trypsinized HPKs were neutralised
by addition of trypsin neutralising solution (Lonza, Slough, UK) before
washing and re-seeding. HPFs and cell lines were frozen by suspension in
FCS and 10% DMSO and placed in a Mr. FrostyTM (Thermo Scientific) at -
80˚C for 24 hours before moving to liquid nitrogen for long term storage.  
HPKs were similarly frozen after suspension in PromoCell freezing media
(PromoCell, Heidelberg, Germany).
Activity assays and transfections were performed in OptiMEM (Life
technologies) supplemented with 0.05 mg/ml streptomycin and 50 U/ml
penicillin (Sigma-Aldrich, UK).
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2.2.5 Cell transfection and siRNA knockdown
Cells were cultured in supplemented growth media to a confluency of 80-90%
in 6-well plates. Prior to transfection, growth media was substituted for
OptiMEM (Gibco, Life Technologies, UK).  1 μg of DNA was diluted in 400 μl 
of OptiMEM and then mixed with 6 μl of TurboFect transfection regent 
(Thermo Scientific, UK). The solution was vortexed and incubated for 15-20
minutes at room temperature before administering to cells in a drop-wise
fashion. After 8 hours the media was removed and replaced with 2 ml of
fresh OptiMEM.
For siRNA knock down, cells were grown as above. For each well, 5 pM
siRNA was diluted in 200 µl of OptiMEM and incubated at room temperature
for 5 minutes.  8 μl of Lipofectamine (Thermo Scientific, Waltham, MA) was 
diluted in 200 μl of OptiMEM and incubated at room temperature for 5 
minutes. The lipofectamine and siRNA preparations were then mixed for 20
minutes at room temperature. 1.6 ml of culture media (without
penicillin/streptomycin) was added to the lipofectamine/siRNA mixture. The
culture media was removed from each well and the siRNA preparations
added. Cells were incubated for 24 hours at 37°C. The culture media was
then replaced with OptiMEM and cells incubated for a further 48 hours.
Following incubation, cell supernatants were removed and frozen at -80°C.
2.2.6 Growth assays
Cells were seeded in 24 well plates at a confluence of 10% with or without
stimulation and grown in an IncuCyte® ZOOM system. Cells were scanned
hourly over a period of growth ranging from 72-96 hours and confluence was
analysed by the IncuCyte ZOOM system once all data were collected.
2.2.7 Cell lysis
Whole cell extracts were prepared by lysing cells in a NP40 lysis buffer
supplemented with protease inhibitors (Complete EDTA-free protease
inhibitors, Roche). Cells were removed from the tissue culture plate in lysis
buffer and left on ice for 20 minutes before centrifugation for 10 minutes at
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15,000 g to remove cell debris. Supernatant from the lysed cells was
removed and samples were stored at -80°C or used immediately.
Cells to be used for activity assays were lysed in a hypotonic cell extract
buffer. Cells were re-suspended in cell extract buffer and incubated on ice
for 20 minutes, before being transferred to a Dounce-type homogeniser and
undergoing homogenisation with 15 strokes of a B-type pestle.
Centrifugation of the lysates at 15,000 g for 10 minutes removed cellular
debris before storage at -80°C.
2.2.8 Cell fractionation
Cells were resuspended in cell fractionation buffer and incubated on ice for
20 minutes, before being transferred to a Dounce-type homogeniser and
undergoing homogenisation with 15 strokes of a B-type pestle. The cell
lysates were centrifuged at 1000 g for 10 minutes to remove nuclei and cell
debris. Supernatant was collected then centrifuged at 15,000 g for 10
minutes to separate the lysosomes from the cytosol. After removing and
storing the cytosol at -80°C, the lysosomes were resuspended in cell extract
buffer and incubated on ice for 20 minutes. The lysosome fractions were
subject to 3 serial freeze-thaw cycles before centrifugation at 15,000 g for 30
minutes to remove debris. Supernatants were stored at -80°C until use.
2.2.9 Activity assays
HaCaTs were plated at 105 cells/well (24-well plate) in supplemented DMEM
(as described in section 2.2.4) and grown to approximately 70% confluency
before the media was replaced with OptiMEM. Treatments detailed in results
were added in conjunction with OptiMEM and cells were incubated for 24
hours at 37°C. Lysosome fractions were pre-incubated with protease
inhibitors for 3 hours at 4°C before being added to HaCaTs when performing
inhibition studies. For cell supernatant activity assays, A549 cells, primary
keratinocytes or primary fibroblasts were plated at 0.5x105 cells/well (6-well
plate) in supplemented DMEM. Once 100% confluent, the media was
replaced with OptiMEM and cells incubated for a further 24 hours. Following
incubation, the conditioned media was removed and frozen at -80°C. Prior to
36
activity assays, the conditioned media was supplemented with 0.1 mM DTT.
The conditioned media was added to HaCaTs with or without the proteins
being tested, as detailed in the results. Following incubation, cell
supernatants were removed and frozen at -80°C.
2.2.10 Apoptosis induction
HaCaTs were grown in supplemented DMEM to a confluency of 70% before
initiating serum starvation. Cells were then washed 3 times with PBS to
remove residual serum and media was replaced with serum free DMEM with
or without proteins tested. Cells were serum starved for 24 hours before
treatment with staurosporin (48 hours for cells to be analysed for caspase-3
activity). 500 ng/ml staurosporin was added to cells for 4 hours to induce
apoptosis. Staurosporin-containing media was removed and cells were
washed in PBS to remove residual staurosporin. Cells were then either
immediately analysed for caspase-3 activity or incubated for a further 24
hours in serum free DMEM with or without stimulation before analysis of
PARP cleavage or nuclear isolation and analysis of DNA degradation by flow
cytometry.
2.2.11 Annexin V PI assays
Apoptosis assays were carried out using an annexin V PI staining kit
obtained from BioLegend in accordance to the provided protocol and
analysed by flow cytometry. Adherent cells were dissociated using EDTA to
minimise cell membrane damage.
2.2.12 CellEvent Caspase-3/7 activity assay
CellEvent Caspase-3/7 green detection reagent sourced from ThermoFischer
Scientific was used to label apoptotic cells. After induction of apoptosis
(detailed in section 2.2.10), cells were incubated with CellEvent at 5 µM for
30 minutes. Fluorescent cells were imaged by an IncuCyte using an
excitation wavelength of 460 nm and an absorption wavelength of 524 nm,
and by phase contrast. Data was analysed by the IncuCyte Zoom software.
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2.2.13 Nuclear isolation and staining
Cells were trypsinized and washed 2x in cold PBS before re-suspension in
nuclear isolation lysis buffer at 106 cells/ml. Cells were gently vortexed and
left on ice to lyse for 30 minutes. The lysed cells were centrifuged at 1000 g
for 5 minutes at 4˚C to pellet the nuclei.  The cytoplasmic fraction was 
removed and stored at -80˚C for future analysis.  The nuclear pellet was 
washed 2x in nuclear isolation wash buffer, then 105 nuclei were re-
suspended in 100 µl nuclear isolation staining buffer and stained with
propidium iodide at 50 µg/ml for 15 minutes. The samples were made up to
500 µl in nuclear isolation staining buffer and analysed by flow cytometry.
2.2.14 Flow cytometry
Flow cytometry was performed on a BD LSRFortessa machine and data
collected using BD FACSDiva software. 5000 – 10,000 events were
collected and data was analysed with FlowJo software.
2.2.15 Fixing and staining cells for immunofluorescence
Following culture of cells on a 13mm glass cover slip in a 24 well plate cells
were washed 3 times with PBS. 4% paraformaldehyde was then added to
cells and incubated at room temperature for 15 minutes. Cells were washed
with PBS 3 times then permiabilized with 0.1% saponin for 10 minutes.
Following another wash cells were blocked with 2% BSA in PBS for 30
minutes at room temperature with agitation. Cells were incubated with 1
µg/ml of primary antibodies diluted in PBS containing 2% BSA and 0.05%
saponin for 1 hour at room temperature with agitation. After 4 washes in
PBS, cells were incubated in the dark with 1 µg/ml of secondary antibody
diluted in PBS containing 2% BSA and 0.05% saponin for 1 hour. The cells
were thoroughly washed with 4 x 10 minute washes in PBS before being
mounted onto microscope slides using ProLong® Gold antifade containing
4',6-diamidino-2- phenylindole (DAPI) (Life Technologies). Once mounted,
slides were kept at 4°C before imaging using an inverted LSM700 confocal
microscope coupled to a LSM Image Browser.
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2.2.16 Mouse inoculation and antibody titre analysis
Mouse inoculation was performed by Dr Delyth Reid at the University of
Aberdeen. Mice were subcutaneously immunised with 200 µl PBS
containing 50 µg of either recombinant IL-36α K6, IL-36γ S18, IL-36Ra V2 
and IL-38 in combination with Complete Freund’s Adjuvant (CFA). A second
subcutaneous immunisation was performed 3 weeks later with 200 µl
containing 25 µg of the same proteins in combination with Incomplete
Freund’s Adjuvant (IFA). Tail bleeds were performed 7 days after the second
subcutaneous immunisation by cutting off 0.5 cm of the mice tails and
collecting 100 µl blood. Blood was allowed to clot and serum was removed.
Antibody titre was estimated by serial dilution of serum over a 96 well plate
coated with 200 ng/well of antigen and detecting bound antibody by addition
of HRP-conjugated anti-mouse antibody. A final intra-peritoneal
immunisation was performed 4 days prior to the fusion without any adjuvant.
2.2.17 Hybridoma fusion and positive selection
Hybridoma fusion was performed with the help of Dr Delyth Reid. Immunised
mice were humanely killed by authorised personnel. Mice were rinsed with
70% ethanol before removal of the spleen via an abdominal incision. The
spleen was rinsed with serum free RPMI before homogenisation. Frosted
microscope slides were rinsed with 70% ethanol and allowed to air dry before
wetting with serum free RPMI. The spleen was homogenised by grinding
between the frosted microscope slides to release cells. Homogenised spleen
was washed with serum free RPMI to collect cells and filtered through a BD
falcon strainer into a falcon tube.
Mouse splenocytes were fused with SP2 myeloma cell line obtained from
ECACC. SP2 cells were washed in HBSS before mixing with mouse
splenocytes at a ratio of 5:1. After washing in RPMI, cells were resuspended
by gentle tapping. 1 ml PEG1500 was added drop-wise over 30 seconds
whilst simultaneously gently agitating the SP2/splenocyte mix in a 37°C
water bath. After a further 30 seconds, 1 ml of RPMI was similarly
administered over 90 seconds, then 4 ml over 2 minutes, followed by 5 ml
over 2 minute. The cells were rested for 2-3 minutes before washing with
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RPMI. The pellet was resuspended in 100 ml RPMI supplemented with 20%
Foetal Calf Serum and hypoxanthine-aminopterin-thymidine (HAT) then
plated out into 10 x 96 well plates. Spleen cells and SP2 cells were added
separately to 2 wells for controls to ensure HAT selection was working.
Media was refreshed after 3 days by replacing 100 µl of media with fresh
HAT selection media. After 5 days HAT media was replaced with HT
medium to remove the selective pressure and colonies were allowed to grow.
2.2.18 Monoclonal hybridoma screening and selection
Immunosorbent 96 well plates were coated with avidin at 5 µg/ml overnight
then washed and coated with biotinylated target proteins at 2 µg/ml. Once
fusion colonies reached a size visible to the naked eye, 100 µl of neat
hybridoma supernatant was removed and tested by ELISA. 1:10000 diluted
HRP-conjugated goat anti-mouse antibody (SIGMA) was used as a detection
antibody, and TMB solution used for colorimetric analysis. Positive colonies
were grown up to be subject to a limiting dilution for monoclonal hybridoma
selection.
Bulked up positive polyclonal hybridomas were diluted to 10 cells per ml and
plated out into 2 x 96 well plates per clone, 100 µl per well, to give 1 cell per
well. These were grown until colonies became visible to the naked eye
before screening for positive colonies as above. Isolated positive monoclonal
hybridomas were bulked up for antibody production.
2.2.19 Tape stripping
Tape stripping was performed by Dr Anna Keszegpal. Samples were
collected with written informed consent in place of the patients, taken in
accordance with the Declaration of Helsinki. Written consent was also
sought for collecting samples from healthy volunteers recruited from the
University of Leeds. The severity of lesions was clinically assessed before
sample collection using D-squame adhesive discs of 3.8 cm² (Cuderm;
Dallas TX). Non-lesional skin samples were taken preferably from the ventral
lower arm area whereas location of lesional samples was guided by lesion
appearance. Only non-erosive, non-oozing lesions were tape stripped. The
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tapes were administered to the skin using gentle pressure for 5 seconds.
The first tape was discarded and 10 subsequent tapes collected were put in
an empty container and immediately stored on dry ice for transportation, or
storage at -80°C until processing for protein extraction. For extraction tapes
were placed in tape stripping lysis buffer for 30 min at 4 °C. Samples were
sonicated for 20 seconds 3 times with a 20 second interval on ice between
each sonication. Samples were centrifuged for 10 min at 15,000g before
removal of supernatants and subsequent storage at -80°C.
2.2.20 Candida skin equivalent experiments
Skin equivalents and Candida albicans skin equivalent experiments were
cultured and conducted by Dr Jeanette Wagener from the University of
Aberdeen.
2.3 Molecular biology
2.3.1 Agarose gel electrophoresis
Gels were prepared with electrophoresis grade agarose dissolved in 1x TBE
containing 0.2 μg/ml Ethidium Bromide.  Samples were mixed with 6x DNA 
loading dye and run at 100 V alongside 1 kb or 10 kb DNA ladders
depending on size of the sample. DNA in agarose was observed and
photographed under short-wave UV light for observation or long-wave UV
light when further cloning was required.
2.3.2 SDS-Polyacrylamide gel electrophoresis (PAGE)
Samples were mixed with loading buffer and boiled for 5 minutes. Following
brief centrifugation, samples were loaded onto a 4% polyacrylamide stacking
gel (pH 6.8) and resolved on a 10-15% acrylamide gel (pH 8.8) alongside
molecular weight markers (New England Biolabs). 1.5 mm gels were cast
and run using a Mini PROTEAN III gel system (Biorad). Gels were run in
SDS-PAGE running buffer at 0.03-0.04 Amps per gel until good separation
was achieved. Gels were either analysed by Coomassie staining followed by
de-stain or were used in Western blots.
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2.3.3 Western and dot blot
For western blotting, electrophoresis resolved polypeptides were transferred
to HybondC+ nitrocellulose (Amersham biosciences) membranes in transfer
buffer by applying 100V for 1 hour. In dot blotting samples were dotted
directly onto HybondC+ nitrocellulose membranes applied through a dot blot
apparatus via suction. Dot blot and transferred western membranes were
blocked for 1 hour in blocking buffer before addition of primary antibodies
diluted to the concentration advised by the manufacturer in blocking buffer.
Membranes were incubated with agitation for 1 hour at room temperature
and then washed with PBS 0.1% Tween-20 3 times each for 5 minutes at
room temperature with agitation. Secondary horse radish peroxidase (HRP)
antibodies (Sigma-Aldrich, UK) were diluted to a concentration advised by
the manufacturer in blocking buffer and membranes were incubated for 1
hour with agitation at room temperature. Membranes were then washed as
before. The ECL was used as per manufacturer’s instructions (GE
Healthcare) to detect specific antibody binding to membranes and emitted
light was detected on X-ray film (GE Healthcare) following incubation of
varying incubation times from 10 seconds to 5 minutes.
2.3.4 PCR for cloning
The proteins of interests’ sequences were amplified from template DNA using
sequence-specific primers (see Appendix) in conventional PCR using KOD
hot start DNA polymerase (Novagen). Samples of the amplified PCR
products were run on 1% agarose gels and compared to a DNA marker to
verify the product size. PCR products to be ligated into TA overhang
constructs (Champion pET SUMO expression system, Invitrogen, USA) were
incubated with TAQ polymerase (Promega, USA) for 20 minutes at 72˚C to 
generate an adenosine overhang. After incubation, the products were run on
a 1% agarose gel for purification, excised carefully with the aid of short wave
UV for DNA visualisation, and extracted by QIAquick gel extraction kit
(Qiagen) in accordance to the manufacturer’s instruction.
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2.3.5 Restriction digest
PCR products and vectors were incubated with relevant restriction enzymes
with 1% BSA in optimal buffers (New England Biolabs) at 37˚C for 3 hours.  
Alkaline phosphatase was added to the vector for the final hour of incubation
to prevent vector re-ligation. The digest products were run on a 1% agarose
gel then excised and purified using QIAquick gel extraction kit (Qiagen)
following manufacturer’s instructions.
2.3.6 Ligation
Digested PCR products and vectors were ligated at a molar ratio of 1:3, with
1 ng of insert and 3 ng of vector. T4 ligase was added to the manufacturer’s
instruction (Invitrogen, USA), and the reaction was incubated at 16˚C 
overnight.
2.3.7 Transformation
The ligation mix was added to thawed competent bacteria on ice for 30
minutes.  The bacteria/DNA mix was then heat shocked at 42˚C for 30 
seconds and returned to ice for a further 2 minutes, before addition of SOCS
medium (Invitrogen, USA) and incubation at 37˚C for 1 hour.  The 
transformed bacteria were then plated out on 1% agar plates containing
relevant selective antibiotics and incubated overnight at 37˚C. 
A colony PCR using TAQ polymerase (Promega, USA) was performed on
colonies that had formed overnight to identify successful ligation and
transformation. Positive colonies were grown up in 2YT media and plasmid
DNA was extracted by QIAprep Spin Miniprep Kit (Qiagen) before being sent
to GATC-Biotech, Germany for Sanger-sequencing to confirm insert DNA
sequence.
2.3.8 Expression of proteins in E. coli
Sequence-verified constructs were transformed into the expression strain of
E. coli BL21-CodonPlus(DE3)-RIPL (E. coli B F– ompT hsdS(rB – mB–)
dcm+ Tetr gal λ(DE3) endA Hte [argU proL Camr] [argU ileY leuW 
Strep/Specr]) that contain a plasmid encoding a Lac inducible T7 polymerase
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(DE3) and a plasmid encoding rare tRNAs required for the expression of
mammalian proteins (RIPL). Starter cultures 1/50th the volume of the desired
expression culture were incubated overnight at 37˚C in 33 µg/ml kanamycin 
and 33 µg/ml chloramphenicol in order to inoculate the larger cultures
containing the same antibiotics.  The expression cultures were grown at 37˚C 
until an optical density of 0.6-0.8 (at 600 nm), indicative of an exponential
growth phase, was reached. Expression was then induced by addition of
isopropyl β-D-1-thiogalactopyranoside (IPTG) at 0.8 mM and cultures were 
incubated at 25˚C overnight. 
Cultures were centrifuged at 4000 g for 10 minutes to pellet the bacteria.
Supernatant broth was discarded and the cells were re-suspended in
bacterial lysis buffer with additional lysozyme (0.35 mg/ml) and DNase (20
µg/ml). The cells were sonicated on ice over 10 cycles of 15 seconds on 45
seconds off. The soluble and insoluble bacterial fractions were separated by
centrifugation at 15,000 g for 50 minutes. The soluble fractions containing
the expressed recombinant proteins were filtered through 0.45 nm syringe
filters prior to purification by Ni2+ affinity chromatography.
2.3.9 Protein purification
Recombinant proteins were purified from filtered bacterial soluble fractions by
Ni2+-affinity chromatography with a GE Healthcare HisTrap column as the
protein constructs had N-terminal His-tags incorporated into their N-terminal
SUMO-tags. The column was equilibrated in 20 mM imidazole Ni2+ column
buffer and the samples were made up to 20 mM imidazole by addition of 500
mM imidazole Ni2+ column buffer before running through the HisTrap column.
The column was then washed with 5 column volumes of 20 mM Ni2+ column
buffer followed by 5 column volumes of 50 mM Ni2+ column buffer. The
recombinant proteins were eluted in 5 column volumes of 500 mM Ni2+
column buffer.
Ni2+-affinity purified proteins were further purified by Size Exclusion
Chromatography (SEC). Proteins were passed through a GE Healthcare
Superdex 75 or Superdex 200 column depending on the size of the protein.
Columns were washed through with 1 column volume of de-ionized, filtered
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and degassed water then equilibrated in SEC buffer. Before purification,
samples were filtered and concentrated to a suitable volume.
2.3.10 SUMO cleavage
SUMO protease ulp1 was added to SUMO proteins as a ratio of 1:50
protease to protein for 24-48 hours at 4°C. Cleavage was assessed by gel
electrophoresis and then Coomassie staining. SUMO and ulp1 are both His
tagged so were removed from the incubated samples by Ni2+ affinity
chromatography leaving the pure untagged protein behind. For all constructs
that were to be used for cell stimulation the Ni2+ column was thoroughly
washed with 0.5 M NaOH before calibration with 20 mM imidazole Ni2+
column buffer. The sample was then added and the column eluent containing
pure untagged protein collected. This was further purified by size exclusion
chromatography to ensure protein purity. All glassware used to make buffers
and the column itself was thoroughly washed with 0.5 M NaOH.
2.3.11 Antibody production and purification
Isolated monoclonal hyridomas were bulked up and frozen down in
hybridoma freezing media for stocks. Monoclonal hybridomas were weaned
onto hybridoma serum free media (H-SFM) over a period of 7 days and then
grown up in 1 litre of H-SFM. Once at 1 litre, monoclonal hybridomas were
allowed to grow until cell viability dropped below 40%, (approximately 4-5
days). Hybridoma media was then centrifuged to remove cells prior to
antibody purification. Purification was carried out using 1ml PierceTM Protein
G agarose beads (ThermoFischer Scientific) packed in a column. The
column was equilibrated in PBS before adding the antibody-containing
media. The flow-through was collected and run through the column twice
more to maximise antibody capture. After a PBS wash, the purified antibody
was eluted in 5 ml pH 2.6 Glycine buffer neutralised by 500 μl pH 9 TRIS 
buffer. Finally, the antibody was dialyzed into PBS.
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2.3.12 Biotinylation
Biotinylation of proteins and antibodies was achieved by N-
hydroxysuccinimidobiotin (NHS-Biotin) from ThermoFisher Scientific, in
accordance to the manufacturer’s protocols. Proteins were dialysed into PBS
prior to biotinylation.
2.3.13 Dialysis
Proteins dialysed were contained in 10 kDa cut-off dialysis membrane
(Pierce) and suspended in 500x volume of the desired buffer with stirring for
5 hours. Dialysis was then repeated using fresh dialysis buffer.
2.3.14 Mass Spectrometry
Liquid chromatography mass spectrometry was performed in-house by the
Mass Spectrometry Facility of the Faculty of Biological Sciences, University
of Leeds.
2.3.15 Protease cleavage assays
Recombinant proteases and inhibitors were used at the concentration
recommended by the manufacturer. Proteins of interest were incubated with
cell supernatant or recombinant proteases at 37˚C for periods ranging from 2 
minutes to 24 hours. Inhibitors were pre-incubated with the recombinant
protease or cell supernatant for 30 minutes at 37˚C prior to addition of the 
protein of interest. Results were analysed by SDS-PAGE or western blot.
2.3.16 ELISA
Nunc-ImmunoTM MicroWellTM 96 well plates (Scientific Laboratory Supplies
LTD) were coated with capture antibody and ELISA proceeded as detailed in
manufacturer instructions when using DuoSet human ELISA kits (RnD
Systems, Abingdon, UK or BioLegend, Hatfield, UK). When using our
antibodies, antibodies were diluted in PBS and 100 µl added to each well
overnight at 4°C. After washing 5x in PBS 0.1% Tween-20 coated plates
were blocked for 1 hour using 200 µl per well of ELISA blocking buffer at
room temperature with agitation. After removal of blocking buffer 100 µl per
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well of samples were added for 1 hour with agitation. Samples, if necessary,
were diluted in ELISA blocking buffer. Plates were washed as before, then
biotinylated detection antibody diluted in ELISA blocking buffer was added for
1 hour with agitation. After washing, 100 µl per well of Avidin-HRP
(BioLegend) diluted 1/1000 in ELISA blocking buffer was added for 30
minutes. Plates were washed 6 times in PBS 0.1% Tween-20 before
addition of 100 µl per well of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate
solution. Reaction was stopped by addition of 100 µl per well of 2M H2SO4
and then absorbance was read using a Biotek PowerWave XS2 machine.
2.3.17 Immunoprecipitation
Samples were pre-cleared by addition of a quantity of PierceTM Protein G
agarose beads equal to that used in the pull down step. Samples were
mixed with beads for 3 hours at 4°C whilst applying rotatory mixing. Clearing
beads were removed by centrifugation, and immunoprecipitating antibodies
were added to the samples at 5x concentration of target protein. Samples
and antibodies were allowed to mix overnight at 4°C by applying rotatory
mixing. PierceTM Protein G agarose beads were added and mixed by
rotatory action for 3 hours before beads and antibody complexes were
removed by centrifugation at 8000 g for 2 minutes. Supernatant was
removed and frozen at -20°C for later analysis. Beads were washed in 5
times in 100 µl PBS 0.1% Tween-20. Immunoprecipitated protein was either
eluted for further analysis by ELISA, or denatured by addition of gel
electrophoresis buffer for analysis by gel electrophoresis. Elution was
performed using 1.5 M NaCl solution. Beads were incubated in 1.5 M NaCl
for 15 minutes on ice with gentle agitation every 5 minutes. Beads were
removed by centrifugation at 8000 g for 2 minutes and eluted protein was
removed and stored at -20°C for further analysis.
2.3.18 Quantitative PCR
Quantitative real-time PCR was carried out by a RotorGen (Qiagen, Hilton,
Germany) and a ΔΔCT-analysis formed from the generation of standard 
curves for the house keeping genes and genes of interest. RNA isolation
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was carried out using the Qiagen RNeasy Mini Kit. cDNA was generated by a
first strand cDNA synthesis kit (Thermo Fischer Scientific). Qiagen
QuantiFast SYBR green PCR was used to carry out the qRT-PCR according
to the manufacturer’s protocol.
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Chapter 3 - Generation and characterisation
of anti-IL-36γ antibodies 
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3.1 Introduction
Research on the IL-36 family has been greatly hindered by the lack of
effective commercially available antibodies. Without such antibodies, most
significant research has been conducted on mice, via the examination of
mRNA expression, recombinant proteins, or through the use of biological
reporter assays utilising IL-36R transfected cell lines. In order to dissect the
role of endogenous IL-36 cytokines that lack epitope tags and quantify IL-36
cytokine concentrations from patients or in vitro systems, it was therefore
necessary to generate specific IL-36 antibodies.
IL-36γ is of particular interest as it is the most highly expressed IL-36 
cytokine present in the skin compartment and is highly associated with
psoriatic inflammation.  Indeed, there is strong evidence implicating IL-36γ as 
a psoriasis-specific disease marker [143]. The ability to measure
endogenous IL-36γ from patient samples may help differentiate what are 
otherwise phenotypically very similar conditions, as can be the case with
psoriasis and atopic dermatitis. Furthermore the ability to extract
endogenous IL-36γ from such patients by immunoprecipitation may provide 
further information regarding the dynamics of IL-36γ activity.  In addition to 
the clinical aspect, IL-36γ specific antibodies will greatly facilitate research. 
There is a lot of uncertainty surrounding the expression, secretion and
processing of IL-36γ which is in part compounded by the lack of biological 
tools necessary to dissect these questions.  Therefore, anti-human IL-36γ 
monoclonal antibodies were produced in mice in the hope that they improve
molecular analysis of IL-36γ and provide a means of diagnosis in skin-based 
inflammatory disease.
3.2 Generating recombinant active IL-36γ for 
immunisation
Recombinant IL-36γ was engineered with an N-terminal SUMO tag directly 
upstream of the IL-36γ start codon.  In addition to facilitating purification via 
the SUMO His-tag, the very precise removal of the SUMO tag by SUMO
protease (Ulp1) maintains the integrity of the recombinant protein N-terminus
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by avoiding adding or removing any extra amino acids. This is of particular
importance with the IL-36 proteins given the effect of N-terminal truncation on
their activation, as discussed in the introduction.
Truncated IL-36γ cDNA encoding Ser18-D169 was cloned into the Champion 
pET SUMO expression system and transformed into DH5α.  Verified clones 
were subsequently expressed by the E. coli strain BL21-Codon plus (DE3)-
RIPL which are deficient in proteases Lon and OmpT, possess rare tRNAs
and for mammalian codon bias and λDE3 lysogen inducible T7 driven 
expression.
Once expressed, the recombinant IL-36γ was initially purified by Ni2+ affinity
chromatography, then by size exclusion chromatography, before removal of
the SUMO tag by incubation of the recombinant protein with Ulp1. The
cleaved tag and protease were purified away from the truncated recombinant
protein by further Ni2+ affinity chromatography as both protease and tag
contain His-tags that the truncated protein does not. A final purification by
size exclusion was conducted to ensure a clean recombinant protein. The
pure active recombinant IL-36γ was then tested on IL-36 responsive cells to 
validate activity. All instruments used in the purification process had been
cleaned by 0.5 M NaOH in order to reduce LPS contamination that could
interfere with subsequent assays. This process is outlined in Figure 3-1.
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Figure 3-1: Production and purification of recombinant IL-36γ S18 
(A) Diagram illustrates the process of cloning IL-36γ S18 and producing recombinant protein.  
(B) Diagram illustrates the process of removing N-terminal SUMO tag and purifying
recombinant protein. (C) Purified recombinant IL-36γ S18 was tested on primary human 
keratinocytes to confirm activity of the produced protein. Keratinocytes were grown to 70%
confluence before addition of recombinant IL-36γ S18 at 50 nM with or without 500 nM IL-
36Ra. IL-36 activity was assessed by measuring secreted IL-8 via ELISA. n=2
3.3 Generation and production of human IL-36γ 
specific monoclonal hybridomas
Mice were immunised with recombinant IL-36γ at Aberdeen as described in 
methods section 2.2.16. Analysis of mouse serum from tail bleeds 7 days
after their second immunisation showed IL-36γ-immunised mice had an 
antibody titre of <1/100 which was too low to proceed with the fusion,
however no cross-reactivity against other IL-36 family members was detected
(Figure 3-2). Therefore the mice were boosted again, as described in section
2.2.16, and re-tested the following week. The tail bleed showed an antibody
titre of >1/1000 (data not shown – performed in Aberdeen), which was
deemed adequate to proceed with spleen harvesting and hybridoma fusion.
Following the fusion, successfully fused hybridomas were selected by growth
in hypoxanthine-aminopterin-thymidine (HAT) supplemented media. The
selected hybridomas were then screened for identification of clones
producing IL-36γ-specific antibodies as described below.  At this point 
positive colonies were potentially polyclonal, containing hybridomas derived
from multiple different B-cells. Therefore, positive colonies were amplified
and further subjected to a limiting dilution resulting in a single cell per well of
a 96 well plate thus generating monoclonal colonies (process detailed in
methods section 2.2.18). Another round of screening was performed to
identify monoclonal hybridomas generating IL-36γ-specific antibodies.  These 
colonies were amplified and their expressed antibodies were purified as
outlined in methods section 2.3.11. This process is outlined in Figure 3-2.
Screening was performed in an ELISA-like assay. Initially 200 ng/well
recombinant IL-36γ was plated directly onto immunosorbent plates and then 
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probed with hybridoma supernatants. IL-36 binding antibodies were detected
using anti-mouse-HRP conjugate and subsequent incubation and colour
change of the TMB substrate (measured at 450 nm) (as detailed in methods
section 2.2.18).
Intriguingly, it was later observed that direct adsorption of recombinant IL-36γ 
to the plate surface altered the protein’s structure to the point of selecting
antibodies unable to bind native protein. Therefore, in order to present IL-
36γ to the antibodies in a soluble form, recombinant IL-36γ was conjugated 
to a biotinylated linker (EZ-Link NHS-Biotin, Pierce, UK) and added to avidin-
coated immunosorbent plates. Screening using directly adsorbed protein
generated a single monoclonal hybridoma producing IL-36γ specific 
antibodies, named 4A9. After modification of the screening process, an
additional three were identified named 6A11, B5A2 and B5B2. Initially
approximately 20 positive “clones” were identified by screening, however
after isolation and expansion of each clone, subsequent screens revealed
many of the hybridomas had stopped producing IL-36γ-specific antibodies, 
leaving only the four denoted above. This is likely due to chromosomal
instability and non-clonal populations.
This process was also performed for IL-36α and IL-36Ra.  Whereas the IL-
36α fusion did not yield and IL-36α-specific antibody-producing hybridomas, 
one monoclonal hybridoma was isolated which generated IL-36Ra-specific
antibodies which function in western blot.
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igure 3-2: Diagram illustrating generation and selection of hybridomas
A) Mice were inoculated with a subcutaneous (s.c.) injection of 50 μg IL-36γ with Complete 
reund’s Adjuvant (CFA).  After 3 weeks mice received a s.c., booster of 25 μg IL-36γ with 
ncomplete Freund’s adjuvant (IFA). Tail bleeds were then analysed to assess antibody titre.
erum was isolated and diluted 1:1 in PBS before addition to immunosorbent plates coated
ith 200 ng/well IL-36α, IL-36γ, IL-38 and IL-36Ra to check both antibody titre and cross-
eactivity. Tail bleed serum was then subject to 1:10 serial dilution in PBS from left to right.
ice were boosted again by intraperitoneal (i.p.) injection of 25 μg IL-36γ without adjuvant 
nd antibody titre was retested. After another 4 days mice were killed and spleen harvested.
B) Isolated splenocytes were fused with mouse myeloma SP2 cells and successful fusions
ere selected by culturing in hypoxanthine-aminopterin-thymidine supplemented RPMI.
ybridomas were grown until colonies were visible by the naked eye then screened for
ositive colonies. Positive colonies were isolated and expanded before being subject to a
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limiting dilution and allowed to grow until colonies were visible and screened again.
Monoclonal hybridomas were then isolated and expanded for antibody purification.
3.4 Antibody characterisation
Once positive hybridomas were observed by screening, these were grown up
and stocks were frozen down (10% DMSO 90% FCS). The positive
monoclonal hybridomas were then grown up in 1 litre 10% IgG depleted FCS
RPMI and weaned onto serum free media over five days. Antibodies were
purified via Protein G (ThermoFischer Scientific) as described in methods
section 2.3.11 which generated approximately 1-2 mg/litre of conditioned
hybridoma media. Antibodies were analysed by Coomassie stained SDS-
PAGE to examine their purity, and were isotyped by Bio-Rad mouse
isotyping test kit (shown in Table 3-1). They were tested on their ability to
specifically detect IL-36γ in both native and denatured conformations through 
dot blot and western blot (Figure 3-3).
All antibodies specifically recognise IL-36γ when immobilised by dot blot, 
though B5A2 and 4A9 appear to generate the strongest signal. When
analysed by western blot analysis, IL-36γ is only recognised by antibodies 
B5B2 and 4A9. Again, 4A9 appears to generate the strongest clear signal.
Furthermore, no cross-reactivity is observed against other IL-36 family
member IL-36α and IL-36Ra (Figure 3-3B and 3-3C). 
Having established 4A9 is able to specifically detect recombinant IL-36γ by 
western blot, it remained to test whether this antibody would recognise native
IL-36γ expressed by a cellular source.  HaCaTs, a keratinocyte cell line 
known to express IL-36γ, were stimulated for 48 hours with IL-17 and 
poly(I:C) at 50 ng/ml and 10 μg/ml respectively, both of which have been 
described to induce expression of IL-36γ.  Analysis of HaCaT cell lysates and 
supernatants by western blot using 4A9 as the primary antibody showed the
presence of a single band present at 17 kDa in lysates of the stimulated
HaCaTs that matched that of recombinant IL-36γ run in parallel (Figure 3-3). 
These results indicate the IL-36γ-specific antibody 4A9 functions as a 
primary western blot antibody capable of detecting IL-36γ expressed by a 
cellular source.
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igure 3-3: Characterisation of purified antibodies
) 2 μg of each purified antibodies were subject to SDS PAGE under reducing conditions 
nd analysed by Coomassie staining.  Purified antibodies were run alongside 2 μg of a 
ndom mouse IgG as a positive control (+ve). Antibodies were also tested for their ability to
pecifically detect recombinant IL-36γ by both western blot (B) and dot blot (C).  1 μg of 
combinant IL-36α (α) and IL-36Ra (Ra) were used to determine occurrence of cross-
activity whilst 1 μg of IL-36γ (γ) was serially diluted by 1:2 down to 0.12 μg.  Proteins were 
ither resolved by SDS PAGE and transferred to nitrocellulose (B) or immobilised on
itrocellulose by dot blotting (C). Membranes were then probed with 6A11, B5A1, B5B2, or
A9 and detected by an anti-mouse secondary antibody. Antibody 4A9 was tested on its
bility to detect endogenous IL-36γ expressed by HaCaTs (D).  HaCaTs were cultured to a 
onfluence of 70% in 6 well plates before addition of 50 ng/ml IL-17 or 10 µg/ml poly(I:C).
ysates and supernatants were collected and analysed alongside recombinant IL-36γ (rγ) by 
estern blot using 4A9 as a primary antibody and HRP-conjugated anti-mouse secondary
igma).
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Antibody Isotype
6A11 κIgG1 
B5A2 κIgG1 
B5B2 κIgG1 
4A9 κIgG2b 
Table 3-1: Antibody isotypes
Table denoting purified antibody isotypes as characterised by Bio-Rad mouse isotyping test
kit.
3.5 ELISA development
One of the greatest obstructions in IL-36 research is the absence of an
antibody pair that functions in ELISA. Without this, it is very difficult to
accurately measure low levels of protein and much research is limited to the
mRNA level. As such, a primary objective has been to produce a pair of
monoclonal antibodies that function as an ELISA pair.
3.5.1 Determining capture and detection ability
The antibodies were first tested on their ability to bind and retain soluble IL-
36γ once adsorbed onto the surface of an immunosorbent plate. Antibodies 
unable to do so would not be suitable as a capture antibody in an ELISA pair.
Similarly, the antibodies were also tested on their ability to detect IL-36γ 
immobilised and presented off the surface of an immunosorbent plate,
mimicking the capture antibody-presented antigen.
In order to test their ability to function as capture and detection antibodies
ELISA-like tests were developed. To test their capturing ability,
immunosorbent plates were coated with the antibodies to be tested at 2
µg/ml and then probed with biotinylated IL-36γ. The plates were then probed 
with HRP-conjugated avidin which would bind to any biotinylated IL-36γ 
captured by the antibodies adsorbed to the plate. The addition of TMB
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solution would then produce a quantifiable colour change to detect the
captured IL-36γ.  In order to generate a signal against which the antibodies 
could be compared, wells were coated with biotinylated mouse antibodies at
2 µg/ml and detected with HRP-conjugated avidin. To test the detection
ability of the antibodies, biotinylated IL-36γ (biotinylated as described in 
methods section 2.3.12) was added to avidin-coated plates (2 µg/ml) to
present the antigen away from the surface of the plate.  The presented IL-36γ 
was then probed with the antibodies being tested. Antibodies that had bound
the immobilised IL-36γ were detected by the addition of HRP-conjugated 
anti-mouse antibodies and subsequent addition of TMB solution. As a
positive control plates were coated with 2 µg/ml of mouse antibodies and
detected by HRP-conjugated anti-mouse antibody.
Tested in this manner, as shown in Figure 3-4, the antibodies 6A11 and
B5A2 produced a strong signal when acting as both capture and detection
antibodies. B5B2 and 4A9, however, in both tests produced a signal that
was not significantly greater than that produced by the negative control, and
as such would not be suitable as either capture or detection antibodies.
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3.5.2 Antibody compatibility in sandwich ELISA
Having established both 6A11 and B5A2 function independently as capture
and detection antibodies, it was necessary to determine whether they work
as an ELISA pair. As both B5B2 and 4A9 tested very poorly for both capture
and detection antibodies, these were not tested.
In order to test whether 6A11 and B5A2 were compatible with one another, a
standard ELISA was performed. Immunosorbent plates were coated with
either 6A11 or B5A2, washed with recombinant IL-36γ and probed with the 
other antibody. The detection antibodies were biotinylated to enable
recognition by HRP-conjugated avidin and amplify the signal produced upon
addition of TMB solution.
Initially, both capture and detection antibodies were used at 2 µg/ml as this is
a standard concentration suggested for use in monoclonal antibody ELISAs.
IL-36γ was added across a broad range of concentrations (1 µg/ml, 10 ng/ml, 
and 100 pg/ml). As shown in Figure 3-5, a strong signal was produced with
both 6A11 and B5A2 as capture antibodies at 1 µg/ml of IL-36γ and a signal 
was also detectable at 10 ng/ml, albeit to a lesser degree. However, with the
reaction allowed to progress for 5 minutes, no signal was detected at 100
pg/ml. The signal produced with B5A2 capturing and 6A11 detecting was
slightly stronger than with 6A11 capturing and B5A2 detecting, suggesting
this orientation would be more effective and sensitive for the detection of IL-
36γ. 
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-5: Functionality of B5A2 and 6A11 in sandwich ELISA
rbent plates were coated with 2 µg/ml of either 6A11 or B5A2 before addition of
nt IL-36γ at 1 µg/ml, 10 ng/ml, and 100 pg/ml.  IL-36γ was detected with 2 µg/ml of 
B5A2 or 6A11. Reaction was allowed to progress for 5 minutes before reaction
ed and absorption read at 450 nm. For a negative control, blocking buffer was
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30 minutes in order to allow the reaction to produce as much signal as
possible.
This optimisation greatly increased the amount of signal produced by the
ELISA when compared to the absorbance produced with 10 ng/ml of IL-36γ. 
The results shown in Figure 3-6 indicated 2.5 µg/ml of capture B5A2 used
with 5 µg/ml of detection 6A11 produced the highest absorbance reading with
the lowest acceptable level of background signal.
Figure 3-6: Optimisation of B5A2:6A11 IL-36γ ELISA 
Immunosorbent plates were coated with capture B5A2 antibody at a starting concentration of
10 µg/ml and serially diluted 1:2 from left to right to establish columns of varying capture
antibody concentration.  The last column was coated with blocking buffer.  IL-36γ was added 
to all wells excluding the 1st column at 2 ng/ml. Blocking buffer was added to the first column
in place of IL-36γ to act as a blank.  Biotinylated 6A11 detection antibody was added at a 
starting concentration of 10 µg/ml and serially diluted 1:2 from top to bottom to establish
rows of varying detection antibody concentration. The last row was detected using blocking
buffer alone. Detection antibody was detected using a constant concentration of avidin-
HRP. Values in white boxes denote the concentration of capture or detection antibody in
µg/ml. Values in coloured boxes are the absorption value detected at 450 nm.
Despite the improvement, the absorbance generated by the optimised
concentrations of capture and detection antibody was significantly less than
that produced by commercial ELISA kits. A standard curve generated by
serially diluting IL-36γ from 2 ng/ml to 31.25 pg/ml IL-36γ indicated the ELISA 
pair was still not sensitive enough to accurately quantitate low levels of
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protein, despite producing absorbance readings at a concentration of 125
pg/ml.
To further increase the sensitivity of the ELISA, a commercial biotinylated
polyclonal detection antibody obtained from R&D Systems was tested
against both B5A2 and 6A11 capture antibodies. The polyclonal detection
antibody was first optimised in a similar fashion as with B5A2 and biotinylated
6A11. Both capture and detection antibodies were serially diluted against one
another in the manner shown in Figure 3-6. The polyclonal detection
antibody was added at a starting concentration of 1 µg/ml as opposed to 10
µg/ml as non-specific binding is more common from polyclonal antibodies,
and as such background may be more pronounced.
After having established the optimal concentrations of capture and detection
antibody, standard curves were produced from 2 ng/ml of IL-36γ using both 
6A11 and B5A2. The standard curves were then compared against those
produced by the B5A2 and 6A11b monoclonal pair and a commercial IL-8
ELISA (Figure 3-7). The results from this comparison show that whilst the
monoclonal pair is capable of detecting low levels of IL-36γ it is not as 
sensitive as when using the biotinylated polyclonal detection antibody. They
also show that whilst the B5A2 capture and polyclonal detection antibodies
are more sensitive than the monoclonal pair, the signal produced is not as
strong as that produced by the commercial IL-8 ELISA.
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igure 3-7: Comparison of IL-36γ ELISA standard curves 
LISA was performed with recombinant IL-36γ serially diluted from 2 ng/ml to 31.25 pg/ml 
sing ELISA pairs B5A2:6A11b, B5A2:pcsecondary, and 6A11:pcsecondary. Standard
urves were generated and interpolated from absorbance readings in GraphPad Prizm.
tandard curve generated by a commercial IL-8 ELISA (BioLegend) from 1 ng/ml to 15.625
g/ml was also included for comparison.
.5.4 Establishing LoB, LoD, LoQ
n the development of a commercial ELISA it must be established to what
evel an ELISA pair can both reliably detect and quantify their antigen. This
s done by establishing a Limit of Blank (LoB), Limit of Detection (LoD) and
imit of Quantification (LoQ). The LoQ can often be circumstantial, dictated
y the purpose the ELISA serves and to what level of confidence that
urpose requires, but is never less than the LoD. The LoD, however, is
efined by the Clinical and Laboratory Standards Institute (CLSI) as the
owest concentration at which the measured analyte can be reliably
istinguished from the LoB [144]. LoB can be defined as the highest
pparent concentration of analyte found by measuring replicate samples
ontaining no analyte. In order to establish how sensitive the B5A2 and
A11 IL-36γ ELISAs are, the LoB and LoD for each were identified.  For the 
urposes of these studies, the LoQ was defined as the LoD as the ELISAs
eed only be reliable enough to identify increases or decreases in IL-36γ 
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expression.  Were it vital that precise IL-36γ concentrations were quantified 
with a high confidence, a more stringent LoQ would have been established.
To define the LoB and LoD of each ELISA, four replicate standard serial
dilutions were performed for each antibody from 2 ng/ml with a lowest
concentration standard at 31.3 pg/ml. Replicate blanks consisting of the
assay diluent were also included to establish the LoB. LoB was estimated by
using the mean absorbance and the standard deviation of the blank
replicates, according to the formula shown below:
LoB = meanblank + 1.645(SDblank)
LoD was then estimated using the LoB and the standard deviation of the
lowest concentration replicate samples in the serial dilutions, utilising the
formula outlines below:
LoD = LoB + 1.645(SDLow concentration sample)
The serial dilutions of IL-36γ for each ELISA were plotted to generate 
standard curves. From this, the LoD for each antibody was plotted on the
standard curves and extrapolated to generate a concentration value, as
shown in Figure 3-8. The B5A2 ELISA has an estimated LoD of 26 pg/ml,
whilst the 6A11 ELISA has an LoD of 48 pg/ml. From this, it is clear the
B5A2 ELISA is more sensitive, yet both ELISAs are capable of detecting
concentrations of a level often secreted from cellular sources. As such, they
both shall be viable to use for the quantification of IL-36γ protein, and shall 
prove invaluable for future use in IL-36γ research. 
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3.5.5 Measurement of endogenous IL-36γ by B5A2 ELISA
The results above have shown that the B5A2 ELISA is capable of reliably
detecting recombinant IL-36γ from a concentration of 26 pg/ml. It was 
therefore necessary to test whether this can be applied to actual research,
measuring endogenous IL-36γ from a cellular source.  Keratinocytes were 
stimulated for 48 hours with 50 ng/ml of IL-17, TNFα and IFNγ; all of which 
are thought to induce expression of IL-36γ.  Both cell supernatants and cell 
lysates were measured by B5A2 ELISA. Figure 3-9 shows the ELISA
successfully detected IL-36γ in both supernatants and lysates, showing 
stimulation by both IL-17 and TNFα to greatly increase expression of IL-36γ 
whereas IFNγ induced no increase in expression.  These results indicate the 
B5A2 ELISA is capable of detecting endogenous IL-36γ and as such would 
be appropriate to use in a research environment.
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to its largely increased expression in psoriatic tissue. Whilst RNA analysis is
a useful indicator of protein expression it does not always equate to the
actual protein levels expressed.  The ability to measure actual IL-36γ levels 
from diseased tissue may provide vital diagnostic information that may
enable differentiation between otherwise phenotypically similar inflammatory
conditions.
With this in mind, the B5A2 ELISA was tested on skin tape-strip biopsy,
synovial and serum samples from both healthy donors and patients with
atopic dermatitis (atopic eczema), psoriasis, psoriatic arthritis (PsA) and
rheumatoid arthritis to assess the ELISAs capability of detecting IL-36γ in 
each biopsy method. Tape stripping was performed by Anna Keszegpal as
outlined in methods section 2.2.19.  As shown in Figure 3-10 IL-36γ can be 
measured in samples of all biopsy methods.
Indeed, with regard to the tape-stripping biopsies it appears the high level of
IL-36γ expression in psoriatic skin is emulated at the protein level, lending 
credit to IL-36γ being a psoriasis-specific disease marker.  An ROC curve 
generated from the data obtained from the tape-strip samples demonstrated
that psoriasis can be differentiated from atopic dermatitis to a confidence of
95% when a lesional epidermal concentration of IL-36γ is in excess of 540 
pg/µg of total protein (Figure 3-10). This therefore shows great promise for
developing the IL-36γ ELISA into future diagnostic tests. 
Cut-off level Sensitivity % 95% CI Specificity % 95% CI Likelihood ratio
> 316.1 100 89.11% to 100% 85.71 63.66% to 96.95% 7
> 376 96.88 83.78% to 99.92% 85.71 63.66% to 96.95% 6.781
> 387.9 96.88 83.78% to 99.92% 90.48 69.62% to 98.83% 10.17
> 461.8 96.88 83.78% to 99.92% 95.24 76.18% to 99.88% 20.34
> 532.7 93.75 79.19% to 99.23% 95.24 76.18% to 99.88% 19.69
> 538.6 90.63 74.98% to 98.02% 95.24 76.18% to 99.88% 19.03
> 540.5 90.63 74.98% to 98.02% 100 83.89% to 100%
> 560.3 87.5 71.01% to 96.49% 100 83.89% to 100%
> 592 84.38 67.21% to 94.72% 100 83.89% to 100%
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Figure 3-10: IL-36γ is detectable in blood serum, synovial fluid and by 
tape stripping
IL-36γ levels were measured by B5A2 ELISA in synovial fluid of patients with either psoriatic 
arthritis (PsA; n = 4) or rheumatoid arthritis (RA; n = 4) (A) and in blood serum from healthy
volunteers (H; n = 3) or patients with psoriasis (Pso; n = 8) (B). Red points denote samples
that had an undetectable level of IL-36γ. Epidermal IL-36γ was also measured by tape 
stripping (C). 10 CuDerm tapes were taken from healthy volunteers (n = 16) and lesional
sites of patients with atopic dermatitis (n = 21) and psoriasis (n = 32). As there was no
difference between non-lesional epidermal IL-36γ these samples were combined from 
patients with atopic dermatitis and psoriasis. Only samples from patients with a confirmed
diagnosis were included. Data shown are mean ± S.D. Data from (C) were used to generate
an ROC curve of atopic dermatitis versus psoriasis to determine the diagnostic potential of
epidermal IL-36γ concentration in differentiating psoriasis and atopic dermatitis (D).  The 
tabulated data from the ROC curve (E) indicate the cut-off for specific detection of psoriasis
is at 540 pg/µg total protein.
3.6 Immunoprecipitation development
The ability to detect IL-36γ at the protein level would prove instrumental in 
further IL-36 research and have great potential as a diagnostic tool in a
clinical setting.  Whilst ELISA can quantitate the IL-36γ levels, it cannot 
elucidate any information on the activity of the protein. Knowledge of
whether IL-36γ is present as processed active protein or the inactive 
precursor would prove to be extremely useful information, potentially giving
more insight into disease phenotype. Whilst there is highly convincing
evidence for IL-36γ S18 being the active form of IL-36γ, neither this truncated 
form nor indeed any form has been isolated from human tissue or a primary
source. This would be made possible through immunoprecipitation followed
by mass spectrometry interrogation.  Therefore, the IL-36γ specific antibodies 
were tested on their ability to precipitate and purify IL-36γ. 
6A11, B5A2, B5B2 and 4A9 antibodies were added to a solution of
recombinant IL-36γ with bovine serum albumin.  The precipitated antibody 
complexes were then analysed by western blot using an IL-36γ-specific 
primary antibody (as detailed in methods section 2.3.17). As shown in Figure
3-11 antibodies 6A11 and B5A2 appear to successfully precipitate IL-36γ as 
IL-36γ is strongly detected in the precipitation fraction with both antibodies 
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and is absent from the immunoprecipitation supernatant. In contrast, after
immunoprecipitation by B5B2 and 4A9 IL-36γ is strongly detected in the 
supernatant and absent from the precipitated fraction, indicating neither
B5B2 nor 4A9 are suitable for immunoprecipitation.
Figure 3-11: Immunoprecipitation of IL-36γ by purified antibodies 
500 ng recombinant IL-36γ was mixed with 5 µg of either 6A11, B5A2, B5B2 or 4A9 
overnight at 4°C. Antibodies were precipitated by addition of protein G Agarose beads for 3
hours at 4°C with rotatory mixing. Precipitated antibodies were collected by centrifugation
and supernatant (SN) and immunoprecipitation (IP) fractions were analysed by western
blotting.  500 ng recombinant IL-36γ was included (γ) to facilitate identification of successful 
immunoprecipitation. Immunoprecipitation was repeated substituting precipitating antibodies
with PBS as a negative control (-ve).  IL-36γ was detected using 4A9 primary antibody and 
HRP-conjugated anti-mouse secondary (Sigma). Arrows indicate proteins corresponding to
bands. Red circles indicate successful immunoprecipitation.
After establishing 6A11 and B5A2 can precipitate recombinant IL-36γ under 
controlled conditions, it was examined whether endogenous IL-36γ 
expressed by a cellular source could be precipitated. As shown in Figure 3-
9, keratinocytes express high levels of IL-36γ upon stimulation with IL-17.  
Therefore, primary keratinocytes were grown to a confluence of 70% and
stimulated with IL-17 for 48 hours and immunoprecipitation was performed on
cell lysates.
By measuring the concentration of IL-36γ in the keratinocyte lysates before 
and after immunoprecipitation an idea can be gauged of the success of the
experiment.  Figure 3-12 shows that a significant amount of IL-36γ (82% of 
the total lysate IL-36γ) was removed from the keratinocyte lysates after 
immunoprecipitation with B5A2, suggesting this antibody successfully
precipitated IL-36γ.  Furthermore, after elution of IL-36γ from B5A2 antibody 
by incubation in 1.5 M NaCl, purified IL-36γ was detected (albeit significantly 
less than was removed from the lysate after immunoprecipitation). These
results indicate that B5A2 is capable of precipitating endogenous IL-36γ. 
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3.7 Blocking function
Antibodies are not only invaluable in a research setting but are being used as
“biologics” in an increasing number of diseases, especial against
inflammatory mediators [145]. Anti-IL-17 monoclonal antibodies such as
secukinumab and the anti-IL-23p19 monoclonal antibody ustekinumab have
both been shown to be very effective when used to treat psoriasis [146, 147].
Infliximab, an anti-TNFα antibody, is now widely used in the treatment of 
various inflammatory conditions and is well documented to be an effective
treatment [148]. These antibodies typically function by chelating their
inflammatory target peptide, preventing them from binding and activating
their respective receptors. Given the importance IL-36 plays in psoriatic
inflammation, particularly IL-36γ in the skin, anti-IL-36γ treatment may be a 
very attractive option to complement and use in conjunction with the existing
monoclonal antibody biological treatments.  Therefore the purified anti-IL-36γ 
antibodies were tested for their ability to prevent IL-36γ mediated signalling. 
Antibodies were mixed with IL-36γ at various molar ratios and incubated for 
20 minutes at room temperature prior to administering to HaCaTs for 48
hours. IL-8 secretion was measured as a read-out of IL-36 activity. As
shown by Figure 3-13 neither 4A9 nor B5B2 showed any sign of blocking IL-
36 activity at any of the molar ratios tested. In contrast, both 6A11 and B5A2
successfully reduced IL-36-dependent secretion of IL-8. The addition of
6A11 and IL-36γ in combination exhibited a significant reduction in IL-8 
secretion at all the molar ratios tested when compared to IL-36γ alone.  B5A2 
appeared to have only a slight effect on IL-8 secretion at an equimolar
concentration, however when used at higher molar ratios the antibody
reduced the secretion of IL-8 to a level seen when cells are pre-treated with
IL-36Ra prior to IL-36γ treatment. Furthermore this reduction of IL-8 secretion 
appears to be dose dependent, with IL-8 decreasing further as the molar ratio
of B5A2 to IL-36γ is increased.  These observations indicate both 6A11 and 
B5A2 are capable of blocking IL-36 signalling through binding of IL-36γ and 
sterically preventing receptor binding. The ability to block agonist signalling
indicates the antibodies may be useful in future blocking studies, with
perhaps a long term aim to consider use in therapeutics.
Figure 3-
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3.8 Immunofluorescence
Little is known about the intracellular localisation and tracking of IL-36γ.  As 
with many IL-1 family proteins the IL-36 cytokines lack a signal peptide and
as such are not thought to enter the normal secretory pathway. The
alternative pathways for protein secretion are not well described and quite
difficult to interrogate, and as such research into the secretory pathway taken
by IL-36 proteins has been quite sparse and often inconclusive. The ability to
visualise intracellular IL-36 would prove to be very useful in further
investigating the intracellular trafficking of IL-36, enabling visualisation of
protein interactions and intracellular localisation.  Therefore the anti-IL-36γ 
proteins were examined for their ability to function in immunofluorescent
staining of fixed cells.
Prior to examining their ability to detect native IL-36γ, a positive control was 
established against which the efficacy of the anti-IL-36γ antibodies was 
tested.  HEK293T cells were transfected with IL-36γ constructs containing C-
terminal FLAG tags. The transfected HEK293T cells were fixed and stained
with either mouse M2 anti-FLAG, 4A9, B5B2, B5A2 or 6A11 primary antibody
as described in methods section 2.2.15. The mouse M2 anti-FLAG clone is
well established to function well in immunofluorescence so should serve as a
good positive control against which to compare the other antibodies. As all
the primary antibodies used are mouse antibodies the same anti-mouse
alexa-fluor 488 secondary was used on all samples. A negative control was
also produced by staining FLAG-tagged IL-36γ expressing cells with the 
secondary antibody alone (not shown). All cells were also counter-stained
with DAPI.
 A B
CFigure 3-14: Detection of IL-36γ in IL-36γ-transfected HEK293T cells 
HEK293T cells were cultured to 90% confluence before transfection with C-terminal FLAG
tagged IL-36γ.  Transfected cells were cultured for an additional 24 hours before fixation in
4% paraformaldehyde and staining with either 6A11 (A), B5A2 (B), or M3 anti-FLAG (C) and
an alexa-fluor 488 conjugated anti-mouse secondary (ThermoFischer Scientific). Cells were
counterstained with DAPI and slides were imaged by an inverted LSM700 confocal
microscope coupled to a LSM Image Browser.As sho
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6A11 and B5A2 anti-IL-36γ antibodies may be suitable primary antibodies 
with which to investigate the intracellular expression and location of
endogenous IL-36γ in primary cells. 
Although the transfection of HEK293T cells with FLAG-tagged IL-36γ is seen 
above to be a good method of validating whether these antibodies are
capable of staining IL-36γ under different fixation conditions, it is not 
necessarily an apt method for determining their ability to visualise
endogenous protein. Therefore primary keratinocytes were stimulated with
IL-17 to induce a high level of IL-36γ expression and were stained with both 
6A11 and B5A2 anti-IL-36γ antibodies.  However, no significant IL-36γ 
staining was observed despite IL-36γ ELISA data demonstrating a significant 
up-regulation in IL-36γ by IL-17 stimulation, suggesting perhaps either these 
anti-IL-36γ antibodies are not suitable for the visualisation of endogenous IL-
36γ expressed by primary cells, or the cells are not expressing enough IL-
36γ to be detected. 
3.9 Discussion and future work
As illustrated in the introduction, the IL-36 cytokines are of great importance
in psoriatic inflammation, and are becoming established as important
mediators of inflammation in various epithelial barriers.  IL-36γ in particular 
has been identified to be of significant importance in both the skin and lungs,
as a proposed psoriasis-specific disease marker in the skin and with strong
up-regulation noted in lung tissue in response to smoke condensate [103,
143]. However, much of the research conducted on IL-36 cytokines has
been performed in mice models, or through RNA analysis. There are few
human IL-36 specific antibodies available on the market, and those that are
available have been found to be inadequate. This chapter, therefore, aimed
to produce and characterise human IL-36γ specific monoclonal antibodies 
with which IL-36γ-specific research could be conducted, with a particular 
focus on developing an IL-36γ-specific ELISA.  
By collaborating with Dr Delyth Reid at the University of Aberdeen, mice were
inoculated with active IL-36γ and mouse hybridomas were generated from 
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the immunised mice splenocytes. After a series of selection and screening
processes, four IL-36γ-specific monoclonal hybridomas were isolated and 
grown, from which monoclonal antibodies were purified. These were
characterised and tested for their ability to function in a number of antibody-
mediated protein assays, including ELISA, immunoprecipitation,
immunofluorescence and activity blocking studies. An overview of each
antibody and their characterised functions are listed in Table 3-2 below.
Antibody Isotype Western Dot
blot
ELISA IP IF Blocking
function
6A11 κIgG1      
B5A2 κIgG1      
B5B2 κIgG1      
4A9 κIgG2b      
Table 3-2: Characterised antibodies
Table to summarise purified antibodies and their optimised functions. ‘’ indicates
antibodies could detect transfected IL-36γ but not endogenous IL-36γ 
When screening the hybridomas for colonies that were expressing IL-36γ-
specific antibodies, numerous positive hits were identified and cultured for
antibody production. However a significant proportion of these stopped
producing IL-36γ antibodies after an extended period of growth.  As a result 
only 4 distinct clones were obtained from approximately 25 positive hits. This
is likely due to chromosomal instability after cell fusion resulting in the loss of
chromosome 12 or 6, containing the genes encoding IL-36γ-specific heavy 
and light immunoglobulin chains [149]. It has been observed that within
clones of the same origin, those with fewer chromosomes proliferate at a
greater rate [150]. It is therefore possible, over a period of prolonged growth,
for an unstable monoclonal hybridoma population to become repopulated
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with a clone of the same origin that has lost a chromosome encoding IL-36γ-
specific antibody, and thus stop producing IL-36γ-specific antibody.  
As shown in Table 3-2 the antibodies 4A9 and B5B2 functioned quite
differently to 6A11 and B5A2 when examined in different antibody-mediated
protein assays. Whereas both 6A11 and B5A2 functioned quite similarly and
both performed relatively well in many of the assays tested, 4A9 and B5B2
only performed well in western and dot blot. This may, in part, be due to the
different screening techniques utilised. As mentioned above, screening was
initially performed by coating antigen directly onto the surface of
immunosorbent plates to which hybridoma supernatants were added. It was
noted, however, that this may have been altering the structure of the
adsorbed protein to the point where the antibodies selected would not bind
native soluble IL-36γ.  The adsorption of proteins to plastic polymers is often 
mediated through hydrophobic interactions, and this has been demonstrated
to cause a change in protein structure. This has been illustrated through the
adsorption of both human growth hormone and lysozyme onto various solid
surfaces, which have been shown to result in a less compact protein
structure [151]. It may be possible that similar structural changes take place
upon adsorption of IL-36γ to the point that adsorbed protein epitopes are 
distinct from soluble protein epitopes. Therefore, as the 4A9 hybridoma was
selected by screening against directly adsorbed IL-36γ it is possible 4A9 
antibodies do not bind soluble IL-36γ.  Indeed, this seems to be supported 
when noting that 4A9 did not function as a capture antibody or a detection
antibody, but recognised denatured IL-36γ when resolved by SDS-PAGE. 
The antibodies 6A11, B5A2, and B5B2 were selected after screening against
biotinylated IL-36γ presented off the surface of the plate by avidin.  
Presented in this way, IL-36γ should retain its soluble form, and as such the 
antibodies selected should bind native IL-36γ.  Indeed, both 6A11 and B5A2 
were shown to function as capture and detection antibodies, and could
function in immunoprecipitation, indicating they bind native soluble IL-36γ.  
Furthermore, neither 6A11 nor B5A2 could detect IL-36γ by western blotting 
after resolution by SDS PAGE but were both capable of detecting native IL-
36γ after immobilisation on nitrocellulose membrane by dot blotting, 
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indicating the epitope recognised by these antibodies is dependent on the 4
dimensional structure of the native protein. Intriguingly, despite being
selected using avidin-presented IL-36γ, B5B2, like 4A9, did not function in 
immunoprecipitation or ELISA, but could detect IL-36γ immobilised on 
nitrocellulose and after resolution by SDS-PAGE in western blot,
The primary objective after production of IL-36γ-specific monoclonal 
antibodies was the development of an ELISA. During characterisation of the
purified antibodies, 6A11 and B5A2 were identified as capable of both
capturing soluble recombinant IL-36γ after adsorption onto immunosorbent 
plates and detecting biotinylated IL-36γ immobilised on avidin-coated 
immunosorbent plates. Furthermore they were shown to be compatible with
each other in a sandwich conformation. However, further analysis revealed
the sensitivity achieved by a B5A2 to 6A11 sandwich ELISA was not
adequate for reliable quantification of low levels of recombinant IL-36γ.  
When compared to a commercial IL-8 sandwich ELISA, 1 ng/ml of IL-8
produced a 450 nm absorbance reading of 2 after only 10 minutes of
incubation of the HRP substrate where 1 ng/ml of recombinant IL-36γ 
detected by B5A2 and 6A11 produced a 450 nm absorbance reading of 0.25
after allowing the colorimetric reaction to proceed for 30 minutes. Therefore
commercial biotinylated polyclonal IL-36γ antibodies (RnD pcAb) were used 
to detect recombinant IL-36γ captured by either B5A2 or 6A11.  This was 
shown to be an effective combination, with 1 ng/ml of IL-36γ detected by 
B5A2 and RnD pcAb generating a 450 nm absorbance reading of 1.2 after 30
minutes of incubation with HRP substrate. Further analysis revealed the
B5A2 RnD pcAb ELISA could reliably detect recombinant IL-36γ down to 26 
pg/ml, providing evidence of a sensitive ELISA. Finally the ELISA was
demonstrated to detect endogenous IL-36γ in both cell lysates and cell 
supernatants of stimulated and non-stimulated primary keratinocytes, and
thus was considered suitable to analyse the expression of IL-36γ protein.   
Psoriasis and eczema are phenotypically similar conditions and often require
an experienced dermatologist to differentiate between the two. In many
cases, particularly when differentiating hand eczema and palmoplantar
psoriasis, the only definitive method of differentiation is by punch biopsy and
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histological examination; both a time-consuming diagnosis and an
unpleasant painful procedure [152]. However, examination of mRNA
expression from inflammatory skin lesions indicate increased IL-36γ 
expression is specific to psoriasis [143]. Using the ELISA generated in this
chapter and tape-stripping biopsy methods the level of IL-36γ protein present 
in the epidermis of atopic eczema and psoriasis patients was evaluated to
see whether the expression of IL-36γ could be used to differentiate the two 
conditions.  In order to test whether a high level of IL-36γ correlates to a 
psoriatic disease phenotype, it was necessary to test patients that have a
clearly defined diagnosis. In this fashion it has been demonstrated that high
IL-36γ concentration strongly correlates with psoriatic inflammation.  Indeed 
the ROC curve generated from this tape-strip data determined that skin-
based IL-36γ in excess of 540 ng/µg is indicative of psoriasis to a confidence 
of 95%. It would therefore be interesting to determine whether measuring IL-
36γ levels in skin lesions from patients not yet diagnosed by an experienced 
dermatologist would be able to correctly and reliably diagnose psoriasis, and
furthermore distinguish phenotypically ambiguous psoriatic patients from
eczema patients.
During the development of the ELISA it was observed that the monoclonal
detection antibody was not sensitive enough to detect low levels of IL-36γ, 
yet that by using a polyclonal detection antibody with the same monoclonal
capture antibody, the sensitivity of the ELISA was improved significantly.
Intriguingly the polyclonal detection antibody significantly improved the
sensitivity of the ELISA when used with either B5A2 or 6A11 as capture
allowing for a LoD of 26 pg/ml and 48 pg/ml respectively, implicating that
both B5A2 and 6A11 are capable of efficiently capturing IL-36γ and thus are 
to effectively bind IL-36γ.  Yet once captured by one antibody, the other is not 
able to sensitively detect IL-36γ, as illustrated by the difference in signal 
produced by the monoclonal and polyclonal antibodies. This could be
explained by a number of different scenarios. Firstly, as antibodies are large
proteins and IL-36γ is relatively small, it is possible the capture antibody is 
partially masking the epitope of the detection antibody, causing fewer
detection antibodies to successfully bind their target. Secondly, it has been
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demonstrated that antibody binding can cause long-range conformational
changes in the target antigen that can allosterically inhibit binding of a
second antibody [153, 154]. It may therefore be possible that capture
antibody binding is causing conformational changes in IL-36γ that reduces 
the affinity of the monoclonal detection antibody for its epitope. In both these
cases the polyclonal detection antibody would maintain a high signal as it
contains multiple clones of antibodies that recognise distinct epitopes, thus
can compensate if an antibody is sterically or allosterically inhibited by the
capture antibody. Finally there is the possibility the monoclonal detection
antibodies were simply not adequately biotinylated, and were therefore not
producing a strong signal after addition of avidin-conjugated HRP. This
possibility should be explored in future experiments.
Ideally the ELISA developed in this study should undergo further
development to establish a functioning pair of monoclonal antibodies. Whilst
the monoclonal B5A2 capture to RnD polyclonal detection antibody pair have
been shown here to function well, polyclonal antibodies are generated on an
individual basis and as a result are subject to batch-to-batch variation, thus
background and sensitivity in the ELISA can also vary. Indeed this is evident
in Figures 3-7 and 3-8 when comparing the standard curves generated for
comparison of monoclonal to monoclonal antibody, monoclonal to polyclonal
antibody, and a commercial IL-8 ELISA (Figure 3-7) and for the determination
of LoD (Figure 3-8). A different batch of polyclonal detection antibody was
used for each figure whilst all other variables were maintained the same, yet
batch 1 in Figure 3-7 generated a peak absorbance of 2.2 at 450 nm whilst
batch 2 in Figure 3-8 generated a peak absorbance of 1.1 at 450 nm. As this
ELISA may eventually be utilised in the diagnosis of psoriasis consistency is
of vital importance. It is therefore necessary to develop an effective
monoclonal detection antibody against IL-36γ that is compatible with B5A2 
capture antibody. This should be relatively achievable by generating new
hybridomas in a different species, such as rat or rabbit, and selecting for
monoclonal hybridomas that produce compatible antibodies by screening
against B5A2-presented IL-36γ.  By using a different species for the 
detection antibody it is possible to differentiate positive hits from the capture
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antibody by using species-specific antibodies. Screening for a monoclonal
detection antibody in this manner will also select for antibodies that are not
affected by steric and allosteric interference.
The antibodies generated in this chapter were also tested on their ability to
block IL-36γ-mediated signalling.  Both 6A11 and B5A2 appeared to have 
blocking capabilities, with B5A2 reducing IL-36-mediated IL-8 secretion in a
dose dependent manner. Antibody therapy is a rapidly expanding field, and
has been shown to be very effective in a number of inflammatory and
rheumatologic conditions. In particular, biologics targeting IL-23 and IL-17
have demonstrated great efficacy in the treatment of psoriasis.
Ustekinumab, approved for use in the USA and Europe in 2009, targets the
p40 subunit shared by IL-23 and IL-12 and has been shown to be effective
with 67.5% of patients achieving PASI 75 (a 75% reduction in psoriasis
assessment and severity index (PASI) score) after 12 weeks of treatment
[146]. In 2015 secukinumab, which targets IL-17A, was approved for use in
the USA and Europe as a first-line of treatment of moderate to severe plaque
psoriasis. Secukinumab has shown excellent efficacy, with 79% of patients
achieving PASI 90 (a 90% reduction in PASI score) in 16 weeks [147]. IL-23
and IL-17 are both pivotal cytokines in the development of psoriatic plaques.
IL-23 promotes the differentiation of TH17 cells when in the presence of IL-6
and TGFβ, and subsequently promotes their survival [155].  The 
differentiated TH17 cells produce high levels of IL-17, which promotes the
development of psoriatic plaques by inducing secretion of neutrophil
chemokines, AMPs and growth factors [156-158]. IL-36 has been proposed
to be an attractive target for biologic treatment in psoriasis as it is an
upstream cytokine that has been shown to initiate and regulate IL-17, IL-22
and IL-23 mediated inflammation [113]. As its expression is mostly limited to
epithelial barriers, unlike IL-17, IL-22, IL-23 or TNFα, targeting IL-36 
signalling is less likely to have adverse systemic side effects. Whilst it might
be argued that targeting IL-36R would be more effective than simply targeting
IL-36γ alone, given that IL-36R may have a role in wound healing completely 
blocking IL-36-mediated signalling may have detrimental long-term effects
[125].
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The treatment of conditions such as psoriasis, which often has localised
areas of inflammation amongst uninvolved tissue, with systemic biologics can
have disadvantageous side effects since the molecules targeted, such as IL-
17, IL-23 and TNFα, are important in many aspects of immune function, not 
just the pathogenesis of psoriasis. In brodalumab clinical trial AMAGINE-3
(targeting IL-17 receptor A) it was identified that 56.8% of patients
experienced adverse treatment-related effects with 1.4% developing serious
adverse events after 12 weeks of treatment [159]. This included neutropenia
and susceptibility to C. albicans infections, which is observed in patients that
have IL-17 and IL-17RA deficiencies [160]. However, it may be possible to
target biologic treatment specifically to a desired tissue or cell type through
engineering recombinant bi-specific antibodies, thus limiting systemic side
effects. It has been demonstrated that by linking a macrophage-specific
single-chain antibody to a TNFα-specific high-affinity single domain antibody 
TNF inhibition can be specifically restricted to macrophages. By doing so the
efficacy of the anti-TNF treatment is significantly enhanced [161]. Whilst IL-
36 signalling is emerging as important in a number of different tissues, with
implications in lung-based fungal defence and a wound healing protective
role in the gut, psoriasis is primarily skin-based [124, 125]. Using a similar
method as described by Efimov et al. it would be possible to specifically
target skin-based IL-36-mediated inflammation through engineering bi-
specific IL-36γ antibodies. 
In addition to their blocking function and the development of an IL-36γ ELISA, 
the antibodies generated in this chapter were tested in immunoprecipitation
and immunofluorescence. It was demonstrated that both 6A11 and B5A2
could immunoprecipitate recombinant IL-36γ and that B5A2 was capable of 
immunoprecipitating endogenous IL-36γ expressed by primary keratinocytes.  
As yet the endogenous active form of IL-36γ has not been isolated.  With a 
functioning immunoprecipitating antibody this may be possible. Given that
IL-36γ is measurable by ELISA from patient tape strips it seems logical that it 
should be possible to immunoprecipitate IL-36γ from these samples, and that 
provided enough is immunoprecipitated this could be analysed by mass
spectrometry to provide information on the forms of IL-36γ present in the 
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sample. Furthermore, this may have a diagnostic application by providing
information on how much of the present IL-36γ is in its active form.  In 
immunofluorescence both B5A2 and 6A11 could detect IL-36γ expressed by 
HEK293Ts after transient transfection, yet neither could detect endogenous
IL-36γ expressed by primary keratinocytes after stimulation with IL-17.  This 
may be an issue with lower levels of expression compared to the transfected
HEK293Ts as opposed to recognition of the antigen, however further
optimisation is required to discern this. It may be worth trying different
fixation conditions in case epitope masking is reducing the binding
capabilities of B5A2 and 6A11 to IL-36γ and attempting antigen retrieval to 
reverse any epitope masking that might occur.
To conclude, the work undertaken in this chapter has produced 4 IL-36γ-
specific antibodies which between them facilitate detection of IL-36γ in 
western blot, dot blot, ELISA and immunofluorescence, and
immunoprecipitation of endogenous IL-36γ.  Furthermore it has produced a 
reliable IL-36γ ELISA that has shown great potential for use as a diagnostic 
tool with which to differentiate psoriasis from eczema, and
immunoprecipitating antibodies that should facilitate the isolation of
endogenous active IL-36γ. 
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Chapter 4 - Proteolysis of IL-36 family
members
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4.1 Introduction
Like many IL-1 family cytokines, the IL-36 proteins require N-terminal
truncation in order to become biologically active [99]. As mentioned
previously, it has been demonstrated that this cleavage must be very precise,
occurring exactly 9 amino acids upstream of the conserved A-X-D motif
residing in the IL-1-like domain (illustrated in Figure 1-3). Inaccurate
cleavage even by one amino acid upstream or downstream of this cleavage
site will severely reduce the proteins’ activity [99]. However, unlike other IL-1
family proteins the IL-36 members have no consensus cleavage site at their
N-terminus, and the amino acid sequence surrounding the truncation sites
bear little homology to one another (Figure 1-3). It has therefore proven
difficult to predict any proteases that digest the IL-36 proteins and at the start
of this research no IL-36 cleaving protease had been identified.
In order for cleavage to occur, the IL-36 proteins must come into contact with
a protease. Given that IL-36 expression is predominantly restricted to lung,
skin and joint tissue it is logical to assume that any endogenous activating
proteases are present in these same tissues. The overabundance of IL-36
proteins in psoriatic lesions and their role in aggravating skin-based
inflammation implicate the skin as a good candidate tissue from which to
identify an IL-36 activating protease. The proteolytic cleavage and activation
of IL-36 members was therefore investigated through the use of inflammatory
and skin resident cells.
4.2 Neutrophil proteases truncate IL-36 members
Activation of the IL-36 members only requires removal of a small number of
amino acids from the N-terminus. As such, cleavage would not be easily
identified by SDS-PAGE or western blot. Therefore, incubations were
performed using recombinant N-terminal SUMO-tagged IL-36 fusion proteins
(illustrated in Figure 4-1). These were generated in the same fashion as
detailed in chapter 3. By adding an N-terminal tag, the size of the peptide
removed through cleavage significantly alters the size of the protein allowing
88
detection in both SDS-PAGE and western blot. Due to problems producing
recombinant IL-36β, no experiments were conducted on this IL-36 cytokine. 
SUMO-tagged full length IL-36α (IL-36α FL), IL-36γ (IL-36γ FL) and IL-36Ra 
(IL-36Ra FL) were incubated with media conditioned by keratinocytes, PMA-
activated polymorphonuclear cells (PMNs) and fibroblasts for 24 hours
(Figure 4-1). Analysis by SDS-PAGE showed that whilst no cleavage was
seen in any of the proteins by keratinocyte or fibroblast conditioned media,
PMN conditioned media cleaved all SUMO-tagged IL-36 cytokines.
Furthermore, the cleaved products were approximately 17 kDa in mass which
approximates to the size of the active IL-36 members. This suggests
neutrophils may cleave IL-36 members in the region of their truncation site.
F
p
(
d
c
a
d
k
S
h
m
SIL36x C
SUMO
domainHisx6
rIL-36 SUMO fusion protein
Truncation siteA
Bi
r
A
a
y
c
o
e
u
o
i
2
3
1akD89
gure 4-1: Polymorphonuclear cells truncate recombinant SUMO-IL-36
oteins
) Diagram depicts the SUMO-IL-36 fusion proteins used in the cleavage assays. The
shed red line depicts the approximate truncation site required for activation of the IL-36
tokine. (B) SUMO-IL-36 recombinant proteins were incubated with supernatants of
tivated PMNs, keratinocytes and fibroblasts. PMNs isolated from whole blood of healthy
nors were stimulated with 100 ng/ml of PMA for 1 hour at 37 °C. Human primary
ratinocytes and fibroblasts were stimulated with 100 ng/ml of PMA for 24 hours at 37 °C.
pernatants were removed and incubated with SUMO-IL-36 recombinant proteins for 1
ur at 37 °C alongside a PBS control before analysis by western blot using mouse
onoclonal anti-IL-36α, anti-IL-36γ and anti-IL-36Ra primary antibodies (R&D Systems and 
gma-Aldrich) and HRP-conjugated anti-mouse secondary (SouthernBiotech).
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4.1 IL-36 proteolysis is mediated by neutrophil serine
proteases
Neutrophils produce a vast number of proteases involved in inflammation,
wound healing and tissue remodelling. In order to identify candidate
proteases from those expressed by neutrophils, further refinement is
required.
The proteins were again incubated with activated neutrophil conditioned
media, but in the presence of molecular inhibitors that target specific
protease families. The addition of iodoacetic acid (IAA),
phenylmethylsulfonyl fluoride (PMSF), α1-antitrypsin and EDTA specifically 
inhibited cysteine, serine and metalloproteinases respectively to enable
identification of a protease family actively cleaving IL-36. Western blot
analysis revealed all SUMO-IL-36 proteins underwent cleavage when in the
presence of IAA and EDTA, indicating the cleaving proteases were neither
cysteine proteases nor metalloproteinases (Figure 4-2). Incubation with
PMSF and α1-antitrypsin, however, prevented the cleavage of all SUMO-IL-
36 members. This result suggests neutrophil-expressed serine proteases
cleave IL-36 cytokines.
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4.2 Neutrophil elastase cleaves IL-36Ra to produce to
produce both active and inactive IL-36Ra
Identifying neutrophil serine proteases as responsible for IL-36 cleavage
refined the pool of candidate proteases. Therefore, SUMO-IL-36 proteins
were incubated with a panel of recombinant serine proteases commonly
expressed by neutrophils. SDS-PAGE analysis of the incubations revealed
cathepsin G, neutrophil elastase and proteinase 3 all truncated IL-36Ra
(Figures 4-3). Mass spectrometry analysis identified 2 major truncation
products. IL-36Ra was cleaved by both cathepsin G and proteinase 3
between the third and fourth amino acid, leaving a serine at its N-terminus
(IL-36Ra S4). Neutrophil elastase, however, generated an abundant
truncated protein cleaved between the first and second amino acid leaving an
N-terminal valine (IL-36Ra V2) (Figure 4-3). To ensure the cleavage
generated by each protease was not influenced by the N-terminal SUMO tag,
cleavages were repeated using IL-36Ra FL without an N-terminal SUMO tag.
Mass spectrometry analysis showed the same results.
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4-3: Neutrophil serine proteases efficiently truncate IL-36Ra
combinant SUMO-IL-36Ra was incubated with recombinant neutrophil serine
es cathepsin G (CG), elastase (E), and proteinase 3 (PR3) at a ratio of 1:100
e:SUMO-IL-36Ra and incubated at 37°C for 1 hour. Proteolysis was analysed by
sie stained gel. (B) SUMO-IL-36Ra was incubated with elastase at a ratio of 1:100
e:SUMO-IL-36Ra over a period of 5 hours at 37°C with various time points taken
out the incubation. Proteolysis was analysed by Coomassie stained SDS-PAGE. (C)
hromatography mass spectrometry result of neutrophil protease-incubated IL-36Ra
truncation products produced by elastase (Ela), proteinase 3 (PR3) and cathepsin
. Numbers denote mass of truncations whilst letters indicate the truncations’ starting
cids.
The IL-36Ra S4 truncation has an N-terminus that is 7 amino acids upstream
from the A-X-D motif and therefore would not be predicted to be active. The
IL-36Ra V2 truncation, however, produces an N-terminus precisely 9 amino
acids upstream of the A-X-D motif generating a protein that would be
predicted to have antagonistic activity. In order to test the biological activity
of each IL-36Ra truncation compared to IL-36Ra FL, recombinant IL-36Ra
V2 and IL-36Ra S4 were generated and used to stimulate IL-36-responsive
cells. Primary keratinocytes were stimulated with active IL-36 agonists with
or without IL-36Ra FL, IL-36Ra V2 and IL-36Ra S4 for 48 hours. Cell
supernatant IL-8 concentration tested by ELISA was used as a biological
read-out of IL-36 activity. As predicted, neither IL-36Ra FL nor IL-36Ra S4
showed any antagonistic activity. IL-36Ra V2, however, significantly reduced
IL-36-mediated secretion of IL-8 (Figure 4-4). This strongly suggests
neutrophils may be capable of activating IL-36Ra through the secretion of
neutrophil elastase.
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4.3 Neutrophil-mediated proteolysis of IL-36 agonists
produces inactive truncations
As shown in Figure 4-5, IL-36α and IL-36γ are also truncated by cathepsin G, 
neutrophil elastase and proteinase 3. Mass spectrometry analysis of the
truncations showed cathepsin G, neutrophil elastase and proteinase 3 all
cleaved IL-36α between the sixth and seventh amino acid leaving an N-
terminal isoleucine (IL-36α I7). Proteinase 3 and cathepsin G truncated IL-
36γ between 15th and 16th and the 16th and 17th amino acids respectively,
producing IL-36γ Y16 and IL-36γ Q17, whilst neutrophil elastase generated 
both truncations (Figure 4-5).
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Figure 4-5: Proteolytic processing of IL-36 cytokines by neutrophil
serine proteases
(A) Recombinant SUMO-IL-36α and SUMO-IL-36γ were incubated with recombinant 
neutrophil serine proteases cathepsin G (CG), elastase (E), and proteinase 3 (PR3) at a ratio
of 1:100 protease:SUMO-IL-36 and incubated at 37°C for 1 hour. Proteolysis was analysed
by Coomassie stained gel.  Mass spectrometry results of IL-36α (B) and IL-36γ (C) after 1 
hour incubation with neutrophil proteases. Numbers denote mass of truncations whilst
letters indicate the truncations’ starting amino acids. (D) Diagram to illustrate the sites at
which each neutrophil serine protease truncates the IL-36 cytokines as identified by liquid
chromatography mass spectrometry. Arrows show cleavage position whilst colour denotes
the cleaving protease, as shown in the key.
The truncations produced by these neutrophil serine proteases would not be
predicted to be biologically active. As mentioned above, in order to produce
biologically active IL-36 cytokines cleavage must occur precisely 9 amino
acids upstream of the A-X-D motif [99].  For IL-36α this means cleavage 
between amino acid five and six to produce IL-36α K6, yet the proteases 
tested here produce the truncation IL-36α I7.  For IL-36γ cleavage must 
occur between amino acids 17 and 18 to produce IL-36γ S18, yet the 
truncations produced by the neutrophil serine proteases are IL-36γ Y16 and 
IL-36γ Q17.  By producing recombinant IL-36α I7, IL-36γ Y16 and IL-36γ Q17 
and comparing them against full length agonists and the active IL-36α K6 
and IL-36γ S18, it is shown that the truncations produced by these neutrophil 
serine proteases indeed have little or no agonist activity (Figure 4-6). These
results show that whilst neutrophils are capable of cleaving IL-36 cytokines,
they may not mediate their activation.
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ary fibroblasts were grown to a confluency of 70% before stimulation with the
L-36 agonists generated by neutrophil serine proteases. (A) The biological
L-36α I7, IL-36α FL, and the active IL-36α K6 were compared.  (B) The biological 
L-36γ Y16, IL-36γ Q17, IL-36γ FL, and active IL-36γ S18 were compared. 100 
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4.4 IL-36γ-activating protease is expressed within 
skin-resident cells
As previously mentioned, proteases are not only secreted but are also
present intracellularly. Certainly, much IL-1 family proteolysis takes place
within the cell prior to secretion of the processed protein. The IL-36 agonist-
activating proteases may have been missed in previous experiments as only
secreted proteases were interrogated.
Indeed, during the course of this research Henry et al. demonstrated that IL-
36 agonists can be activated by incubation with neutrophil lysates [134].
Despite not identifying IL-36 cleavage products, a sensitive biological activity
assay was employed to demonstrate IL-36 activity and subsequently identify
the proteases involved in activation. As the cleavage via neutrophil
proteases was not particularly efficient we hypothesised that the primary
activator of IL-36 agonists would be present within the epithelial-type cells
that express IL-36 agonist rather than infiltrating neutrophils. To test this, full
length agonists were incubated with A549 cell lysates and IL-36 activity was
examined by a biological reporter assay.
A549 cells were lysed in a hypotonic buffer, and lysates were added to the
HaCaTs with or without IL-36α FL or IL-36γ FL, and IL-8 was used as a read 
out of IL-36 activity. When either A549 lysates or full length IL-36 agonists
were added independently to HaCaTs, no increase was seen in IL-8
secretion.  The same was true when IL-36α FL was added with A549 lysate, 
however when IL-36γ FL and A549 lysates were added together a modest 
yet significant increase in IL-8 secretion was observed (Figure 4-7). This is
suggestive of an IL-36γ-activating protease present within A549 cells.  
Indeed, this increase in IL-8 secretion is ablated by the addition of IL-36Ra,
indicating the observed IL-8 increase is dependent on IL-36 signalling.
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Figure 4-8: A549 lysosomal protease activates IL-36γ 
(A) HaCaTs were grown to a confluence of 90% before addition of 50 nM IL-36γ FL (36γ), 
A549 cytosolic fraction (C), IL-36γ FL and cytosolic fraction in combination, with or without 
500 nM IL-36Ra, A549 lysosomal fraction (L) and lysosomal fraction in combination with IL-
36γ FL with and without IL-36Ra (RA) for 24 hours.  IL-36 activity was assessed by 
measuring supernatant IL-8. (B) A549 cytosol and lysosome fractions were analysed by
western blot using anti-LAMP-1 (abcam) and anti-GAPDH (Gene Tex) primary antibodies for
lysosomal and cytosolic markers respectively. A one-way ANOVA was used to determine
statistical significance of differences between treatment groups. *, p < 0.05, **, P<0.01. Data
shown are mean ± S.E. (n = 3)
A549 cells are a cell line derived from alveolar epithelia and have been used
for convenience as they grow rapidly and are easy to work with. Whilst they
are a relevant cell line to work with, as lung tissue is known to express IL-36,
it is important to test whether skin-derived cells also possess intracellular
proteases that activate IL-36γ.  Therefore lysosomal fractionations were 
performed on HaCaTs, primary keratinocytes and primary fibroblasts and
activity assays were repeated using these skin cell fractionations. As shown
in Figure 4-9, analogous to A549 lysosome fractions a strong IL-36-
dependent induction of IL-8 was observed when each skin-cell lysosomal
fraction was added with IL-36γ FL to HaCaTs.  These results seem to 
suggest an IL-36γ activating proteases are commonly expressed by skin-
resident cells.
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igure 4-9: Keratinocyte and Fibroblast lysosomes contain IL-36γ-
ctivating protease
aCaTs were grown to a confluence of 90% before addition of 50 nM IL-36γ FL (36γ), 
ysosomal fraction (L) of either primary human fibroblasts (A) or primary human keratinocytes
B) alone and in combination with IL-36γ FL with and without 500 nM IL-36Ra (RA) for 24 
ours. IL-36 activity was assessed by measuring supernatant IL-8. A one-way ANOVA was
sed to determine statistical significance of differences between treatment groups. ***, p <
.001, ****, p, 0.0001. Data shown are mean ± S.E. (n = 3).
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4.5 Activation of IL-36γ dependent upon lysosomal 
cathepsin S
As previously mentioned, a broad spectrum of proteases is expressed within
the lysosome.  In order to identify the protease responsible for IL-36γ 
activation, activity assays were repeated in the presence of the serine and
cysteine protease molecular inhibitors 4-(2-aminoethyl)benzenesulfonyl
fluoride hydrochloride (AEBSF) and E64 respectively. The addition of the
serine protease inhibitor AEBSF had no effect on the activation of IL-36γ, 
however IL-8 secretion was completely ablated after addition of E64
indicating a cysteine protease is responsible for the activation of IL-36γ 
(Figure 4-10).
Lysosomal cysteine proteases are typically active at pH 4-5, yet the activity
assays were performed at a buffered physiological pH (pH 6.8). This in itself
rules out a large number of the candidate proteases and strongly implicates
the cysteine protease cathepsin S as this protease has been well
documented to function at a neutral pH [162, 163]. The activity assay was
therefore repeated again in the presence of the specific cathepsin S inhibitor
CATSi. Similarly, Figure 4-10 shows the addition of CATSi completely
ablated the secretion of IL-8 observed when A549 lysosomal fractions and IL-
36γ FL are added to HaCaTs.   
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Lysosomal cysteine protease cathepsin S activates IL-36γ 
e grown to a confluence of 90% before addition of either 50 nM IL-36γ S18 
bination of 500 nM IL-36γ FL (36γ) and A549 lysosomal fraction in the 
sence of cysteine protease inhibitor (E64) or serine protease inhibitor
hours. (B) Experiment was repeated with the addition of a cathepsin S
(CAT S). The inhibitors were incubated with the proteins and lysosomal
urs at 4°C at 10 µM (E64), 100 µM (AEBSF) and 10 mM (CAT S). IL-36
essed by measuring supernatant IL-8. A one-way ANOVA was used to
tical significance of differences between treatment groups. **, p < 0.01, ****,
a shown are mean ± S.E. (n = 3).
 of IL-36γ FL to its active form IL-36γ S18 was further confirmed 
 recombinant SUMO-IL-36γ FL with recombinant cathepsin S at 
ours.  SDS-PAGE showed cathepsin S rapidly cleaved IL-36γ 
truncated form of approximately 17 kDa. Mass spectrometry
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confirmed a protein of 17031 Da, corresponding precisely to IL-36γ S18.  To 
rule out the possibility of the N-terminal SUMO tag affecting the cleavage,
this was repeated with un-tagged IL-36γ FL (Figure 4-11).  The same product 
was identified and confirmed by N-terminal sequencing.
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4.6 Endogenous secretion of cathepsin S activates
IL-36γ 
Although lysosomal cathepsin S was demonstrated to activate IL-36γ, this 
may not necessarily be physiologically relevant as IL-36γ may not come into 
contact with cathepsin S within the cell. However, cathepsin S is known to
be readily secreted by many cell types and thus may come into contact with
IL-36γ in the extracellular environment.  Therefore it was investigated 
whether secreted cathepsin S was capable of activating IL-36γ. 
Cathepsin S was shown to be present in the conditioned media of A549 cells,
primary keratinocytes and primary fibroblasts after 24 hours of culture at
100% confluence in 6 well plates. HaCaTs were then incubated with DTT-
supplemented conditioned media from each cell type with 10 nM IL-36γ FL, 
in the presence or absence of 50 nM IL-36Ra. IL-8 secretion was
significantly increased by the addition of both IL-36γ FL and conditioned 
media from all cell types (Figure 4-12).
To determine whether the observed IL-36γ FL processing by conditioned 
media was mediated by cathepsin S, siRNA was utilised to specifically down-
regulate the expression of cathepsin S in A549 cells. Cathepsin S secretion
was significantly reduced after transfection with cathepsin S siRNA when
compared to non-transfected and scrambled siRNA transfected cells (Figure
4-12). Repeating the activity assays showed that the decrease in cathepsin S
secretion seen by cathepsin S siRNA transfected cells coincided with a
significant decrease in IL-36γ FL activity, showing a dependency on 
cathepsin S for IL-36γ FL processing.  These results indicate secreted 
cathepsin S is capable of activating IL-36γ.   
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before being added to 90% confluent HaCaTs in
F).  HaCaTs were incubated for 24 hours after addition 
ed by measuring supernatant IL-8. A one-way ANOVA
ificance of differences between treatment groups. *, P
mean ± S.E. (n = 3).
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4.7 Neutrophil proteases have a regulatory effect on
IL-36γ activity 
The results generated in this chapter have demonstrated that cathepsin S
released by skin-based cells cleaves and activates IL-36γ, and that whilst 
neutrophil serine proteases are also capable of processing IL-36γ the 
truncations generated are predominantly inactive. However there is evidence
in the literature to suggest neutrophil serine proteases are capable of
activating IL-36γ to induce IL-36-mediated inflammation [134].  It therefore 
seemed appropriate to evaluate and compare the activating ability of
neutrophil serine proteases and cathepsin S.
IL-36γ FL was incubated with either cathepsin S alone or cathepsin S with 
neutrophil serine proteases at a number of different molar ratios at 37˚C for 1 
hour and then added to HaCaTs for 24 hours. IL-36-mediated signalling was
then assessed by measuring IL-8 secretion. In doing so it was observed that
at a ratio of 1 ng of protease to 100 ng IL-36γ FL the addition of neutrophil 
serine proteases to cathepsin S and IL-36γ FL reduces the subsequent IL-
36-dependent secretion of IL-8 (Figure 4-13). This suggests neutrophil
serine proteases have a more regulatory impact than inflammatory when
involved in the proteolysis of IL-36γ. 
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tial of cathepsin S
-36γ FL was incubated with 0.01 – 10 ng of cathepsin S alone, or in combination with 
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ted with proteases for 1 hour at 37°C before addition to 90% confluent HaCaTs for 24
IL-36 activity was assessed by measuring IL-8 secretion.
Discussion and Future work
IL-1 family, consisting of 11 cytokines with a multitude of distinct
ons, has been well established as of huge importance in innate
nity and inflammatory conditions [164]. As the activity of IL-1 cytokines
vily reliant upon proteolytic processing, the IL-1 regulating proteases
erefore of equal importance. To have an in depth understanding of the
-1 family cytokines play in inflammation it is imperative to consider their
lytic regulation. This is illustrated in cases where the function of IL-1-
ting proteases are affected, such as a dysregulated activation of
se-1 leading to increased amounts of active IL-1β secretion that can 
in cryopyrin-associated periodic syndromes [165]. The correct balance
lammation and regulation needs to be maintained for an effective
ne response and resolution to occur. In cases where the regulatory
ce is lost, such as in DIRA and DITRA, severe systemic life-threatening
mation can result [166]. It is therefore vital to understand the dynamics
IL-1 cytokine activity is affected by proteolytic processing.
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While proteolytic activation and regulation has been identified in many
members of the IL-1 family, few advances have been made regarding the
proteolytic processing of the IL-36 cytokines. It has been demonstrated that
precise cleavage must occur for their activation, but until now there has been
little convincing evidence implicating the proteases responsible for their
activation. Given the importance IL-36 signalling plays in the pathological
inflammation of psoriasis and its emerging role in wound healing and
resolution of inflammation, it is imperative to understand the dynamics of their
regulation and activation to properly comprehend the role IL-36 cytokines
play in innate immunity. It was thus the objective of this chapter to
investigate the proteolytic processing of IL-36 cytokine members and the
effects this had on IL-36-mediated inflammation.
IL-36 cytokines were initially incubated with conditioned media derived from
keratinocytes, fibroblasts, and neutrophils. Thus, activated neutrophil
supernatant was demonstrated to cleave IL-36 members α, γ, and Ra in the 
region of their N-terminal IL-1-like domains. By a series of cleavage
inhibition assays it was identified that neutrophil serine proteases cathepsin
G, proteinase 3 and neutrophil elastase were responsible for cleavage, yet
only neutrophil elastase cleavage of IL-36Ra produced a biologically active
cytokine.  The truncation products of the IL-36 agonists IL-36α and IL-36γ 
produced by neutrophil cleavage showed no – or very limited – biological
activity. However, through the use of a biological activity assay it was
demonstrated that lysosomal cathepsin S contained within epithelial cells
was capable of activating IL-36γ and that, furthermore, cathepsin S secreted 
by primary keratinocytes, fibroblasts and A549 cells was able to activate IL-
36γ and induce IL-36-mediated signalling.  
Cathepsin S is a lysosomal cysteine protease that is primarily expressed by
antigen presenting cells with a central role in antigen presentation. However,
its expression is also present in human keratinocytes and can be strongly
induced by stimulation with interferon-γ [167].  Unlike many lysosomal 
cysteine proteases, which require an acidic pH and reducing environment for
optimal activity, cathepsin S is stable at a neutral pH [162]. Indeed whilst
most lysosomal cysteine proteases become irreversibly deactivated after
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release from the lysosome due to an increase in pH, cathepsin S retains its
activity [163].  Intriguingly, when considering the expression of IL-36γ, 
cathepsin S is found expressed at much higher levels in psoriatic
keratinocytes than in healthy. Furthermore the expression of cathepsin S in
psoriatic keratinocytes is inducible by stimulation with TNFα, which also 
leads to cathepsin S secretion [168]. This is likely significant with regards to
IL-36-mediated inflammation in psoriasis, given that the work in this chapter
identified cathepsin S as a primary activator of IL-36γ.  Due to an abundance 
of inflammatory cytokines in the epidermis of psoriatic tissue, it seems likely
there should be increased levels of extracellular cathepsin S and thus
increased activation of IL-36γ (which was demonstrated in chapter 3 to be 
present at significantly high levels in psoriatic epidermal tissue). Therefore
cathepsin S is likely a central mediator of IL-36γ-driven inflammation in 
psoriatic tissue.
The release of IL-1 cytokines into the extracellular environment is a complex
and poorly understood process. As the IL-1 family cytokines lack a signal
peptide they are not channelled into the secretory pathway and thus must be
released via non-classical means. Many mechanisms of release have been
proposed, the most well established being release of IL-1β and IL-18 after 
activation of the inflammasome with intracellular protein processing a
prerequisite for secretion [169]. However, for those members that are not
internally processed the mechanisms involved in cytokine release are ill-
defined and difficult to dissect. Despite this, it is well established that IL-1
members can act as DAMPs following release into the extracellular
environment after necrotic cell death [87]. Regarding the release of IL-36
cytokines, there is very little evidence of active secretion and no evidence of
intracellular processing, but it has been identified that IL-36γ is released upon 
necrotic cell death [170]. When considering that keratinocytes constitutively
express IL-36γ and that this expression in strongly enhanced upon microbial 
insult, this may lend weight to the hypothesis that IL-36γ acts as a DAMP 
released in its inactive form that requires the presence of extracellular
cathepsin S to initiate an inflammatory reaction.
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In addition to an increased expression in psoriatic keratinocytes, cathepsin S
expression has also been identified as elevated in dextran sulphate sodium-
induced colitis [171]. Furthermore, through mouse knockouts, cathepsin S
has been demonstrated to have an active role in the development of
inflammation in trinitrobenzene sulfonic acid (TNBS) -induced colitis [172].
Given that IL-36γ expression is also increased in inflammatory bowel disease 
it seems logical that cathepsin S might contribute to intestinal inflammation
through activation of IL-36γ.  Additionally, like IL-36γ, expression of cathepsin 
S has been shown to increase upon stimulation of mice with smoke
condensate and respiratory syncytial virus in a model of chronic obstructive
pulmonary disease [173].  The mirrored expression of both IL-36γ and 
cathepsin S in a number of distinct inflammatory conditions lend weight to the
hypothesis that cathepsin S is a primary activator of IL-36γ. 
With the notion that IL-36γ-mediated inflammation is subject to cathepsin S 
activity, it becomes important to consider the regulation of cathepsin S.
Indeed the balance of proteases involved in the processing of inflammatory
mediators and the inhibitors that regulate them is crucial to maintain a
controlled inflammatory response. This is illustrated in the case of Netherton
syndrome; a disorder in which loss-of-function mutations in the gene
encoding lymphoepithelial Kazal-type-5 serine protease inhibitor (LEKTI)
results in development of a life-threatening form of ichthyosis with associated
chronic skin inflammation [174]. Without the balance of LEKTI, unchecked
serine protease activity compromises stratum corneum cohesion through
elevated proteolytic activity. Subsequent stratum corneum thinning occurs
with associated hypernatremic dehydration which can prove fatal in severely
affected infants [175, 176]. LEKTI is important in the inhibition of kallikrein-
related peptidase 5 (KLK5) which can induce the production of pro-
inflammatory mediators by activating protease activated receptor-2 (PAR-2).
Without functioning LEKTI, over-activation of PAR-2 induces expression of
TH2 polarising cytokines and inflammatory mediators such as TNFα, which 
results in an inflammatory phenotype similar to atopic dermatitis [177].
It is therefore important to understand the balance between cathepsin S and
IL-36γ in order to properly assess IL-36γ-mediated inflammation.  A good 
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understanding of the regulation and activity of cathepsin S might lead to the
development of new treatment strategies to control IL-36γ-mediated 
inflammation. Cathepsin S is regulated on a number of different levels.
Firstly, through its differential expression induced upon inflammatory stimuli
as mentioned above. Secondly, cathepsin S is produced as an inactive
zymogen thus itself requires activation through proteolytic processing.
Finally, cathepsin S is irreversibly inhibited by cystatin C [178]. So if
cathepsin S is a primary activator of IL-36γ, it stands to reason that IL-36γ-
mediated inflammation can be controlled through the modulation of cathepsin
S regulators.
It has previously been reported that neutrophil serine proteases are
responsible for contributing towards IL-36 cytokine activation, yet the results
of this chapter seem to contradict this observation. It has been identified that
incubation of IL-36α and IL-36γ with cathepsin G and neutrophil elastase 
respectively produced active truncations that induced IL-36-mediated
signalling in an activity assay [134]. However, the results obtained in this
chapter identified the major IL-36 agonist truncation products produced by
cathepsin G and neutrophil elastase to have little or no biological activity
when used to stimulate IL-36-responsive HaCaTs. This was hypothesised to
be due to cleavage not occurring 9 amino acids upstream of the A-X-D motif
that has been shown to be crucial for IL-36 activation by Towne et al. [99].
Indeed, the truncations identified for neutrophil elastase-cleaved IL-36γ by 
Henry et al. were identical to those identified in this chapter, thus would also
be predicted to be inactive. Furthermore, it was demonstrated here that the
addition of neutrophil serine proteases to cathepsin S and IL-36γ FL reduced 
IL-36γ-mediated IL-8 secretion, suggesting neutrophil serine proteases may 
have a regulatory effect on IL-36γ-mediated inflammation.  This experiment 
therefore suggests an influx of neutrophils into an environment with cathepsin
S and IL-36γ present would dampen IL-36γ-mediated inflammation rather 
than compound it. The exposure of neutrophil proteases prevented
cathepsin S dependent activation of IL-36, so it is therefore conceivable that
under conditions of excess neutrophil activity the inflammatory effect of IL-36
might be regulated through cleavage and degradation. Such a phenomenon
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has been observed in the lungs of cystic fibrosis patients in which the
presence of neutrophils degrades inflammatory mediators such as IL-6 [179].
Furthermore, neutrophil serine proteases can deactivate a number of
inflammatory chemokines including macrophage inflammatory protein 1α 
(MIP-1α) and RANTES through proteolytic processing, so the concept of 
neutrophil-mediated regulation through the degradation of inflammatory
mediators is already well established [180, 181]. The regulation of IL-36-
mediated inflammation is further supported when considering that neutrophil
elastase was shown here to activate IL-36Ra.
Furthermore, when considering the concept of IL-36 cytokines functioning as
DAMPs it seems more logical that IL-36-activating proteases are constantly
present, or immediately inducible, so that a reaction can be immediately
mounted in response to tissue damage. Indeed, in line with this hypothesis,
cathepsin S is expressed in keratinocyte lysosomes and as reported here is
readily released into the surrounding medium and likely to be released upon
tissue damage, thus is able to immediately activate released IL-36γ and 
initiate an inflammatory response [167]. Yet activation by neutrophil serine
proteases would require a pre-existing inflammatory response and a
chemokine gradient to facilitate an influx of neutrophils, as neutrophils are not
present in the epidermis under normal healthy conditions. Furthermore,
activation of the IL-36 cytokines would then require neutrophil stimulation to
mediate release of serine proteases. In light of this, the hypothesis of
neutrophils activating IL-36 cytokines and IL-36 cytokines acting as DAMPs
do not necessarily corroborate. It might, however, be hypothesised that IL-
36γ alone in the skin acts as a DAMP, whilst IL-36α and IL-36β act as 
traditionally pro-inflammatory cytokines.  In the skin, whilst IL-36α and IL-36β 
are induced upon microbial insult and inflammatory stimulation, only IL-36γ 
appears to be constitutively expressed [108].  In analogy to IL-1α, this 
indicates there are cellular stores of IL-36γ, but not IL-36α or IL-36β, 
available for activation in the event of tissue damage. Furthermore, whereas
the work here has demonstrated that neutrophil serine proteases might
regulate IL-36γ-mediated signalling, it is possible they may enhance 
activation of the other IL-36 cytokines. Indeed, the findings reported by
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Henry et al. did identify the predicted active form of IL-36β (IL-36β R5) after 
incubation with cathepsin G and proteinase 3 [134]. It is clear, either way,
that neutrophils are involved IL-36 biology, but further work is required to
clarify their role in IL-36-mediated inflammation. Future work should
endeavour to identify IL-36α-activating proteases so that a broader picture of 
IL-36 activation and regulation can be established.
To conclude, the work conducted in this chapter has identified that cathepsin
S is a primary activator of IL-36γ in the skin and perhaps lung tissue.  
Furthermore, this work demonstrated that though neutrophils are involved in
the post-translational processing of IL-36 cytokines, they may act in a more
regulatory fashion. Not only do they produce inactive IL-36 agonist
truncations, but they also activate IL-36Ra and have been shown to reduce
the signalling capacity of cathepsin S-incubated IL-36γ FL.  With the 
culmination of this work and that conducted by others it is now possible to
start building a comprehensive idea of the proteolytic regulation of the IL-36
cytokines.  Proteases have now been identified that activate IL-36Ra, IL-36β, 
and IL-36γ, and that also regulate IL-36 signalling.  Through studying these 
proteases a better understanding of IL-36-mediated inflammation should be
attainable, and potentially further down the line manipulated for a favourable
disease outcome. However, further work is still required. An activating
protease is yet to be identified for IL-36α, and the dynamics between 
neutrophil proteases and local epithelial proteases in the regulation of IL-36
cytokines requires clarification.
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Chapter 5 -  Role of IL-36γ in Immune 
Defence
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5.1 Introduction
As discussed in the introduction, whilst a lot of research is centred on the role
of IL-36 cytokines in pathological inflammation, there is a limited
understanding of the physiological roles of IL-36 cytokines. It has been
postulated that like other IL-1 members IL-36 cytokines act as DAMPs
released by mechanical damage to epithelial tissue, but evidence exists to
suggest a more involved role, with implications in both wound healing and
protection against invading pathogens at epithelial barriers [87, 125, 182].
Psoriatic sufferers exhibit a skin phenotype that closely resembles fighting a
skin-based fungal infection, with an increased expression of AMPs,
thickening of the epidermis and polarisation of a TH1 and TH17 phenotype
[54]. The overexpression of IL-36 cytokines, a hallmark in psoriatic
inflammation, produces very similar phenotypes when induced in mice [112,
143]. A recent publication has shown that IL-36 expression is induced by
exposure to Aspergillus fumigatus, a fungal pathogen that is constantly
challenging our pulmonary epithelial barrier, and suggests IL-36 may have a
role in combating A. fumigatus infection [124]. Additionally IL-36 cytokines
are inducible upon TLR stimulation. Given this information and the effect IL-
36 has in the skin compartment it seemed plausible that IL-36 may also
function to combat skin-based fungal infection.
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5.2 IL-36α and IL-36γ offer resistance against 
Candida in a skin epidermis model
To further investigate the relationship between IL-36 members and skin-
based fungal infection, a skin equivalence model was utilised to model a
skin-based C. albicans infection. Collaborators in Aberdeen grew epidermal
skin equivalent models in the presence or absence of IL-36α and IL-36γ for 5 
days before introducing live C. albicans to the surface of the epidermis for 12
hours, according to the model employed by Eyerich et al. [183]. Models
grown with active IL-36 agonists suffered less epidermal damage, as
measured by LDH release and histological observation, than models grown
with inactive agonists or PBS control (Figure 5-1). In addition, the colony
forming units (CFU) from C. albicans-infected epidermal raft were reduced in
the presence of active IL-36 agonists. This resistance to C. albicans infection
demonstrated an IL-36 dependent trend as the addition of IL-36Ra ablated
the effects seen in the skin models grown with active IL-36 agonists.
Furthermore, skin models grown with IL-36Ra alone showed more severe
epidermal damage and higher C. albicans CFUs than the non-treated control
skin models suggesting that endogenous IL-36γ and IL-36α may have a 
protective effect (although IL-36 levels were not measured at the time of
experiments). IL-36 appears to increase the resilience of epidermal cells,
reducing the amount of cell death, and reducing C. albicans viability.
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5-1: IL-36 agonists promote resistance to epidermal Candida
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in this figure was conducted by collaborators at the University of Aberdeen.
l skin equivalents were grown with and without active and inactive IL-36α or IL-36γ 
and infected with C. albicans at day 5 for 12 hours (A) (IL-36α-treated models 
ly). Epidermal cell death was analysed by LDH release (B) and viable C. albicans
by measuring the colony forming units (CFU) from each infected model at the end
ction period (C).
5.3 Antimicrobial peptide expression is induced by
IL-36 stimulation
Keratinocytes play a key role in the immune defence of the skin as the first
point of contact to microbial intrusion. Not only do they help initiate the
immune response through the release of pro-inflammatory mediators such as
IL-8 and IL-1 cytokines, but they are capable of directly combating infection
by secreting numerous AMPs. In psoriatic plaques, several AMPs are known
to be up-regulated. Amongst them is hBD2, which has been demonstrated to
have antimicrobial activity against C. albicans [184]. Given that the viability of
C. albicans is reduced in skin models grown with IL-36 agonists, it could be
hypothesised that IL-36 stimulation is causing secretion of AMPs that are
directly killing the C. albicans. As such, the effect of IL-36 stimulation on
secretion of hBD2 was examined.
Human keratinocytes were stimulated with IL-36γ at 50 nM with and without 
IL-36Ra at 500 nM for 48 hours. The concentration of hBD2 was then tested
by ELISA.  hBD2 levels were increased upon addition of IL-36γ agonists and 
reducible by the addition of IL-36Ra, indicating the increase was IL-36γ 
dependent (Figure 5-2).
Figure 5-2: IL-36
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are mean ± S.E. (n=2)
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5.4 IL-36 promotes epidermal/keratinocyte growth
Maintaining barrier integrity is an important aspect of defence against skin-
based infections. Once invading pathogens breach the epidermis they are
more capable of establishing infection and causing greater tissue damage.
The skin barrier function can be maintained by an increase in epidermal
keratinocyte proliferation, increasing the buffer between infecting pathogens
and the epidermal basement membrane. The skin models grown with IL-36
agonists appeared to suffer less damage and showed greater integrity
compared to those that had either not been treated or were grown with both
IL-36 agonists and antagonist. IL-36 may be helping maintain skin integrity
by promoting keratinocyte growth in addition to inducing C. albicans killing via
AMP induction. Therefore, the effect of IL-36 on keratinocyte proliferation
was further investigated.
HaCaTs and human keratinocytes were grown in media with and without IL-
36 agonists for 3 days. As shown in Figure 5-3, by monitoring and plotting
their confluence throughout this period of growth it was noted that cells grown
in the presence of IL-36α and IL-36γ grew at a faster rate than those without.  
Cells grown with both IL-36 agonists and antagonist grew at a rate elevated
from the non-stimulated control, but at a lesser rate than those incubated with
agonists alone, indicating an IL-36-dependent increase in proliferation.
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igure 5-3: IL-36 stimulation promotes epidermal proliferation
aCaTs were plated at 10% confluence and grown for 67 hours in the presence of 50 nM IL-
6γ S18 (dark blue 36) with and without 250 nM IL-36Ra V2 (pink 36 + Ra) and compared to 
n untreated control (light blue NS). Confluence was measured throughout the 67 hour
eriod by an IncuCyte and analysed by the IncuCyte Zoom software.
.5 IL-36 increases resistance to apoptosis
s a breakdown in barrier integrity is primarily instigated through cell death,
arrier integrity may also be maintained by preventing or delaying apoptosis.
he C. albicans-infected skin models grown with IL-36 agonists suffered less
ell death than those grown with both IL-36 agonists and antagonist. Whilst
his may be due to the IL-36-mediated increase in epidermal proliferation and
illing of the infecting C. albicans, IL-36 may also be influencing the survival
apabilities of epidermal keratinocytes. In such a way, IL-36 may help
aintain skin barrier function by delaying and resisting cell death. As such,
he effect of IL-36 on apoptosis was further investigated.
poptosis is a highly controlled and complex programmed cell death that can
e initiated in a variety of ways, but all culminate in the initiation of a caspase
cascade after activation of caspase-3. This results in DNA fragmentation,
degradation of cellular and nuclear proteins, and ultimately the formation of
apoptotic bodies expressing ligands that mediate uptake and clearing by
phagocytic cells [185]. Given the complexity of this process, apoptosis was
measured by a number of different methods at varying stages of the
cascade. Typically, apoptosis is measured by an annexin V assay, however,
as shown in Figure 5-4, this proved unsuitable with adherent keratinocyte cell
lines as the processes required to dissociate the cells from their wells caused
membrane damage that resulted in false positives. Instead, caspase-3
activation was measured via a caspase-3 activity assay and through the
detection of PARP cleavage. In addition to this, apoptosis was measured by
examining cellular degradation of DNA. By measuring multiple stages of
apoptosis, a comprehensive picture was established.
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5-4: Annexin V analysis not viable for measuring apoptosis in
s
were grown to a confluence of 70% prior to treatment with 500 ng/ml staurosporin
rs. Apoptotic and necrotic cells from non-stimulated (NS) and staurosporin treated
aTs were analysed by flow cytometry by Annexin V expression and PI counter
‘H’ indicates viable population, ‘A’ indicates apoptotic population, ‘N’ indicates
population. Percentages of each population are displayed in their respective
s.
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Initially, apoptosis was induced by 48 hours of serum starvation to produce a
mild apoptotic state that might be rescuable, however serum starvation alone
proved insufficient to induce measurable apoptosis. Therefore, HaCaTs
were serum starved for 48 hours and treated with staurosporin to induce a
strong measurable apoptotic response in which IL-36 activity could be
assessed (detailed in methods section 2.2.10). HaCaTs were grown to a
confluence of approximately 70% before addition of IL-36 proteins and
initiation of serum starvation for 48 hours. Staurosporin was added at 500
ng/ml for 4 hours, with or without IL-36 proteins, immediately prior to
measuring caspase-3 activity or 24 hours prior to measuring DNA
degradation and PARP cleavage. As shown in Figure 5-5, the addition of
staurosporin to serum starved cells produced a strong induction of caspase-3
activity, noticeable PARP cleavage, and a significant amount of DNA
degradation. Figure 5-5 also shows HaCaTs starved in the presence of IL-
36γ suffered approximately 30% less DNA degradation than those without IL-
36γ after the induction of apoptosis.  Examining PARP cleavage showed 
whilst cleavage was evident in both IL-36γ stimulated and non-stimulated 
cells, less cleaved PARP was present in those grown with active IL-36γ.  
Finally, 12 hours after induction of apoptosis, 15% of cells grown with IL-36γ 
showed caspase-3 activity compared to 20% of cells grown either without
stimulation or stimulated with both agonist and antagonist. These results
suggest IL-36γ may act to increase epidermal resistance to apoptosis, which 
in turn may help to maintain skin barrier integrity.
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5.6 TLR stimulation induces expression of IL-36γ  
In order to respond to and fight off invading pathogens, they must be
recognised by the immune system. This is achieved through detection of
pathogen associated molecular patters (PAMPs) by pattern recognition
receptors (PRRs) [8]. As epithelial cell types are often the first point of
contact for invading pathogens it is of no surprise that epithelial cell types
express a broad range of PRRs [10, 186]. The most prominent group of
PRRs are the toll-like receptors (TLRs) which respond to a wide range of
PAMPs. As different types of pathogens require different immune responses,
the PRRs will initiate a tailored response specific to the type of pathogen
detected. Since it has been demonstrated that IL-36 cytokines appear to
play a role in the skin-based immune defence, it seemed pertinent to see
how TLR stimulation would affect IL-36 expression. Additionally, expression
favoured by stimulation of bacterial, fungal or viral associated PRRs may
allude to a function in immune defence.
Keratinocytes were stimulated with LPS to initiate the TLR4 pathway
associated with a bacterial response, zymosan to initiate the TLR2/6 and
dectin-1 pathway associated with a fungal response, and poly(I:C) to initiate
a viral immune response through activation of TLR3. After incubation with
the PAMPs for 48 hours, the conditioned cell media and lysates were tested
for IL-36γ by ELISA.  As shown in Figure 5-6, LPS stimulation appeared to 
have no effect on IL-36γ expression by keratinocytes.  Stimulation with 
zymosan, however, caused a significant increase in IL-36γ expression 
lending supporting evidence to the hypothesis that IL-36γ is involved in 
fungal defence. Surprisingly, stimulation with poly(I:C) also strongly induced
expression of IL-36γ suggesting that IL-36 may perhaps also be of 
importance in a viral immune response.
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Figure 5-7: Zymosan and poly(I:C) induce
primary keratinocytes
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truncation of IL-36 cytokines and little evidence of release in response to
stimulation.  Therefore, the effect of TLR stimulation on release of IL-36γ was 
examined.
Primary keratinocytes were stimulated with zymosan, LPS and poly(I:C) for
48 hours. As the release of many IL-1 family cytokines is dependent upon
inflammasome activation a second stimulus of ATP or nigericin was also
administered. Supernatants and cell lysates were then collected and
analysed for IL-36γ concentration and the released IL-36γ was expressed as 
the percentage of total IL-36γ contained within the supernatant.  As shown in 
Figure 5-8, treatment with poly(I:C), but not zymosan or LPS, caused a
significant release of IL-36γ.  Furthermore, treatment with ATP and nigericin 
had no significant effect on secretion. These results indicate that whilst
zymosan does induce expression of IL-36γ it does not cause a significant 
increase in its release. Poly(I:C), however, appeared to both strongly induce
IL-36γ and result in its release.  However, as poly(I:C) induces necrosis it is 
possible this release is due to cell death and further experiments are required
to dissect this.
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5-8: poly(I:C) stimulation, but not zymosan or LPS, causes
 of IL-36γ 
keratinocytes were cultured to 70% confluence before stimulation with 100 ng/ml
µg/ml zymosan and 10 µg/ml poly(I:C) for 48 hours and then treated with either
µM ATP or 10 µM nigericin for 5 hours. Lysates and supernatants were tested by
r IL-36γ concentration and released IL-36γ was expressed as a percentage of the 
uced IL-36γ present in the supernatant.  A two-way ANOVA was used to determine 
lly significant differences between treatment groups. **, p < 0.01. Data shown are
.E. (n = 2).
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ted that IL-36γ has a role to play in the immune defence against A.
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It was first examined whether A. fumigatus proteases cleaved IL-36γ.  SUMO 
tagged full length IL-36γ (IL-36γ FL) was incubated with A. fumigatus
conditioned media (CEA10) (provided by Dr Sarah Herrick from the
University of Manchester) and cleavage was analysed at various time points
by electrophoresis. The results show that incubation with CEA10 cleaves IL-
36γ producing products of ~17 kDa (Figure 5-9).  Indeed, mass spectrometry 
analysis identified a cleavage product of 17029 Da, matching the mass of the
active truncation IL-36γ S18 (±2 Da) (Figure 5-9). 
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5-9: A. fumigatus conditioned media cleaves SUMO-tagged IL-
 SUMO-tagged IL-36γ FL was incubated with 20 ng total protein from A. fumigatus
ned media and incubated at 37˚C. Various time points were taken and analysed by 
sie-stained SDS-PAGE. Arrows indicate full length fusion protein and cleaved
 (A).  Cleavage was repeated using untagged IL-36γ FL and cleavage products 
d by liquid chromatography mass spectrometry (B).  Arrow indicates active IL-36γ 
cation.
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Given that the active IL-36γ S18 truncation was identified by mass 
spectrometry after incubation with A. fumigatus proteases, an activity assay
was performed to determine whether CEA10-mediated activation of IL-36γ 
could be reproduced in a bioassay and generate a measurable IL-36γ-
dependent response.  CEA10-incubated untagged IL-36γ FL was added to 
HaCaTs with or without IL-36Ra alongside non-incubated IL-36γ FL.  To 
determine whether the A. fumigatus proteases might further digest and
deactivate active IL-36γ, the incubation was also performed on IL-36γ S18.  
The proteins were incubated with CEA10 for 3 hours at 37°C before being
stopped by addition of Roche total protease inhibitor and added to HaCaTs
for 24 hours.  The HaCaTs were then examined for IL-36γ activity by 
measuring IL-8 secretion. As shown in Figure 5-10, whilst non-incubated IL-
36γ FL had a negligible effect on IL-8 secretion, after incubation with CEA10 
there is a significant increase in IL-8. Furthermore, this increase in IL-8
secretion is completely ablated by the addition of IL-36Ra indicating the
response is IL-36-dependent. When comparing CEA10-incubated and non-
incubated IL-36γ S18 it is evident CEA10 does not reduce IL-36γ activity.  On 
the contrary, a significant increase in IL-36γ activity was observed.  This may 
be due to a priming effect from fungal PAMPs that might be contained within
the conditioned media. In an attempt to dissect whether the CEA10
associated enhancement of IL-36γ S18 activity was conferred via PAMP 
priming, HaCaTs were primed with boiled or un-treated CEA10 for 3 hours
before stimulation with IL-36γ S18.  As shown in Figure 5-10, there was no 
noticeable difference in IL-8 secretion between primed or non-primed IL-36γ 
S18 stimulated cells, however this may be due to an inadequate period of
contact with the cells required for the priming effect.
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5.8 Discussion and future work
IL-36 has primarily been studied in the context of pathological inflammation
due to its overexpression and pathological role in psoriasis. As a result, the
physiological function of IL-36 cytokines in non-pathological inflammation has
not yet been clearly elucidated. It has been proposed that IL-36 cytokines,
like many other IL-1 family cytokines, act as alarmins, alerting surrounding
cells to tissue damage [87]. Whilst this is probable, increased interest and
research into the endogenous function of IL-36 cytokines is producing
evidence to suggest they also may be involved in microbial defence and
wound healing. It has been identified that infection of macrophages with
Mycobacterium tuberculosis results in an increase in IL-36γ expression, and 
that M. tuberculosis growth is restricted in an IL-36R-dependant manner
[188].  Recently published work has postulated IL-36γ plays a critical role in 
immune defence in the human reproductive tract (FRT) after identifying
expression of IL-36γ in FRT epithelial cells increased in response to microbial 
insult [182]. In particular, it seems likely the IL-36 cytokines play an active
role in the defence against fungal infection. It has been demonstrated that
the IL-36 cytokines enhance production of TH17 polarising cytokines, which
are of great importance in fungal defence [106]. Furthermore challenging
human peripheral blood mononuclear cells with Aspergillus fumigatus
strongly induces expression of IL-36γ, further indicating a role in fungal 
defence [124]. In light of these observations, the work in this chapter sought
to investigate the physiological role of IL-36 cytokines in the context of
microbial infection and presents data implicating IL-36γ as significantly 
involved in maintaining epithelial integrity against pathogenic invasion, as
summarised in Figure 5-11.
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igure 5-11: Physiological role of IL-36γ at epithelial barriers  
iagram to summarise the physiological activity of IL-36γ at epithelial barriers as implicated 
y the results of this thesis.  Pathogen-induced cell damage induces release of IL-36γ and 
athepsin S. Exogenous pathogen proteases and released cathepsin S cleave and activate
L-36γ leading to resistance of apoptosis, promotion of proliferation, secretion of chemotactic 
actors and antimicrobial proteins, all of which promote epithelial integrity and pathogen
learance.
y infecting epidermal skin models with C. albicans and treating with active
L-36 agonists, collaborators from the University of Aberdeen demonstrated
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occurring in response to fungal challenge, it was demonstrated that fungal
proteases are capable of activating IL-36γ and initiating IL-36-mediated 
signalling, providing a direct link between fungal infection and IL-36-mediated
inflammation. It may be hypothesised that a fungal presence would both
increase expression of IL-36γ and result in its release through inducing 
damage and cell death.  The released IL-36γ would then be susceptible to 
cleavage by both host and pathogen proteases and initiate an inflammatory
response.
The resistance against skin-based C. albicans infection generated by IL-36
cytokines appeared to work at three levels; induction of AMP secretion,
resistance to cell death, and promotion of epidermal growth. Importantly all
of these mechanism act entirely on the epidermis and do not depend of the
adaptive arm of the immune system, implicating a first line defence against
microbial insult.  The induction of hDB2 by IL-36γ may in itself be indicative of 
an anti-fungal role as hBD2 has been demonstrated to have fungicidal
activity against Candida species in the skin, and may also act against
Aspergillus species in the lungs [184, 189, 190]. However, in the
experiments performed in this chapter only hBD2 expression was examined.
It would be interesting to analyse the effect of IL-36γ stimulation on the 
expression of a broader range of AMPs as this may provide more information
on the antimicrobial effect IL-36 cytokines have. Whilst hBD2 is known to be
fungicidal, hBD3 has been demonstrated to have more potent fungicidal
activity and so an IL-36-dependent increase in hBD3 may be more supportive
of an antifungal role than increased expression of hBD2 alone [184].
Furthermore, in light of the pathological links of IL-36 cytokines to psoriasis, it
may prove interesting to examine the effect IL-36 cytokine stimulation has on
the expression of LL37; an AMP that is associated with a break-down in
tolerance in the development of psoriasis [191]. It might also be interesting
to investigate whether the IL-36 cytokines have any direct antimicrobial
activity as have been shown with other cytokines such as IL-26 [192].
Immunohistochemistry micrographs of skin biopsies from patients with
various forms of inflammatory conditions show that expression of IL-36γ, 
when detectable, is most concentrated in the upper levels of the epidermis,
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which is characteristic of many AMPs [143]. Given that at as the
keratinocytes differentiate and progress to the upper layers of the epidermis
they become unresponsive, it seems unlikely that these keratinocytes would
respond to the present IL-36γ.  It seems plausible then, since IL-36γ appears 
most concentrated in the upper-most layers, that IL-36γ might have another 
role independent of keratinocyte stimulation.
The results in this chapter demonstrated that IL-36γ might promote epidermal 
integrity by promoting keratinocyte proliferation. Whilst the data
demonstrating IL-36 cytokines increased proliferation of HaCaTs is quite
preliminary, and there was no investigation into the mechanisms of how this
enhanced proliferation, the notion that IL-36 cytokines might promote
proliferation is not new. It has been shown in the literature that IL-36
stimulation of keratinocytes induces secretion of the keratinocyte mitogens
transforming growth factor β (TGF-β) and granulocyte colony stimulation 
factor (G-CSF), and growth factors such as heparin binding EGF-like growth
factor (HB-EGF) [109, 113]. These observations all support the idea that IL-
36 cytokines promote epidermal growth. Furthermore, they also implicate a
role in wound healing. HB-EGF is an important growth factor for
epithelialization after cutaneous damage, demonstrated to promote wound
healing by accelerating keratinocyte migration and fibroblast proliferation
[193, 194]. Given the IL-36-mediated increase in expression of factors
associated with wound healing, it would be interesting to further investigate
the wound healing and inflammation-resolving capacity of IL-36 activity in the
skin. Indeed, as previously mentioned, IL-36R has been shown in mice to be
crucial for the resolution of dextran sodium sulphate-induced colitis [125]. In
the wound healing process, keratinocyte and fibroblast migration is crucial for
re-epithelialization and wound closure to occur, and angiogenesis is
necessary to deliver oxygen to the repairing tissue [186].  Given that IL-36γ 
has been demonstrated to induce the expression of a number of growth
factors, it would therefore be interesting to examine the effects IL-36
cytokines have on cell migration and the induction of angiogenesis.
The work conducted in this chapter identified that IL-36γ-stimulated HaCaTs 
exhibited resistance to apoptosis, however the mechanisms behind this
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resistance were not elucidated and thus require further investigation.
Apoptosis is a complex multi-step process that can be initiated through three
distinct pathways, termed the extrinsic, intrinsic, and perforin/granzyme
pathways, and can be controlled at several points. The extrinsic pathway is
initiated through external stimulation of death receptors whereas the intrinsic
pathway is initiated internally by the release of pro-apoptotic proteins from
the mitochondrial intermembrane space. Each apoptotic pathway converges
on the same execution pathway upon activation of caspase-3, resulting in
DNA fragmentation, degradation of nuclear and cytoskeletal proteins, and the
formation of apoptotic bodies [185]. Mitochondrial membrane disruption is a
feature of both the intrinsic and extrinsic apoptosis pathways and as such,
factors regulating the permeability of mitochondrial membranes have a
regulatory effect on apoptosis. This is largely instigated by the Bcl-2 family
proteins, which can be both pro- and anti-apoptotic depending upon whether
they increase or decrease mitochondrial membrane permeability [195].
Apoptosis can also be controlled by the expression of inhibitor of apoptosis
proteins (IAPs) such as X-linked inhibitor of apoptosis protein (XIAP) and
survivin, which bind to and prevent activation of initiator and execution
caspases [196]. The experiments carried out in this chapter induced
apoptosis by staurosporin treatment, which, though its mechanisms are not
completely understood, results in the activation of caspase-3 and caspase-7
[197]. As these are terminal caspases that mediate the final stages of
apoptosis, any resistance observed after staurosporin treatment is most likely
due to an increase in inhibitors of these caspases. In light of this, it seems
likely IL-36γ-stimulation may increase expression of IAPs.  Further work 
assessing the effect of IL-36γ stimulation on the expression of anti-apoptotic 
Bcl-2 proteins and IAPs are necessary to provide a better understanding of
the mechanisms behind IL-36γ-mediated resistance to apoptosis.  
The findings discussed above provide evidence of a cytokine that acts
directly on the epidermis to maintain epidermal integrity and barrier function
in the face of a destructive fungal infection. However, due to time
constraints, the physiological role of IL-36γ in the epidermis was only 
evaluated through its effect on apoptosis and epidermal proliferation.
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Epidermal integrity can be influenced by a variety of additional factors, most
notably keratinocyte differentiation. Indeed, one of the most significant
characteristics of psoriatic inflammation is the abnormally undifferentiated
epidermis.  Given that IL-36 cytokines – in particular IL-36γ – are strongly 
associated with psoriasis in the epidermis it would be intriguing to investigate
the effect IL-36 cytokines have on keratinocyte differentiation. Furthermore,
given that IL-36γ appears to increase the integrity of the epidermis, it might 
be interesting to examine its effect on keratinocyte adhesion molecules such
as tight junctions and cadherins. This might provide more insight into the
increase in epidermal integrity observed upon IL-36γ treatment. 
The work in this chapter demonstrated that not only did fungal insult in the
skin induce expression of both IL-36γ and its activating protease cathepsin S, 
thus indirectly resulting in IL-36-mediated inflammation, but that Aspergillus
fumigatus conditioned media was able to directly activate IL-36γ and 
therefore directly induce IL-36-mediated inflammation. This is significant as it
provides a direct link between fungal infection and IL-36 cytokine signalling.
The IL-36 cytokines have previously been implicated in the defence against
Aspergillus infection in the lung.  It has been observed that IL-36γ expression 
by peripheral blood mononuclear cells (PBMCs) is strongly increased upon
challenge with both live A. fumigatus conidia and heat-killed hyphae.
Furthermore, it has been shown that the expression of IL-17 and IFNγ in 
response to A. fumigatus challenge is influenced by IL-36 signalling, thus IL-
36 is important for driving the TH1 and TH17 responses in A. fumigatus
infection [124]. In light of this, the observation that A. fumigatus can directly
initiate IL-36γ-mediated signalling strongly implicates a role for IL-36γ in the 
defence against A. fumigatus infection in the lung. A. fumigatus are capable
of expressing a wide variety of proteases, including serine proteases,
aspartic proteases and metalloproteinases [187]. Whilst these are not
considered as virulence factors for invasive A. fumigatus infections, they
have been demonstrated to impact on the host response. Several proteases
secreted by A. fumigatus have been identified as allergens that can induce
an allergic response in atopic individuals [198]. Intriguingly, the
metalloproteinase Asp f 5 and serine protease Asp f 13 have been shown to
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induce inflammation and inflammatory cell infiltration in mice infected with A.
fumigatus, contributing to a TH2 response and an asthmatic pathology [199].
Whereas the proteases expressed by A. fumigatus have primarily been
considered as allergenic in their activity by inducing allergic inflammatory
responses, the initiation of IL-36γ signalling and subsequent TH1 and TH17
responses suggests the immune system may also utilize these proteases to
mount an anti-fungal immune response. Indeed, it has recently been posited
that IL-1β may act as a sensor of pathogen-associated proteolysis that 
occurs in group A Streptococcus (GAS) infection after identifying that GAS-
expressed protease SpeB cleaved and activated IL-1β [200].  The activation 
of IL-36γ by A. fumigatus proteases appears to be analogous to this,
suggesting IL-36 cytokines may potentially act as sensors of fungal
proteolytic activity. Candida species are also known to secrete a range of
proteases that can contribute to its pathogenicity [187]. If IL-36 cytokines act
as sensors of fungal protease activity it would be interesting to examine
whether a mechanism analogous to A. fumigatus-mediated IL-36γ activation 
exists with Candida species in the skin.
In addition to examining the endogenous effects of IL-36γ on the epidermis, 
this chapter also investigated the effect various PAMPs had on both the
expression and secretion of IL-36γ.  The secretion of IL-1 family members is 
a subject of much interest, as the IL-1 family members lack an N-terminal
signal peptide and thus must be secreted via a non-classical mechanism.
The best-characterised mechanism of IL-1 secretion occurs as a two-step
process and is dependent upon formation and activation of the
inflammasome. An initial stimulus induces expression of IL-1 pro-forms and
inflammasome components [80, 81]. Upon a secondary stimulation,
formation of the inflammasome occurs, which recruits and activates caspase-
1 [201]. Subsequently, pro-IL-1 cytokines are truncated to their active forms
and secreted from the cell [202]. However, this mechanism of secretion has
only been described for the caspase-1 susceptible IL-1 family members IL-1β 
and IL-18. Indeed, in the experiments conducted in this chapter, whilst IL-
36γ expression increased in response to an initial PAMP challenge, 
activation of the inflammasome by secondary stimulus of either ATP or
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nigericin had no effect on the release of IL-36γ from the cell.  This 
demonstrates the secretion of IL-36γ is not influenced by activation of the 
inflammasome.
For IL-1 members that are not influenced by inflammasome activation of
caspase-1, it is difficult to elucidate a mechanism of release from the cell,
and this is often shown to occur passively, either as a result of mechanical
cell damage or via necrosis. However, a number of alternative mechanisms
of IL-1 family cytokine release have been proposed. There have been many
conflicting studies implicating the involvement of vesicular transport for
release of IL-1 cytokines in the form of secretory lysosomes, multivesicular
bodies and exosomes [203].  Indeed it has been reported that IL-36γ can be 
secreted by mice lung macrophages in microparticles and exosomes in an
ATP-dependent manner [204]. Another proposed method of secretion is via
secretory autophagy.  It has been shown in the case of IL-1β that pro-IL-1β 
can be sequestered into autophagosomes upon TLR stimulation and that
subsequent autophagy-based secretion can result in its release by serum-
starved cells [205, 206].  With regards to IL-36γ and fungal infection, this is 
potentially interesting as fungal challenge has been shown to induce
autophagy and subsequent unconventional protein secretion in human
macrophages in a dectin-1 dependent manner [207]. Furthermore as
cathepsin S is present in lysosomal fractions, the formation of
autophagolysosomes may bring both cathepsin S and IL-36γ together, thus 
subsequent autophagy-based secretion may release active IL-36γ and 
initiate IL-36-mediated inflammation. However, the results obtained in this
chapter indicate this may not be the case with keratinocytes. Whilst treating
keratinocytes with zymosan, an agonist of dectin-1, did induce an increase in
IL-36γ expression, no significant increase in secretion was observed.   
Whilst with several IL-1 family cytokines it has been demonstrated that
cytokine cleavage can occur internally, this has not been shown with IL-36γ.  
However, although cathepsin S is contained within a separate compartment
to IL-36γ, as they are both expressed within the same cells it seems possible 
activation could happen internally. As mentioned above, cellular processes
such as autophagy might bring cathepsin S and IL-36γ together, which could 
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facilitate its activation. Furthermore, the lysosome is in some cases
susceptible to lysosomal disruption, resulting in of lysosomal contents into
the cytosol. Indeed, it has been shown that lysosomal disruption can lead to
the activation of the NLRP3 inflammasome via cathepsin B activity, so it
stands to reason that cathepsin S released in the same manner might also
activate IL-36γ [201]. Lysosomal disruption has been shown to occur in 
response to crystals of monosodium urate (MSU), a prevalent pathological
characteristic of the inflammatory condition gout [208, 209].
Whilst there was no observed release of IL-36γ in response to zymosan or 
LPS stimulation of keratinocytes, there was a strong increase in both
expression and release in response to the TLR3 agonist poly(I:C). Whereas
the increase in IL-36γ release may be attributed to cell necrosis, as poly(I:C) 
is well characterised as an inducer of necrotic cell death, the significant
increase in IL-36γ production is perhaps an intriguing finding.  TLR3 is 
involved in the recognition of viral pathogens, yet IL-36-mediated
inflammation generally results in the production of TH17 polarising cytokines
not typically associated with anti-viral immunity. However, the poly(I:C)-
induced release of IL-36γ by keratinocytes has also been previously reported 
in the literature. It has been demonstrated that poly(I:C) induces pyroptosis
in keratinocytes and the subsequent release of IL-36γ, supporting the notion 
that IL-36 cytokines act as alarmins passively released upon pyroptotic cell
death [170]. However, another publication has shown that low concentration
stimulation of keratinocytes with poly(I:C) is capable of inducing IL-36γ 
secretion in the absence of pyroptosis via extracellular vesicles, suggesting
there does exist an active and controlled mechanism of IL-36γ release in 
response to viral pathogens [107].
The observation that TLR3 stimulation results in IL-36γ expression and 
possibly secretion is suggestive of IL-36γ having a role in viral immunity.  
This is perhaps supported by the observation that the IL-36γ activating 
protease cathepsin S is also up-regulated and released in response to
poly(I:C) stimulation. Whilst IL-36-mediated inflammation is typically
associated with a TH17 response not typical of viral defence, there is
evidence of IL-36 cytokines being involved in viral infections. Soon after its
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discovery, IL-36γ was found to be up-regulated in response to herpes 
simplex virus-1 infection in mice [210].  IL-36γ was also found to be amongst 
the most consistently overexpressed genes identified by microarray analysis
from recurrent respiratory papillomas caused by human papilloma virus
infection [211]. Rhinovirus challenge of primary bronchial epithelial cells
strongly induces expression of IL-36γ [122].  Additionally, in mouse models of 
chronic obstructive pulmonary disease, a condition in which IL-36γ-mediated 
inflammation is thought to be pathological, infection with respiratory syncytial
virus has been shown to exacerbate inflammation and increase expression of
cathepsin S [121, 173]. In light of this, and the large amount of viral
challenge that must occur within lung epithelial tissue, it seems likely that IL-
36 cytokines may be somehow involved in viral immunity. Were IL-36
cytokines to have an active role in the defence against respiratory viral
infections, it may be interesting to investigate the effect on viral infection on
the activation and secretion of IL-36 cytokines. Many respiratory viruses,
including rhinoviruses, encode viral proteases and induce significant changes
in cellular structure during reproduction, including autophagy, so it would be
interesting to examine the effect this might have on IL-36-mediated signalling
and inflammation.
To conclude, the culmination of the results obtained in this chapter paint an
image of a cytokine that acts directly on the epidermis in response to
invading pathogens to promote the epidermal barrier function by maintaining
its integrity.  The observation that IL-36γ is active in the defence against C.
albicans in the skin, up-regulated in response to fungal PAMPs and activated
by A. fumigatus proteases in lung tissue strongly supports the notion that IL-
36γ is important in fungal defence.  However, in light of the strong up-
regulation of both cathepsin S and IL-36γ in response to TLR3 activation, and 
the correlation noted in the literature of IL-36γ expression and viral infections, 
it seems possible the IL-36 cytokines also have a role in antiviral immunity.
Furthermore, with the observation that inflammasome activation had no effect
on IL-36γ release, yet induction of necrosis resulted in a strong release, it 
seems logical that the primary mechanism of IL-36 cytokine release is
through cell damage and necrosis.  In light of the recent finding that IL-1β 
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acts as a sensor of pathogen-associated protease activity, it should prove an
interesting subject to explore whether a similar mechanism exists for the IL-
36 family of cytokines in response to fungal pathogens.
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Chapter 6 - Discussion
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The IL-36 cytokines have become well established as important mediators of
inflammation in a number of inflammatory conditions, including psoriasis and
chronic obstructive pulmonary disease. However, as relatively newly
discovered members of the IL-1 family, our understanding of the IL-36
cytokines is by no means comprehensive. Whilst they have been implicated
in numerous inflammatory conditions at epithelial surfaces, and have been
shown to orchestrate pathological inflammation, a lot remains unclear
regarding the mechanisms of their activation and role they play under
physiological conditions. The work conducted in this thesis endeavored to
clarify these mechanisms and explore how IL-36 cytokines might influence
their environment, to build a more comprehensive understanding of the role
IL-36 cytokines play in both pathological and physiological inflammation.
6.1 Diagnostic and research potential of IL-36γ 
antibodies
IL-36 cytokines first piqued the interest of researchers after recognizing the
abundance of IL-36 cytokine expression in psoriatic plaques [108, 110]. A
number of subsequent transgenic mouse studies further demonstrated that
IL-36 overexpression is not only a characteristic of psoriasis, but that IL-36
signalling plays a pathological role in psoriatic skin inflammation [112, 113].
It was later identified through analysis of RNA extracted from patients and by
immunohistology that psoriatic tissue specifically had highly elevated levels
of IL-36γ expression when compared to a range of other inflammatory skin 
diseases [143].
There is a significant clinical need for advanced alternative diagnostic
approaches. Firstly, with the lack of available specialists and restrictions to
access of secondary care, GPs are in urgent need for non-invasive
diagnostic tests to inform on inflammatory skin reactions. Uncertainty and
inability to diagnose a skin rash leads to considerable overprescribing of
systemic antibiotics and failure to initiate appropriate treatment pathways.
Secondly, descriptive phenotyping and conventional diagnostic dermato-
histopathology – which depends on invasive and expensive biopsy
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procedures – insufficiently inform on stratified medicine approaches. As pure
phenotype descriptions have failed to inform on the most suitable treatment
approach for a given patient, current “stratified medicine” consortia and
research initiatives in the area of inflammatory skin disease now focus on
“molecular” subtypes or “endotypes” [212, 213].
Diagnostic challenges are also frequently encountered in specialist
dermatology settings with regard to atopic dermatitis (AD) and psoriasis
where special body locations (e.g. outer ear, palm, sole, scalp, skin fold area)
are involved or phenotypic features of both diseases are present (often
referred to as psoriasiform eczema or eczematised psoriasis) [152]. AD and
psoriasis can appear very similar despite the distinct underlying mechanisms
of disease. Whilst AD is typically driven by TH2 responses and has strong
links to allergy, psoriasis has a predominantly TH1 and TH17 profile [51, 59,
60]. There are therefore different inflammatory pathways at play, which
require different forms of treatment.  In this work, specific anti-IL-36γ 
monoclonal antibodies were generated and optimized to work in ELISA.
These were used to measure the level of IL-36γ present in the skin of both 
AD patients and psoriasis patients, which identified that, as predicted by RNA
data, IL-36γ is present at much higher levels in skin of patients with psoriasis 
than with AD.  The results suggest that this difference in IL-36γ expression 
may, in the future, be used to differentiate patients with ambiguous
symptoms that may be either AD or psoriasis. One example for a clinical
setting were this is of specific value refers to the diagnostic criteria of
psoriatic arthritis, where psoriatic skin symptoms are part of the classification
criteria for psoriatic arthritis (CASPAR) [214]. Here, patients are attributed
points according to specific symptoms (including psoriatic skin), and must
have a score of ≥ 3 combined with inflammatory articular disease in order for 
a condition to be classified as psoriatic arthritis (PsA). However, in
suspected early PsA, the symptoms exhibited by patients’ skin can often be
minimal or very limited, complicating and delaying diagnosis.
This ELISA therefore has great potential as a diagnostic tool when used in
combination with non-invasive sample collection by skin surface tape
stripping. Furthermore, IL-36γ can also be detected in synovial fluid and 
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serum. The ELISA may thus be useful in further diagnostic methods for
conditions involving systemic circulating IL-36γ or joint involvement such as 
rheumatoid arthritis or psoriatic arthritis, as well as to investigate lung fluid
from patients with viral or fungal infections.
The potential for clinical use of the antibodies developed in this work is not
limited to the ELISA. As shown in chapter 3, two of the antibodies generated
are capable of blocking the signalling ability of active IL-36γ.  Whilst the 
results are very preliminary these antibodies may have a therapeutic value.
As discussed in chapter 3, IL-36 may be a desirable target in the treatment of
psoriasis as, though still significantly involved in orchestration of
inflammation, its expression is much more restricted than that of other targets
such as TNF, IL-17 or IL-12/IL-23 and thus is less likely to have severe off-
target consequences.
In addition to the demonstrated and potential value for clinical diagnostics
and therapy, these antibodies have proved invaluable throughout the
research conducted in this work. Previously, it has been very difficult to
study the IL-36 cytokines at the protein level as the antibodies available on
the market were inadequate. This made it impossible to measure IL-36
protein expression by cells. However, as demonstrated in chapter 5, the
developed ELISA made it possible to examine the cellular expression of IL-
36γ at the protein level and facilitated the investigation of IL-36γ secretion; an 
aspect of IL-36 cytokine biology that has not been studied in great detail, due
– in part – to the lack of reagents. Furthermore, though not extensively
utilized in this work, the antibodies were also optimized to function in
immunoprecipitation and immunofluorescence, which shall prove of great use
in the future. With the ELISA and immunoprecipitating antibodies it should
be possible to not only determine under which conditions IL-36γ might be 
released from the cell, but whether IL-36γ is released in its active or inactive 
form. Furthermore, with functioning immunofluorescence antibodies it should
also be possible to examine the intracellular trafficking events that occur
upon IL-36γ activation and secretion. 
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6.2 Regulation of IL-36 activity by proteolysis and
microbial insult
As repeatedly mentioned, the IL-1 family cytokines are predominantly
produced as inactive precursors that require truncation to become fully active
[215]. Their activity is therefore heavily dependent on the activity and
expression of the proteases that truncate and activate them. This is evident
in cases where the activity of IL-1 regulating proteases become affected
through genetic mutations; particularly in cryopyrin associated periodic
syndromes [216].
Whilst with some members of the IL-1 family, such as IL-1β, proteolysis can 
occur in a general region of the molecule to enhance its activity, the IL-36
cytokines require precise truncation (as has been demonstrated by Towne et
al. and reiterated by the work conducted in this thesis) [99]. This is a
significant factor to consider with the IL-36 cytokines, as has been illustrated
in the work conducted in chapter 4. Whilst neutrophils are capable of
truncating all IL-36 cytokines in the region of their truncation site, of the
agonists only IL-36β is cleaved precisely 9 amino acids upstream of its A-X-D 
motif to activation [134]. Furthermore, whilst they generate inactive
truncations of IL-36α and IL-36γ, they produce active IL-36Ra, which would 
suggest - contrary to some findings reported in the literature - that neutrophils
may act in a more regulatory fashion with respect to IL-36-mediated
inflammation. This is further supported by the finding presented in chapter 4
that by including neutrophil serine proteases in an incubation of full length IL-
36γ and cathepsin S, the resultant IL-36γ-mediated signalling is reduced. 
In contrast to truncation by neutrophil serine proteases, it was shown that IL-
36γ is efficiently activated by cathepsin S upon truncation at precisely 9 
amino acids upstream of its A-X-D motif. This is significant as cathepsin S is
constitutively expressed by many epithelial cells as shown in chapter 4,
including primary fibroblasts and keratinocytes of the skin, and thus the
environment in which IL-36γ is expressed has the capacity to activate and 
induce IL-36γ-mediated inflammation without the need for an influx of 
inflammatory cells.  Given the physiological role of IL-36γ in the epidermis 
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discussed in chapter 5, this would be crucial for IL-36γ to mount an effective 
defence against microbial insult.
With the observation that cathepsin S is a primary activator of IL-36γ, it has 
become important to also consider the expression and activation of cathepsin
S in relation to IL-36 mediated inflammation. Indeed, in keeping with the
pathological role attributed to IL-36-mediated inflammation in psoriasis, it is
established that cathepsin S is also overexpressed in psoriatic tissue [167,
168].  This would suggest that in addition to elevated expression of IL-36γ, 
psoriatic lesions are also likely to have elevated IL-36γ activity when 
compared to healthy tissue. The identification of cathepsin S as an activator
of IL-36γ may provide a genetic candidate to screen in psoriasis cohorts to 
facilitate a stratified treatment approach. As patients with increased
cathepsin S are likely to have increased IL-36-mediated inflammation,
treatment tailored towards targeting cathepsin S and IL-36 signalling might
prove more efficacious than generalized treatments. Furthermore,
identification of cathepsin S-mediated activation may provide new avenues of
research in mouse models that could help to elucidate the importance of
cathepsin S in IL-36-mediated development of psoriasis in a complex
mammalian system.
Despite several identified methods of non-classical secretion, given the
findings of this work it seems likely that IL-36γ, like IL-1α and IL-33, is 
primarily released upon necrosis and functions as an alarmin [87]. This
seems logical when considering that IL-36γ directly influences the epidermis 
to increase epidermal integrity and wards off invading pathogens without
requiring input from adaptive immune cells.  Furthermore, with both IL-36γ 
and its activating protease cathepsin S expressed by the same cells, it
seems likely that necrosis would cause a release of both cathepsin S and IL-
36γ, thus facilitating its activation and the subsequent alarmin function of IL-
36γ.  
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6.3 Endogenous role of IL-36 cytokines
IL-36 has been primarily studied in the context of pathological inflammation.
However research into its physiological role suggests that the IL-36 cytokines
play a role in microbial defence, and that whilst they are in many cases
involved in the orchestration of pathological inflammation, they may also
have a function in the resolution of inflammation and a progression to wound
healing [124, 125].
Recent research has implicated IL-36 cytokines in the defence against
invading pathogenic infection, with several publications demonstrating an
increase in IL-36γ expression upon microbial insult, and even an active role 
in preventing microbial growth in the case of infection with M. tuberculosis
[188]. Indeed, work in collaboration with the University of Aberdeen,
presented in this thesis, demonstrate another example of where IL-36
cytokines actively protect against microbial insult, by promoting resistance to
epidermal invasion by C. albicans.  Furthermore, it was shown that IL-36γ 
directly influences neighboring keratinocytes and functions to increase the
integrity of the epidermis by three separate mechanisms; promoting growth,
resisting cell death, and promoting secretion of AMPs. When considering
that IL-36γ is constitutively expressed in the skin, has been shown to be 
strongly up-regulated upon challenge by microbial PAMPs (along with its
activating protease cathepsin S), and its primary mechanism of release
appears to be through necrosis and mechanical cell damage, the above
results paint the picture of an alarmin cytokine capable of orchestrating an
immediate defence against invading pathogens by acting directly upon the
epidermal cells. Furthermore, published information points to the fact that IL-
36 cytokines can mobilize both the innate and adaptive immune system by
inducing the production of chemokine gradients and promoting maturation of
infiltrating dendritic cells and macrophages [102, 109, 217].
As discussed in chapter 5, a recent publication has proposed a novel function
for IL-1β as a sensor of group A Streptococcal (GAS) infection, as the
cytokine can be activated by the GAS-produced protease SpeB and the
subsequent IL-1β-mediated inflammation is important for clearance of the 
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infection [200]. The results presented in this thesis have identified a similar
mechanism of function for IL-36γ in relation to Aspergillus infection in the
lung, demonstrating that proteases secreted by Aspergillus fumigatus
activate and facilitate IL-36-mediated signalling. Whilst it was not shown that
IL-36 signalling is crucial for resolution of an A. fumigatus infection, IL-36
signalling is known to promote TH17 responses important in fungal immunity
and it has been previously reported that blockade of IL-36 signalling reduces
IL-17 and IFNγ secretion by A. fumigatus-challenged peripheral blood
mononuclear cells [124]. This would imply that in addition to functioning to
orchestrate the first line of defence against invading pathogens, IL-36γ may, 
analogous to IL-1β, also be able to sense the presence of certain fungal 
pathogens itself and initiate an immediate response without the need for up-
regulation or secretion of a host activating protease.
6.4 Conclusion
To conclude, the work conducted in this thesis has produced four anti-IL-36γ 
specific monoclonal antibodies, which function in a number of assays. Most
notably, the generation of these antibodies has facilitated the production and
optimization of an IL-36γ-specific ELISA which has been used to detect and 
quantitate IL-36γ extracted from patient epidermal tissue.  In doing so, it has 
demonstrated that psoriatic epidermis has significantly more IL-36γ than the 
epidermis of AD lesions, providing a diagnostic tool to differentiate the two
conditions.
This work has identified cathepsin S as a primary activator of IL-36γ 
expressed at epithelial sites, and demonstrated that whilst neutrophils are
capable of processing IL-36 cytokines, their truncations are predominantly
inactive and thus act in a more regulatory capacity. Furthermore this work
has demonstrated a role for IL-36γ in the epidermis to maintain and promote 
barrier integrity in the face of microbial infection – particularly fungal insult –
that may even act as sensors of pathogenic protease activity. The sum of all
the results presented in this thesis provides evidence of a versatile cytokine
family closely controlled through its proteolytic processing that can not only
orchestrate and mobilise a robust immune response, but can itself sense
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microbial invasion and act immediately and directly upon the epithelial
compartment to resist microbial invasion. Future experiments determining
whether there is cross species conservation of these mechanisms will help
pave the way to more insightful mouse models and further investigate the
roles of IL-36 cytokines in pathological inflammation and the immune
response.
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CGCTGTGCTTCCGAATGAAGGACTCGGCATTGAAGGTGCTTTAT
A--L--C--F--R--M--K--D--S--A--L--K--V--L--Y-
TTCTAGCTGGAGGGCTGCATGCAGGGAAGGTCATTAAAGGTGAA
L--L--A--G--G--L--H--A--G--K--V--I--K--G--E-
CCAATCGGTGGCTGGATGCCAGCCTGTCCCCCGTCATCCTGGGT
P--N--R--W--L--D--A--S--L--S--P--V--I--L--G-
AGTGCCTGTCATGTGGGGTGGGGCAGGAGCCGACTCTAACACTA
Q--C--L--S--C--G--V--G--Q--E--P--T--L--T--L-
TGGAGCTCTATCTTGGTGCCAAGGAATCCAAGAGCTTCACCTTC
M--E--L--Y--L--G--A--K--E--S--K--S--F--T--F-
GGCTCACCTCCAGCTTCGAGTCGGCTGCCTACCCGGGCTGGTTC
G--L--T--S--S--F--E--S--A--A--Y--P--G--W--F-
AAGCCGATCAGCCTGTCAGACTCACCCAGCTTCCCGAGAATGGT
E--A--D--Q--P--V--R--L--T--Q--L--P--E--N—G-
TCACAGACTTCTACTTCC
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